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Abstract
The current growth of the older population is unprecedented in U.S. history. Chronic
disease and functional limitation commonly develop prior to old age, leading to prolonged
physical disability and decreased well-being. The development of chronic disease and loss of
independence is associated with lean body mass (LBM) loss and fat mass gain beginning in
middle age. Therefore, it is important to identify modifiable factors to mitigate deleterious shifts
in body composition to promote successful aging (SA). The concept of SA is associated with
longevity, the absence of disease and disability, and subjective components of well-being,
however, an operational definition has yet to be established. For this thesis, we defined SA as
low cardiometabolic risk, preservation of physical function, and a positive state of well-being.
Nutrition is a key driver of SA and is a proposed modulator of cardiometabolic risk, physical
function, and well-being in adults. Among nutrients, several studies have identified dietary
protein and the omega-3 polyunsaturated fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA;
20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), as key supportive nutrients for SA in older
adults. Therefore, the overall objective of this dissertation was to determine the effect of
nutrition, specifically dietary protein and n-3 PUFAs on SA outcomes of cardiometabolic risk,
physical function, and well-being. The central hypothesis of this dissertation was that increased
intake of high-quality dietary protein or n-3 PUFAs would improve SA outcomes of
cardiometabolic risk, physical function, and well-being in adults. Therefore, one meta-analysis
(study 1) and two clinical trials (studies 2 and 3) were designed to test our hypothesis. The
objective of the first study was to systematically evaluate the available evidence of randomized
control trials assessing the effect of beef and beef’s nutrients on well-being in healthy, adults ≥
50 years of age to increase physical function and well-being to promote SA. The objective of the

second study was to determine and compare the acute effects of a high-protein breakfast
containing either animal protein or plant protein on appetite, food intake, energy expenditure,
and substrate oxidation in young versus older men to decrease cardiometabolic risk and promote
SA. The objective of the third study was to determine the individual and combined effect of
protein and n-3 PUFAs on body composition, cardiometabolic risk, indexes of sleep, and mood
states in postmenopausal women to decrease cardiometabolic risk and increase physical function,
and well-being to promote SA. Collectively, the results suggest high-quality protein and n-3
PUFAs act as potential regulators of SA outcomes. However, additional research is necessary to
determine the effectiveness of protein and n-3 PUFA-based nutrition strategies to promote SA.
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CHAPTER 1. Introduction
The number of Americans ages 65 years and older is estimated to nearly double from ~52
million in 2018 to ~95 million by 2060 [1]. The observed growth of the older population
corresponds to the projected increased trends in life expectancy from 78.9 years in 2019 to 85.6
years by 2060 [2]. In contrast to the trend in life expectancy, the healthspan, or period of life
spent free from chronic disease and disability [3], has remained stagnant in the United States [4].
As chronic disease and functional limitation commonly develop prior to old age [5], the
preservation of independence, quality of life, and health is critical [6]. One of the major threats to
living independently is sarcopenia, the loss of muscle mass, strength, and function that
progressively occurs with age [7]. As the human body ages, skeletal muscle mass declines
annually by ~0.1%–0.5% beginning from age 30 and may result in sarcopenia as early as 50
years of age [8, 9]. The progression of sarcopenia is associated with an increased risk of falls
[10], decreased quality of life [11], increased morbidity [12], and early mortality [13]. However,
advancing age is not always associated with significant functional regression [14] and some
individuals maintain a successful aging (SA) trajectory [15, 16]. Therefore, there is a need to
identify modifiable factors to promote the prevalence of SA [17].
SA has yet to be universally defined. However, SA is commonly described as a
multidimensional concept with subjective and objective components relating to psychological
function, physiological function, and well-being [18]. For this thesis, we defined SA in terms of
three components 1) low cardiometabolic risk, 2) preservation of physical function, and 3) a
positive state of well-being with nutrition as an integral component. Nutrition is a key driver of
SA [19], and inadequate nutrition contributes to the increased prevalence of sarcopenia and
chronic disease risk in the older population, reducing the chance for SA [20]. Several studies
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have identified dietary protein and the omega-3 polyunsaturated fatty acids (n-3 PUFAs),
eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), as key
supportive nutrients for older adults [21-28]. Furthermore, an anabolic additive effect of protein
and n-3 PUFAs has been identified in skeletal muscle of middle-aged and older adults [29, 30].
However, it is currently unknown if the observed effects project beyond skeletal muscle anabolic
signaling to promote SA.
Low cardiometabolic risk is the first component of SA [16, 31]. Cardiometabolic risk is
defined as a series of risk factors of metabolic origin (e.g., insulin resistance, dyslipidemia,
elevated systolic/diastolic blood pressure) that increase the risk of the development of chronic
diseases such as cardiovascular disease (CVD) and type 2 diabetes (T2D) [32]. Increased
cardiometabolic risk in older adults is related to changes in both body weight and composition
due to alterations in energy intake and/or total energy expenditure [33, 34]. Basale metabolic rate
(BMR) makes up 60-70% of total energy expenditure and progressively decreases with age [35,
36]. Skeletal muscle is a primary determinant of BMR [36-39]. An increase in BMR is
associated with improvements in body composition and decreases in cardiometabolic risk factors
[40, 41]. In addition, a potentially modifiable component of energy expenditure is the thermic
effect of food (TEF), the increase in post-prandial metabolic rate [42]. As TEF is reduced in
older adults [43], further research investigating dietary factors that affect TEF may lead to better
treatment methods to decrease cardiometabolic risk in older adults [44, 45]. In addition to energy
expenditure, energy intake can influence energy balance and affect SA [34]. In this dissertation,
study two, measured cardiometabolic risk via post-prandial plasma glucose response and energy
balance. Short-term energy balance was tested by measuring post-prandial appetite, energy
expenditure, and 24-hour food intake. In study three, cardiometabolic risk was measured by
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biomarkers of glucose metabolism (glucose, insulin, HOMA-IR) and blood lipid levels
(triglycerides, total cholesterol, and free fatty acids). In addition, body composition was
measured by dual energy x-ray absorptiometry (DEXA).
Physical function is the second component of SA [16, 18, 46]. The decline in physical
function with age differs between individuals and is commonly measured in terms of mobility,
balance, and muscle strength [47]. Skeletal muscle plays a critical role in preserving physical
function [48, 49], especially after 50 years of age [50]. Handgrip strength, a commonly used
assessment of overall muscle strength, is associated with morbidity and mortality in aging adults
[51]. Similar to strength, decreased measures of physical function such as the short physical
performance battery (SPPB) score is a strong indicator of all-cause mortality in older adults [52].
Considering the strong association of physical function with all-cause mortality [53], early onset
interventional strategies are needed to monitor and mitigate physical function decline to promote
SA outcomes [54]. In this dissertation physical function was evaluated in study one and study
three. In study one, a meta-analysis and systematic review, measured physical function via
multiple outcomes such as handgrip strength, SPPB, gait speed, and one-repetition maximum
knee extension. Study three, a randomized clinical controlled trial (RCT), measured physical
function via handgrip strength pre- and post- 16-week intervention.
The third component of SA is well-being [18]. Well-being is generally defined by
emotional well-being such as the presence of positive affect states, life satisfaction, and the
absence of negative affect states; and physical well-being such as sleep quality [55-58]. Positive
affect states are associated with better health outcomes, lower mortality risk, and longevity in the
older population [59-61]. In addition, several studies have reported a relationship between
skeletal muscle mass and depressive symptoms [62-64]. Furthermore, studies in adults have

3

demonstrated an inverse relationship between sleep disorders and poor sleep quality and
outcomes of well-being [65-67] and body composition [68-70]. In this dissertation well-being
was evaluated in study one and study three. In study one, a meta-analysis and systematic review,
aimed to evaluate measures of emotional and physical well-being. However, emotional wellbeing outcomes did not meet the inclusion criteria. Therefore, lifestyle factors positively
associated with well-being were included in the study. Study three, a RCT, measured well-being
via the Profile of Mood States (POMS) questionnaire. In addition, sleep quality was evaluated
subjectively by the Pittsburgh Sleep Quality Index (PSQI) questionnaire and objectively by
accelerometry [71, 72].
Nutrition, specifically dietary protein and n-3 PUFAs, are suggested modulators of
cardiometabolic risk, physical function, and well-being and may promote SA [20, 32, 73-75]. As
the older population grows and life expectancy continues to rise, it is important to consider
optimal nutritional recommendations that will promote SA in older adults [76].
Protein is a dietary focal point for SA as the constituent amino acids (AA) are the
essential building blocks necessary to sustain life [20]. The benefits of dietary protein intake for
older adults above the current recommended dietary allowance (RDA) of 0.8g/kg/day is well
established [20, 77] and experts generally recommend a dietary protein intake between 1.2 and
2.0 g/kg/day or higher and ~30 g of high-quality protein per meal to promote skeletal muscle
mass and physical function in older adults [21, 23, 77-82]. Accordingly, dietary protein
consumed in higher amounts may prevent sarcopenia, maintain energy balance, reduce
cardiometabolic risk, and improve function and well-being in community dwelling middle-aged
and older adults [23].
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Similarly, n-3 PUFAs, EPA and DHA are also associated with SA [75]. Although,
Dietary Reference Intakes (DRI) have yet to be developed, the 2015–2020 Dietary Guidelines for
Americans (DGA) recommends a combined daily intake of 250 mg/day EPA + DHA equating to
approximately 8 oz per week of a variety of fish in adults with and without CVD [83]. However,
the benefits of EPA and DHA intake beyond the recommendations are well-established [83, 84].
Furthermore, 3-4 g of combined DHA + EPA may mitigate deleterious characteristics of aging
via suppression of chronic inflammation, incorporation into cellular membranes, and improved
cell signaling [29]. Accordingly, dietary EPA and DHA consumed in higher amounts may
prevent sarcopenia, improve energy metabolism, reduce cardiometabolic risk, improve physical
function, and well-being in community dwelling older adults [28].
Taken together, high-quality dietary protein and n-3 PUFAs may play an integral role in
promoting SA. Therefore, this doctoral dissertation investigates the impact of high-quality
protein and n-3 PUFAs on components of SA in middle-aged and older adults. The objectives of
this dissertation were:
1. To systematically evaluate the available evidence of RCTs assessing the effect of beef
and beef’s nutrients on well-being in healthy, adults ≥ 50 years of age to promote SA.

2. To determine and compare the acute effects of a high-protein breakfast containing either
animal protein or plant protein on appetite, food intake, energy expenditure, and substrate
oxidation in young versus older men to decrease cardiometabolic risk and promote SA .

3. To determine the individual and combined effect of protein and n-3 PUFAs on body
composition, cardiometabolic health, indexes of sleep, and mood states in postmenopausal

5

women to decrease cardiometabolic risk, and increase physical function, and well-being to
promote SA.
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CHAPTER 2. Literature Review
Nutrition as the Foundation of Successful Aging: A Focus on Dietary Protein and Omega-3
Polyunsaturated Fatty Acids

Abstract
Skeletal muscle is thought to play a critical role throughout the aging process. First,
detectable at ~50 years, the deterioration of skeletal muscle mass and strength and power
(sarcopenia) are estimated to decline annually at a rate of ~0.8–1% and ~2–3% respectively.
People living with sarcopenia often experience diminished quality of life, which can be attributed
to a long period of decline and disability. Therefore, it is important to identify modifiable factors
that preserve skeletal muscle and promote successful aging (SA). We defined SA in terms of
three components 1) low cardiometabolic risk, 2) preservation of physical function, and 3) a
positive state of well-being with nutrition as an integral component. Several studies identify
nutrition, specifically high-quality protein (e.g., containing all essential amino acids (EAA)) and
long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA; 20:5
n-3) and docosahexaenoic acid (DHA; 22:6 n-3), as positive regulators of SA. Recently an
anabolic additive effect of protein and n-3 PUFAs has been identified in skeletal muscle of
middle-aged and older adults. Evidence further suggests the additive effect of high-quality
protein and n-3 PUFAs may project beyond skeletal muscle anabolism and promote SA. The key
mechanism(s) behind the enhanced effects of concomitant intake of high-quality protein and n-3
PUFAs remains to be fully elucidated. Therefore, the first objective of this review is to evaluate
skeletal muscle as a driver of cardiometabolic health, physical function, and well-being to
promote SA. The second objective of this review is to examine observational and interventional
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(whole food and/or supplementation alone, without physical exercise) evidence of protein and n3 PUFAs on skeletal muscle to promote SA. The final objective of this review is to propose
mechanisms by which combined optimal intake of high-quality protein and n-3 PUFAs likely
play a key role in SA.

Introduction
The current growth rate of adults ages 65 and older is recognized as one of the most
substantial demographic trends in United States (U.S.) history [1, 2] and life expectancy is
projected to increase from 78.5 years in 2017 to 85.6 years by 2060 [3]. Maintaining
independence, quality of life, and health is crucial as we age [4]. One of the major threats to
living independently is sarcopenia, the loss of muscle mass, strength, and function that
progressively occurs with age [5]. As the human body ages, skeletal muscle mass declines
annually by ~0.1%–0.5% beginning from age 30 and may result in sarcopenia as early as 50
years of age [6, 7]. The progression of sarcopenia is associated with an increased risk of falls [8],
decreased quality of life [9], increased morbidity [10] and early mortality [11]. However,
advancing age is not always associated with significant functional regression [12] and some
individuals maintain a successful aging trajectory [13, 14].
Successful aging (SA) is used in the gerontological literature to cover the multifactorial
processes of aging throughout the lifespan [15]. SA has recently been identified as a
multidimensional construct with subjective and objective components such as positive and
negative affect states, sleep health, and measures of physical and cognitive function [16].
However, a universal definition or standardized criteria of SA has yet to be established.
Nevertheless, investigators have generally based their definitions of SA on the absence of
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physical disability and maintenance of physical performance and to a lesser extent cognitive
function and well-being with increased age [17]. Due to the variability among SA definitions,
approximately 14-42% of older adults (aged ≥60 years) are classified as successful agers [16-20].
Moreover, there is a need to identify a SA construct which can be quantified with objective and
subjective components in order to promote the development of SA. Therefore, in this review we
defined SA as low cardiometabolic risk, preservation of physical function, and a positive state of
well-being with nutrition as an integral component. Furthermore, evidence suggests the SA
components are influenced by a common physiological factor, skeletal muscle mass [21-23], and
are further supported by adequate nutrition [24].
The first SA component is defined by low cardiometabolic risk [14, 25]. Cardiometabolic
risk is defined as a series of risk factors of metabolic origin (e.g., insulin resistance,
dyslipidemia, elevated systolic/diastolic blood pressure) that increase the risk of the development
of chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes (T2D) [26].
Increased cardiometabolic risk in older adults is related to shifts in body weight and composition
due to alterations in energy intake and/or total energy expenditure (TEE) [27, 28]. Basale
metabolic rate (BMR) makes up 60-70% of TEE and progressively decreases with age [29, 30].
Skeletal muscle is a primary determinant of BMR [30-33]. An increase in BMR is associated
with improvements in body composition and decreases in cardiometabolic risk factors [34, 35].
Furthermore, the thermic effect of food (TEF), the increase in post-prandial metabolic rate [36],
is reduced in older adults [37]. Additional research investigating dietary factors that affect TEF
and TEE may lead to better treatment methods to decrease cardiometabolic risk in older adults
[38, 39].
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The second SA component includes physical function [14, 16, 19]. The decline in
physical function with age differs between individuals and is commonly measured in terms of
mobility, balance, and muscle strength [40]. Muscle strength, a key component of physical
function, is defined by the force-producing capacity of skeletal muscle [41]. Handgrip strength, a
commonly used assessment of overall muscle strength, is associated with morbidity and
mortality in aging adults [42]. Physical function is also defined by whole-body function,
involving skeletal muscle and the peripheral nervous system (e.g., balance), and is related to the
ability to move from one place to another [43]. Considering the strong association of physical
function with all-cause mortality, early onset interventional strategies are needed to monitor and
mitigate muscle strength and performance decline to ensure SA [44].
The third component of SA is well-being [16]. Well-being is generally defined by
emotional well-being such as the presence of positive affect states, life satisfaction, and the
absence of negative affect states; and physical well-being such as sleep quality [45-48]. Positive
affect states are associated with better health outcomes, lower mortality risk, and longevity in the
older population [49-51]. In addition, several studies have reported a relationship between
skeletal muscle mass and depressive symptoms [52-54]. Furthermore, studies in adults have
demonstrated an inverse relationship between sleep disorders and poor sleep quality and
outcomes of well-being [55-57] and body composition [58-60]. Therefore, further research is
needed to examine possible modulators of well-being and potential factors influencing the
relationship between well-being and body composition in older adults.
Nutrition plays an essential role in the health, function, and well-being of older adults
[26, 61]. Nutritional strategies can mitigate the development of sarcopenia [62], cardiometabolic
risk [63], physical impairment [61], and poor well-being [64, 65]. Among nutrients, several
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studies have identified dietary protein and the omega-3 polyunsaturated fatty acids (n-3 PUFAs),
eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), as key
supportive nutrients for skeletal muscle health in middle-aged and older adults [26, 66-72]. In
addition to the proposed benefits on skeletal muscle, optimal protein and n-3 PUFA intake can
help maintain energy balance [73, 74], reduce cardiometabolic risk [26, 68, 75], and promote
well-being [72, 76, 77]. Observational studies have proposed dietary intake as an integral factor
separating usual aging from SA [78-80]. Conversely, as the SA construct has developed in the
gerontological literature, nutrition is rarely viewed as an integral component [16, 81-84].
However, this review proposes that nutrition is a foundational factor promoting SA via
regulation of skeletal muscle mass with advanced age.
Therefore, the first objective of this review is to evaluate skeletal muscle as a driver of
low cardiometabolic risk, high physical function, and positive well-being to promote SA. The
second objective of this review is to examine observational and interventional (whole food
and/or supplementation alone, without physical exercise) evidence of protein and n-3 PUFAs on
skeletal muscle to promote the SA outcomes. The final objective of this review is to propose
mechanisms by which combined optimal intake of high-quality protein and n-3 PUFAs likely
play a key role in SA.

The Role of Skeletal Muscle in Successful Aging
Skeletal Muscle in Cardiometabolic Risk. Advancing age is the greatest risk factor for
increased cardiometabolic risk [85] and the possibility of achieving SA decreases with increasing
age [86, 87]. The age-related reduction in skeletal muscle mass and physical function is
associated with increased morbidity and mortality via the development of cardiometabolic-based
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chronic disease such as T2D, CVD, and obesity [33, 61]. Age-related skeletal muscle loss and fat
mass gain are also associated with a higher prevalence of multiple chronic diseases (MCDs) [88].
Once age-related decline in muscle strength, mass, and function fall below established cut-off
points, older adults (≥ 60 years) are classified as sarcopenic [44]. Sarcopenia, now recognized as
an independent geriatric condition and muscle disease [44], is consistently associated with
elevated cardiometabolic risk [10], all-cause mortality [89], and is exacerbated by obesity [90,
91]. Sarcopenia and obesity act synergistically, which increases the risk of chronic disease,
premature disability, and decreased quality of life [92].
The prevalence of obesity has doubled since 1980. Obesity rates continue to rise with
obesity rates in middle-aged and older adults estimated at 44.8% and 42.8%, respectively [93,
94]. Although 9-16% of obese individuals are metabolically healthy [95], midlife obesity is
associated with decreased likelihood for achieving SA [96]. Moreover, obesity has been linked to
the progression of sarcopenia and is associated with an increased risk for disabilities [97]. One
reason that reduced skeletal muscle mass contributes to the accumulation of excess adiposity is
due to its role in energy expenditure [98]. Total energy expenditure (TEE) is the net energy
utilized by the body to maintain homeostatic function, digest nutrients, and conduct movement
[38]. The TEE consists of three basic components: 1) basal metabolic rate (BMR), 2) the thermic
effect of food (TEF) and 3) the thermic effect of activity (TEA) [99]. BMR makes up 60-70% of
TEE and represents the energy required to maintain the body’s homeostatic processes at a rested
fasting state. Skeletal muscle is the primary determinant of BMR and variances in BMR
contribute to the pathogenesis of obesity [31, 32]. Indeed, BMR declines approximately 1-2%
per decade beginning in the third decade of life and is associated with reduced skeletal muscle
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mass and increased adiposity [30, 33]. Importantly, skeletal muscle is a modifiable contributor to
BMR and can be augmented via lifestyle interventions [100].
In addition to absolute adiposity, relative adiposity, the proportion of muscle mass to fat
mass, the lean-to-fat (LTF) ratio, has been linked to an individual’s overall cardiometabolic risk
[101]. For example, data obtained from the Korean Sarcopenic Obesity Study found the lowest
tertile of LTF (appendicular lean mass to visceral fat) was associated with a 5.43 times higher
odds ratio for metabolic syndrome when compared to the highest LTF in older adults [102]. This
is further supported by a large cross-sectional analysis which identified a lower risk of CVD and
all-cause mortality in adults in the highest LTF quartile (appendicular lean mass to trunk fat
mass) [103].
Skeletal muscle is proposed to have a bi-directional relationship with cardiometabolic
health [104]. Skeletal muscle accounts for approximately 40% of total body mass and is
inversely associate blood glucose levels [33]. Furthermore, skeletal muscle is the primary site of
blood glucose disposal, accounts for approximately 80% of postprandial glucose uptake [105],
and is inversely associated with T2D [106, 107]. Indeed, middle-aged men in an early stage of
T2D have low-density skeletal muscle area compared to healthy individuals [108]. Therefore, the
maintenance of skeletal muscle over the lifespan is critical in regulating blood glucose
homeostasis, reducing cardiometabolic risk, and in the prevention of chronic disease to promote
SA.
The Role of Skeletal Muscle in Physical Function. Independence is a necessary facet of
SA and is highly correlated with skeletal muscle function in older adults [25, 109]. Skeletal
muscle plays a critical role in preserving physical performance [110] and muscle strength in
older adults [111, 112]. Moreover, older adults experience an annual decline of muscle strength
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and power between 1.5% and 3.5%, respectively [113]. Low muscle strength and mass are
identified risk factors of all-cause mortality. For example, two longitudinal studies found
community-dwelling men with low grip strength and appendicular lean mass (ALM) had higher
odds for mortality after approximately 10 years [114, 115]. In addition, decreases in strength are
associated with an increased risk of disability in activities of daily living (ADLs). The inability to
complete ADLs is associated with increased cardiometabolic risk, cognitive decline, and
decreased well-being [116]. Furthermore, older adults without ADL limitation have increased
positive outlook and life satisfaction compared to their counterparts with ADL limitations.
The presence of sarcopenia is associated with increased falls, fractures, and muscle mass
loss, further emphasizing the importance of skeletal muscle preservation to ensure SA.
Moreover, a recent exploratory study investigated a physiological model of SA and identified
muscle strength (i.e., HGS and leg extension) as a significant predictor of SA outcomes
including self-rated health, walking speed, and decreased dependency risk at baseline and after
the 9-year follow up period [25]. In addition, a recent analysis from the Nutrition and Successful
Aging Study (NuAge) found muscle mass decline only explained a small part of the variation of
muscle strength and function in healthy older adults [117]. Therefore, further research is needed
to establish a relationship between skeletal muscle and SA.
Skeletal Muscle and Well-being. Well-being is generally defined by emotional wellbeing such as the presence of positive affect states, life satisfaction, and the absence of negative
affect states; and physical well-being such as sleep quality [45-48]. Well-being and health are
closely linked with advanced age [118], albeit a link to skeletal muscle mass is less established.
A recent prospective longitudinal study in hospitalized older adults identified low skeletal
muscle mass as a risk factor for outcomes of well-being such as depression symptoms and
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decreased quality of life [119]. In agreement, longitudinal and cross-sectional analyses have
identified an association between skeletal muscle mass and subjective well-being, health, and
physiological function in healthy older adults [120, 121]. Sarcopenia is also associated with
decreased well-being indicated by quality of life measures (e.g. SF-12, SF-36, SarQol) [122].
However, other cross-sectional analyses have found little to no relationship between sarcopenia
and well-being aside from subjective health measures [21, 123]. Therefore, further research is
needed to confirm a relationship between skeletal muscle and well-being.
In addition, well-being is commonly correlated with muscle strength and physical
performance [118, 124]. For example, a cross-sectional analysis in older men and women found
negative affect states (total mood disturbances, anger, and depression) were negatively correlated
with physical fitness [125]. In agreement, walking speed is significantly associated with high
levels of emotional well-being including decreased depression, anxiety, and fear of falling
accompanied by increased feelings of vitality [126]. Furthermore, adults with reduced muscle
mass and function are nearly twice as likely to have depression compared to their counterparts
[114]. As the associations of skeletal muscle mass, strength, and performance with well-being
gain strength, behavioral modulators of well-being and skeletal muscle are of great interest.
Sleep is not only a behavior necessary to sustain life, but a proposed driver of SA. Sleep
quality and duration is associated with cardiometabolic risk, physiological function, and wellbeing with advanced age [127]. The 2020 Sleep in America poll found 55% of Americans
attributed daytime drowsiness to disrupted sleep quality as opposed to short sleep duration [128].
Americans further reported daytime drowsiness worsened their mood, irritability, and deterred
them from evening socialization and healthy behaviors (e.g., exercise), all which are aspects of
well-being [128]. Approximately 50% of older adults have continual sleep problems such as
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frequent awakenings and increased sleep latency [129]. Poor sleep duration (<7h or >8h of sleep
each night) is associated with low skeletal muscle health [130, 131] and decreased hedonic wellbeing [132]. A relationship between sleep and low skeletal muscle mass, strength and function is
suggested due to the shared positive associations with age, cardiometabolic risk factors, and
decreased well-being [130, 133]. For example, a cross-sectional study of Chinese community
dwelling older adults found sarcopenia, especially in women, to be associated with poor sleep
quality, cognitive decline, malnutrition, and depression [130]. However, more evidence is needed
to establish a relationship between physical function, between skeletal muscle, and sleep.
Well-being, at the physiological level, is associated with cortisol [134], energy
metabolism [135], inflammation (e.g., IL-6 and CRP) [136], and neurological regulators such as
brain-derived neurotrophic factor (BDNF) [137], and orexin-A (OXA) [138]. Although the
potential mechanisms that mediate the relationship between skeletal muscle and outcomes of
well-being are not fully understood, several mechanisms may contribute to well-being. First,
stress, sleep disruption, and advancing age are associated with cortisol levels [139, 140].
Elevated cortisol is associated with an increased risk for sarcopenia, cognitive decline, and
decreased cardiometabolic health via insulin resistance, loss of hypothalamic and hippocampal
glucocorticoid receptors, and alterations in peripheral gene expression [141, 142]. Furthermore,
decreases in cortisol concentrations are reflective of down-regulation of the hypothalamicpituitary adrenal axis (HPA) and subsequently improvements in cardiometabolic health [142].
Second, BDNF, a member of the neurotrophic family, plays a role in neurite outgrowth,
synaptogenesis, and in the prevention of apoptosis [143]. BDNF has been connected to various
physiological functions in the brain relevant to cognitive function, sleep, and mood states [144].
Lastly, human OXA and orexin-B (OXB) are excitatory neuropeptide solely synthesized in the
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lateral and posterior hypothalamic area and project widely throughout the central nervous system
[145]. OXA has been identified as the peptide of greater physiological relevance due to its ability
to rapidly cross the blood-brain barrier by simple diffusion and its lower degradation rate in the
blood [146]. Furthermore, OXA signals two G protein-coupled receptors, orexin receptor 1
(OXR1) and orexin receptor 2 (OXR2) [147]. OXA is associated with facets of well-being such
as arousal, motivation, and regulation of sleep cycles [138, 145]. Hypothalamic expression of
OXA decreases with age [148], plasma levels decrease with obesity [149], and OXA expression
has been identified in human adipose tissue [150]. However, little is known about the effects of
OXA on human skeletal muscle. Contrarily, in avian species, muscle cells secrete and express
OXA and ORX1 and ORX2, respectively [151]. Therefore, further investigation of OXA as a
promoter of well-being through skeletal muscle is warranted and will be discussed later in this
review.

Nutrition and Successful Aging
Nutrition is a key contributor to SA. Poor nutrition can contribute to the development of
sarcopenia and obesity and increase the risk for chronic disease [61, 152, 153]. As the older
population grows and life expectancy continues to rise, it is important to consider optimal
nutritional recommendations that will promote SA in older adults [154]. Several studies identify
dietary protein and n-3 PUFAs as key nutrients for older adults [26, 61, 62, 152, 153].

Dietary Protein Recommendations and Current and Optimal Intake for Older Adults
Current Dietary Protein Recommendations. Dietary protein is a focal point for SA as the
constituent amino acids (AA) are the essential building blocks necessary to sustain life [61]. The
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current dietary protein recommendations have been based on studies that estimate the minimum
protein intake necessary to maintain nitrogen balance [155]. However, the drawback with relying
on these findings is that they do not address age-related anabolic resistance, measure
physiological and behavioral endpoints relevant to skeletal muscle, nor SA outcomes such as
cardiometabolic risk, physical function, and well-being. Currently, the Food and Nutrition Board
of the Institute of Medicine has set the recommended daily allowance (RDA) for protein at 0.8
g/kg/day, covering the minimum requirements of 97-98% of all healthy adults >18 years of age,
including older adults [156]. In addition to the RDA, recommendations for protein intake are also
provided in the context of a complete diet within the Acceptable Macronutrient Distribution
Range (AMDR) [157]. The AMDR expresses protein intake recommendations as a percentage of
total caloric intake (10-35% of daily energy intake from protein) and is more relevant in the
context of a complete diet than the RDA [67]. The AMDR upper value of 35% far exceeds the
RDA of 0.8 g/kg/day by approximately four times at ~3.0g/kg/day. Surprisingly, the current
percent daily value (DV%) for protein is based off of 50 grams of dietary protein in the context
of a 2000 kcal/d diet equating to 10% of daily intake, the minimum amount of daily protein
according to the AMDR. Contrarily, a moderate or high consumption of 1.2 g/kg/day to 2.0
g/kg/day of dietary protein easily falls within the AMDR and should be considered for older
adults to preserve muscle mass, strength, and performance to promote SA [61, 66, 158].
Therefore, the upper range of the AMDR provides an appropriate recommendation, within
dietary guidelines, to promote SA
Recommendations for Dietary Protein Intake for Successful Aging. Recent dietary
protein and aging research has focused on the optimal daily and per meal intake to promote
skeletal muscle mass and function in older adults [159-161]. Optimal protein intake, defined in
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terms of skeletal muscle, is the minimal dose of protein intake that stimulates a maximal anabolic
response and maintains or improves skeletal muscle mass and function over time [162, 163].
According to the PROT-AGE recommendations, older adults are recommended to consume 2530 g (e.g., 0.4g/kg/bw per meal) [164] of protein and 2.5-2.8 g of the branched-chain amino acid
(BCAA) leucine per meal, equating to 1.0-1.2 g/kg/day of dietary protein intake [165, 166]. In
line with these recommendations, a cross-sectional study in healthy older adults found a positive
associate between daily protein distribution of >25 g of protein per meal and appendicular
skeletal muscle [167]. According to NHANES data, older men and women consume 1.01 ± 0.03
g/kg/day and 0.97 ± 0.04 g/kg/day of dietary protein, respectively [161, 165, 168]. However,
19.21 ± 2.11% and 13.17 ± 1.33% of older men and women respectively fall below the RDA for
dietary protein [168]. In addition, protein consumption in older adults follows a highly skewed
distribution pattern with a disproportionate amount of daily protein consumed during the evening
meal (<60% of daily protein) and far less at breakfast [169]. For example, a cross-sectional
analysis found older men and women consumed 11.4 ± 0.4 g and 15.3 ± 0.5 g of protein at
breakfast compared to 44.5 ± 1.0 g and 44.8 ± 1.0 g at dinner [170].
One potential benefit of optimal dietary protein intake and distribution is to overcome
anabolic resistance, the reduced response to low doses of protein and AA that occurs with age
[171, 172]. There appears to be an AA threshold for stimulation of muscle protein synthesis
(MPS) (fractional synthesis rate) of ~2.5 g leucine, ~15 g of EAA, or ~30 grams of high-quality
protein [173]. For example, Pennings et al. [174], examined ingestion of 10, 20, and 35 g of
whey protein isolate in healthy older adult men (73 ± 2 y). AA absorption and subsequent
stimulation of MPS (fractional synthesis rate) were limited at post-ingestion of 10 g of protein,
but increased from basal levels in a dose dependent manner following 20 g (16 ± 13 %) and 35 g
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(44 ± 16 %) of protein. In addition, Symons et al. [163] investigated the effect of 30 g and 90 g
of high-quality beef protein and found both quantities were equally effective in stimulating MPS
(~50% increase) in healthy young and older men. Although intakes of protein beyond ~30 g may
not further increase MPS, research is suggestive of further benefits via suppression of catabolic
processes and inflammation as well as promotion of cardiometabolic health and physical
function in favor of SA [68, 175]. As older adults may consume dietary protein in a skewed
distribution and below levels recommended by aging experts, protein supplementation and/or
increases in dietary protein exists as a strategy to mitigate anabolic resistance and improve
functional outcomes of SA in older adults.
Dietary Protein and Cardiometabolic Risk. Although most older adults fall within the
RDA for dietary protein intake [168], there is increasing evidence that diets with greater levels of
high-quality protein, especially at the expense of simple carbohydrates, may decrease
cardiometabolic risk [176]. Proposed therapeutic effects a high protein diets include lower
energy intake associated with increased thermogenesis [39] and preservation of skeletal muscle
[177] translating to decreased waist circumference, systolic and diastolic blood pressure,
triglycerides, fasting insulin, and increased HDL [61, 66, 178, 179]. According to observational
data, higher protein diets (1.0 to 1.5 g/kg/day) are associated with lower BMI and waist
circumference and higher HDL cholesterol levels compared to protein intake at the RDA [180].
Similarly, a cross-sectional analysis of middle-aged men (50.5 ± years) found individuals who
consumed BCAAs in the highest quartile (<0.17g/kg/day) had a lower incident of
cardiometabolic risk factors [181]. Furthermore, a recent cross-sectional analysis in female twins
(18-76 years) found higher BCAA intake was associated with lower insulin resistance, systolic
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blood pressure, and adiposity related metabolites [182]. Overall, dietary BCAA intake exists as a
possible strategy to restore cardiometabolic health and promote SA [183].
Several randomized, controlled clinical trials (RCTs) have observed cardiometabolic
benefits following high-protein diets and/or supplementation when coupled with weight-loss
and/or exercise in middle-aged and older adults [184-186]. However, RCTs under caloric
maintenance remain limited, especially in older adults. Therefore, weight maintenance trials will
be reviewed. Layman et al. [187] investigated the effect of following a high protein diet (high
protein: 1.6g/kg/day, ~30% energy) versus the protein RDA (0.8g/kg/day; ~15% energy) after
four months of weight loss on long-term weight maintenance. The high-protein diet was more
effective for long-term fat loss (38% greater fat loss) and produced sustained reduction in
triglycerides and increases in HDL cholesterol [187]. In line with these findings, a meta-analysis
of long-term weight maintenance diets, found individuals following higher protein, low
carbohydrate diets had a higher prevalence of sustained weight-loss and decreases in fasting
triglycerides and insulin levels supporting a cardiometabolic benefit [188]. Contrarily, a RCT
examining the effects of a high-protein diet (high protein: 1.4 g/kg/day versus RDA 0.8g/kg/day)
in older adults (70 ± 5 years) observed no differences in outcomes of cardiometabolic risk (e.g.,
HDL, LDL, fasting glucose, blood pressure) nor markers of inflammation including: tumor
necrosis factor-alpha (TNF- α), interleukin-6 (IL-6), and c-reactive protein (CRP) [189]. In
addition to dietary protein supplementation, EAA mixtures may improve cardiometabolic health
in older adults. For example, an RCT implementing two doses of 8g/day of EAAs (10:00 AM
and 5:00 PM) observed significant reductions in insulin resistance, TNF- α, and increases in
insulin-like growth factor 1 (IGF-1) and lean body mass (LBM) [190]. In agreement,
Scognamiglio et al. [191] supplemented 12g/day of EAA for 3 months and observed significant
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improvements in myocardial performance with non-significant improvements in systolic and
diastolic blood pressure compared to control. Further RCTs are needed to establish the
relationship between protein intake and cardiometabolic health in the absence of weight loss in
healthy middle-aged and older adults.
The Role of Dietary Protein in Physical Function. As previously reviewed, most
middle-aged and older adults consume, at minimum, the RDA for dietary protein. Observational
studies indicate that higher protein intakes are associated with increased strength and physical
performance, comprehensively reviewed elsewhere [192]. In addition, observational data
suggest, the quality of dietary protein (e.g., animal versus plant sources of protein), defined by its
ability to deliver all EAA in proportion to individual requirements, may be an important
modulator of muscle strength and performance [193, 194]. For example, data from the
Framingham Offspring study indicated that animal-protein foods rather than plant-based protein
foods were positively associated with physical performance in older adults [195]. However,
observational studies have also indicated total protein, regardless of source, is positively
associated with muscle strength and performance [196, 197]. In general, these observational data
suggest that increased dietary protein intake promotes and preserves muscle strength and
performance to promote SA.
However, several studies have reported inconsistent results regarding the impact of
protein and AA supplementation on strength and physical performance with some reporting a
positive [198, 199] and others reporting no effect [200, 201]. However, heterogeneity is
commonly high in regard to the studied population (e.g., healthy, frail, diabetic, or sarcopenic
individuals), duration, and supplement form and dose. However, some studies have identified a
positive effect of increased dietary protein and EAA with physical function in older adults [202-
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205]. For example, Mitchell et al. [206] conducted a well-controlled feeding study of 35 healthy
older men to test the effect of protein at the current RDA (0.8 g/kg/day) compared to two times
the RDA (1.6 g/kg/day) for 10 weeks and found the higher protein diet led to increased power
(e.g., knee extension peak power) and strength preservation (handgrip strength) compared to no
change and decreases in the control group respectively. Moreover, in the absence of exercise
[207], weight-loss [208], and multi-nutrient supplementation (e.g., vitamin D, E, and B vitamins)
[209], few studies have investigated the effect of increased protein supplementation on outcomes
of muscle strength and physical performance in healthy middle-aged and older adults. However,
evidence does suggest EAAs promote physical function in older adults with facets of metabolic
syndrome and chronic disease. For example, Borsheim et al, supplemented 11g of EAAs +
arginine two times daily for 16 weeks in older adults with impaired glucose tolerance and found
a significant increase in physical performance measured by gait speed, timed 5-step test, and
timed floor-transfer test compared to baseline [210]. Furthermore, according to a meta-analysis
of 36 studies, the effectiveness of protein in combination with micronutrients supplementation
significantly increases in studies with a duration ≥ 6 months and in frail or malnourished study
populations [211]. Therefore, more evidence is needed to establish the effect of protein and AA
on older adults to promote muscle strength and function prior to the development of frailty and
chronic disease to ensure SA.
The Role of Dietary Protein in Well-being. Dietary protein and its constituent AAs are
essential for maintaining neuronal function and have been linked to affect states in older adults
[69]. The effect of dietary protein and depression in older adults has partially focused on the AA
tryptophan. Tryptophan, the precursor to serotonin, cannot be synthesized in adequate amounts
in the body, therefore must be obtained from dietary sources [212]. Low plasma tryptophan is a
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risk factor for depression as it leads to decreased serotonin levels [213]. Data from NHANES
2001-2002 (n=29,687) found tryptophan intake to be inversely associated with subjective
depression and positively associated with subjective sleep duration despite even the lowest levels
of usual intake surpassing the EAR for tryptophan [214]. The average intake of tryptophan was
826 ± 3 mg/day which is approximately three times the EAR of 4 mg/kg/day tryptophan (~280
mg/day for a 70-kg adult), albeit adults aged 51-70 and ≥ 71 y consumed 9% and 22% lower
levels on average, respectively.
Sleep is an integral facet of well-being and is influenced by diet with equivocal findings
in regard to dietary protein [215]. However, substantial observational data suggest dietary protein
intake is associated with improvements in sleep [216-218]. For example, Kant et al. [216]
conducted a cross-sectional analysis using NHANES data and found short sleepers consumed a
lower percentage of protein, higher total sugars, a lower prevalence of breakfast consumption,
with a higher frequency of snacks. Furthermore, according to a systematic review and metaregression of cross-sectional studies and RCTs [217] good sleeper, defined as sleep duration ≥ 7
hours, PSQI global sleeping score ≤ 5, sleep latency ≤ 30 minutes, and sleep efficiency >85%,
consumed greater amounts of dietary protein and a lower percentage of energy from dietary
carbohydrates and fat than poor sleepers. These studies suggest that consuming greater amount
of dietary protein may benefits sleep quality and healthy adults.
Few RCTs have investigated the effect of dietary protein on sleep quality and duration in
middle-aged and older adults. One RCT conducted by Zhou et al. [219], assessed the effect of a
high protein energy restricted diet for 16-weeks on middle-aged obese adults (56 ± 3 y) and
found high protein diets to improve sleep quality. The mechanism of the effect of protein on
sleep after acute feeding may be related to tryptophan, tyrosine, and the synthesis of the brain
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neurotransmitters serotonin, melatonin, and dopamine [77, 220]. As BCAAs are transported into
the brain across the blood brain barrier via the same carrier that transports large neutral amino
acids (LNAA), phenylalanine, tyrosine, and tryptophan, the competition between BCAAs and
the aromatic amino acids may influence synthesis of some neurotransmitters, including
dopamine, norepinephrine, and serotonin [221]. Although higher protein intake results in greater
postprandial plasma AA, high protein diets do not translate into constant low tryptophan- or
tyrosine-to-LNAAs ratios. For example, Zhou et al. [219], did not find acute changes in the ratio
of tryptophan to LNAAs and tyrosine to LNAAs. The relationship between acclimated protein
intake and the body’s ability to produce or remove brain tryptophan and serotonin is yet to be
elucidated. However, in an intervention conducted in rhesus monkeys, a higher protein diet
increased plasma and cerebrospinal fluid concentrations of tryptophan and serotonin metabolites
indicating a probable beneficial sleep effect [222]. More long-term RCTs are needed to
investigate the relationship between tryptophan: and tyrosine: LNAA ratios in older adults
consuming high protein diets. Therefore, the beneficial effect of dietary protein on sleep has yet
to be established.

Dietary Omega-3 Polyunsaturated Fatty Acid Recommendation, Current, and Optimal
Intake
Current Omega-3 Polyunsaturated Fatty Acid Dietary Recommendations. n-3 PUFAs
play a crucial role in SA [223]. n-3 PUFAs are a group of polyunsaturated fatty acids
characterized by a double bond at the third carbon from the methyl (-CH3) end of the
hydrocarbon chain. The human body is able to metabolize and convert alpha-linolenic acid
(ALA; 18:3 n-3), the essential plant-based n-3 PUFA, to the more biologically active and
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therapeutic longer chain n-3 PUFAs eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic
acid (DHA; 22:6 n-3) by a series of desaturation and elongation reactions primarily in the liver
[224]. The conversion rate to EPA and DHA is inefficient in humans and is further inhibited by
age emphasizing the importance of dietary intake [225]. The 2015–2020 Dietary Guidelines for
Americans (DGA) acknowledges the benefits of n-3 PUFAs and recommends a combined daily
intake of 250 mg/day EPA + DHA equating to approximately 8 oz per week of a variety of fish
in adults with and without CVD [166]. Furthermore, The American Heart Association’s (AHA)
Strategic Impact Goal Through 2020 and Beyond recommends at least two 3.5-oz fish servings
per week, with an emphasis on oily fish (e.g., salmon, mackerel, herring), providing ~500
mg/day of EPA and DHA [226]. DRIs have yet to be established for EPA and DHA and DGA
and AHA recommendations are derived from findings from prospective cohort studies and RCTs
suggesting EPA and DHA rich eating patterns are associated with reduced risk of CVD [166]
The U.S. diet falls short of n-3 PUFA DGA and AHA recommendations. According to
NHANES data (2003–2008) adults ≥ 50 years currently consume far below recommended levels
of fatty fish (~ 0.19 oz/day) equating to 58 mg/day and 81 mg/day EPA and DHA, respectively
[227]. NHANES data further demonstrates that, even after accounting for supplement intake and
potential conversion of plant-based n-3 PUFAs, daily EPA and DHA intake from foods and
supplements is well below recommendations with ~20% and ~10% of adults ≥ 55 years meeting
or exceeding the DGA and AHA recommendations, respectively [228]. The low consumption of
n-3 PUFA in the Western diet is of particular importance in the older population. Older adults
require higher amounts of n-3 PUFAs due to decreased absorption, n-3 PUFA capacity to cross
the blood-brain barrier, and physiological capacity to convert shorter chained fatty acids (ALA)
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into longer fatty acids (EPA and DHA) resulting in a lower composition of n-3 PUFAs in body
tissue [229, 230].
The Recommended Intake of Omega-3 Polyunsaturated Fatty Acids in Aging. To date,
although somewhat conflicting, a growing number of studies indicate that n-3 PUFAs may exert
beneficial effects on the aging brain [231, 232] and skeletal muscle [233] which could result in
decreased cardiometabolic risk, improved physical function, and increased well-being. The
inconsistent findings may be attributed to the inconsistent doses (~200 mg to 5 g) and duration
(~4-wks to 6 months) of RCTs, since n-3 PUFA uptake increases in a time- and dose-dependent
manner [234, 235]. For example, Yee et al. [234] supplemented four varying daily doses of n-3
PUFA for six months ranging from 0.84 g (0.47 g EPA and 0.37 g DHA) to 7.56 g (4.2 g EPA
and 3.36 g DHA). Over the 2- to 6-month period, the two highest doses (5.04 g and 7.56 g)
resulted in a significant increase in total serum lipid EPA and DHA concentrations [234].
Importantly, maximum tissue uptake is tissue dependent and has been reported for plasma
phospholipids (56 days), erythrocytes (180 days), adipose tissue (indefinite), [236] and more
recently, skeletal muscle (≥ 28 days) [237].
Recently, dietary and supplemental n-3 PUFAs have received considerable attention in
the context of nutrition, aging, and skeletal muscle [229, 233, 238]. The beneficial impact of n-3
PUFAs on health is often related to the replacement of omega-six polyunsaturated fatty acids (n6 PUFAs) by n-3 PUFAs in cell membrane phospholipids [239]. It is well recognized that
Western diets have considerably higher n-6 PUFAs: n-3 PUFAs ratios than is considered optimal
(15:1-20:1 versus 1:1-4:1) [240]. This shift in the n-6 PUFAs: n-3 PUFAs acid ratio in cell
membranes has been shown to induce changes in numerous biological processes related to agerelated decline including the expression of pro- and anti-inflammatory lipid mediators and
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cytokines [239], gene expression [241], and is associated with increased chronic disease risk
[242], functional impairment [63, 243], and depression [65]. n-3 PUFA supplementation has
recently been observed to increase the relative and absolute EPA and DHA incorporation into
skeletal muscle phospholipids [237]. The incorporation of n-3 PUFAs into skeletal muscle
phospholipids supports observational findings of a positive and dose dependent relationship
between fatty fish consumption and grip strength [244].
RCTs indicate ~3-5 g/day of combined EPA and DHA can promote skeletal muscle
health and mass in older adults [26, 236]. The effect of n-3 PUFAs on skeletal muscle mass in
adults is strengthened in the presence of an anabolic stimulus such as high-quality protein and/or
EAA [245, 246]. For example, Smith et al., [245] supplemented ~ 4g/day of combined EPA and
DHA for 8-weeks and found, in the presence of insulin and AAs, MPS rates increased by ~100%
in older adults with no changes in basal MPS. Interestingly, inflammatory markers were
unaffected throughout 8 weeks, with anabolic signaling proteins mTORC1 and p70s6k
upregulated suggesting a possible mechanism by which n-3 PUFAs may have an anabolic effect.
Therefore, we hypothesize that n-3 PUFAs may act on skeletal muscle as an anabolic primer,
such that AAs/ high quality protein elicits a greater response when there is greater n-3 PUFA
presence in skeletal muscle [236].
The Role of Dietary Omega-3 Polyunsaturated Fatty Acids in Cardiometabolic Risk. n3 PUFA supplementation is an opportunity to decrease cardiometabolic risk as U.S. adults
consume well below recommended levels [227]. In fact, the most commonly cited health benefit
associated with n-3 PUFAs intake is cardiometabolic health [247] via mitigation of inflammation
[248]. Seminal research in Greenland Inuit people first suggested high EPA and DHA intake was
responsible for low CVD mortality [249]. Moreover, the Zutphen study, conducted in the
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Netherlands, followed middle-aged adults over 20 years and showed a positive relationship
between fish consumption and CVD prevention [250]. In agreement, U.S. prospective cohort
studies have observed an association between higher circulating EPA and DHA and lower total
mortality and coronary heart disease risk in older adults [251]. However, recent studies have
challenged the efficacy of n-3 PUFA supplementation for the management of CVD risk due to
inconsistent findings [252].
In RCTs, EPA and DHA supplementation in older adults on cardiometabolic risk is
conflicting. For example, a 12-week RCT supplementing n-3 PUFAs in older women (N=24;
EPA: 360mg/day; DHA: 1290mg/day) observed a 29% reduction in triglycerides with no effect
on fasted blood glucose or insulin [253]. In agreement, a study supplementing n-3 PUFAs for 3months (N=74; EPA:540mg/day; DHA:360mg/day) in middle-aged women (51.6 ± 7.8 years)
found fish oil alone reduced triglycerides and LDL cholesterol by 5.4% and 8.4% respectively
[254]. In contrast, n-3 PUFA supplementation (EPA: 1860mg/day; DHA: 1500mg/day) for 6
months was not effective in lowering blood lipids (e.g., TG, HDL, LDL) in healthy older adults
[255]. However, muscle mass and strength were significantly improved, indicating n-3 PUFAs
may also reduce overall mortality and cardiometabolic risk apart from blood lipids and via
muscle mass and quality. Similarly, in postmenopausal women, n-3 PUFA supplementation did
not affect markers of inflammation (e.g., TNF- α, IL-6 and CRP), but improved markers of
physical performance (e.g., walking speed) [256]. An extensive 2018 meta-analysis of 79 RCTs
found EPA and/or DHA to have little or no effect on mortality or cardiovascular health [257].
but did not consider outcomes of muscle mass or quality. Therefore, due to the strong
association between cardiometabolic risk and skeletal muscle, future n-3 PUFA research should
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be directed towards simultaneous evaluation of traditional markers of cardiometabolic risk in
conjunction with skeletal muscle mass, strength, and function (reviewed in later sections).
Logan et al. [253] investigated the effects of 12-week n-3 PUFA (Total: 3 g/day; EPA
and DHA) supplementation on body composition, strength, physical function, inflammatory
markers, metabolic rate, and substrate oxidation in community dwelling older women compared
to a placebo olive oil control group. The n-3 PUFA group had a 4% increase in muscle mass, a
7% improvement in the “Timed up and go test”, a 14% increase in RMR, 19% increase in fat
oxidation, and 10% and 27% increases in energy expenditure and fat oxidation during exercise
respectively with no differences in inflammatory markers.
The Role of Dietary Omega-3 Polyunsaturated Fatty Acids in Physical Function.
Recently, dietary n-3 PUFAs have received considerable attention in the context of optimizing
physical function in older adults. First, observational studies have identified a positive
relationship of n-3 PUFAs and strength [244, 258] and physical function [259, 260]. Furthermore
RCTs, notably two seminal RCTs in healthy middle-aged and older adults [245, 261], identified
a potential muscle anabolic effect of combined EPA and DHA [262]. In addition to the observed
anabolic effect of n-3 PUFAs, RCTs have identified a strength and performance effect of n-3
PUFAs in middle-aged and older adults. For example, Smith et al. [255] assessed the effects of 6
months of n-3 PUFA (EPA: 1.86 g/day; DHA: 1.5 g/day) supplementation on muscle mass and
function in older adult men and women. n-3 PUFAs significantly increased muscle thigh volume
(3.6%), handgrip strength (2.3 kg), and 1-repetition max (4.0%) with a non-statistical increase in
isokinetic power (5.6%) when compared to a placebo group. Similarly, Logan et al. [253]
investigated the effects of 12-week n-3 PUFA (total: 3 g/day; EPA and DHA) supplementation
on body composition, physical function, inflammatory markers, metabolic rate, and substrate
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oxidation in community dwelling older women compared to a placebo olive oil control group.
The n-3 PUFA group had a 4% increase in muscle mass and a 7% improvement in the “Timed up
and go test”. In contrast, other RCTs have failed to show benefits of n-3 PUFAs in older adults.
For example, Kryzminska-Siemaszko et al. [263] investigated the effect of 12-week n-3 PUFAs
supplementation (Total: 1.3 g/day; EPA: 660 mg/day; DHA: 440 mg/day) on body composition
and physical function in older adults (74.6 ± 8 years) with decreased muscle mass and found no
significant differences in handgrip strength, “Timed up and go test”, or gate speed. The lack of
significance may be attributed to the low dose of n-3 PUFAs (<4 g/day). The majority of
available data suggest diets including n-3 PUFAs increase physical function to promote SA.
However, more research is needed to confirm these conclusions [264].
The Role of Dietary Omega-3 Polyunsaturated Fatty Acids in Well-being. One of the
primary symptoms of poor well-being in the older population is depression [265]. n-3 PUFAs are
a promising strategy to prevent and mitigate depression, partially, due to the incorporation into
cerebral tissue as DHA levels fluctuate with diet, age, and sex [225]. Low consumption of n-3
PUFAs results in decreased brain DHA levels [266]. Brain inflammation progressively increases
with age, but increased intake of DHA and EPA reduce inflammation by displacing arachidonic
acid and cholesterol from the cell membrane [267]. For example, a recent systematic review and
meta-analysis of RCTs in older adults (≥ 65 years of age) with depression evaluated the effects
of n-3 PUFA supplementation and found an overall positive effect only in individuals with mild
to moderate depression [76]. In addition, a longitudinal cohort study in adults 55-85 years
(Hunter Community Study) found n-3 PUFA consumption to be inversely associated with
depression [268]. Patients with depression have been reported to have low n-3 PUFA levels in
RBC membrane (mg/100mg of total phospholipids) and a low dietary intake of DHA and EPA
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[269]. Although n-3 PUFAs have been investigated in the context of depression, little is known
on the effect of n-3 PUFAs on positive affect states.
In addition to depression, a link between sleep and n-3 PUFAs has been observed in
adults. Observational evidence by Dashti et al. [216] found an association between recommended
sleep duration and low carbohydrate and increased n-3 PUFA intake in older women (65-85
years). The n-3 PUFA index, calculated by the EPA and DHA content of erythrocyte
membranes, expressed as a percentage of total fatty acids, is associated with sleep quality,
metabolic health, and mortality [270]. A low n-3 PUFA index has been identified in obstructive
sleep apnea patients [271]. In a randomized, double blind pilot study, postmenopausal women
with greater baseline DHA RBC content presented less signs of frailty [256] indicating a
relationship between frailty, sleep, and n-3 PUFA status. However, RCTs investigating the effect
of n-3 PUFAs, DHA and EPA, are scarce in middle-aged and older adults. Hansen et al.
investigated the effect of 6-months of fatty fish consumption of 300 g of Atlantic salmon three
times per week (4.8g EPA and DHA per serving) in adults 21-60 years of age compared to a
control group. The investigators found the fish group had significantly lower sleep latency at the
conclusion of the intervention [272]. However, the sleep latency did not change in the
intervention group, but worsened in the control group. Therefore, it cannot be concluded that
fatty fish consumption is beneficial for sleep in this study. Further RCTs are needed to
investigate the role of n-3 PUFAs and sleep in the older population.
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Simultaneous Supplementation of Protein and Omega-3 Polyunsaturated Fatty Acids on
Successful Aging
Increasing dietary protein and n-3 PUFAs intake is a potential strategy to promote
skeletal muscle and SA in middle-age and older adults. However, RCTs examining the effect of
dietary protein and n-3 PUFA combined supplementation have solely been conducted in the
context of a multi-nutrient supplement or in combination with caloric restriction and/or exercise
[273-275]. For instance, Bell et al. [274] investigated the effect of a multi-nutrient supplement
that had 30 g of WPI, 2.5 g of creatine, 500 IU of vitamin D, 400 mg of calcium, and 1.5 g of n-3
PUFAs (700 mg EPA; 445 mg DHA), that was consumed twice daily. After six weeks of
supplementation, LBM and muscle strength increased in healthy older adults. In addition, Su et
al. [275] conducted a caloric restriction intervention in obese women (> 40 years) and found a
high-protein meal replacement (25 g) and fish oil (2,130 mg) reduced percent android fat and the
prevalence of metabolic syndrome by almost twofold in comparison to caloric restriction alone.
As RCTs examining the combined effect of dietary protein and n-3 PUFAs are scarce, the
modest effects observed in the described trials warrant further investigation.

Mechanisms of Successful Aging
According to the existing literature, combined doses of n-3 PUFAs of approximately 4
g/day and dietary protein of approximately 25-30 g/meal meets the suggested recommended
nutritive doses to activate MPS in middle-aged and older adults [63, 162]. The mechanisms
explaining an additive effect of protein and n-3 PUFAs remain to be fully understood. However,
we speculate that n-3 PUFAs may promote SA outcomes by increasing neurotransmitter
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sensitivity, membrane fluidity, and by enhancing the anabolic effects and neurotransmitter
synthesis from EAA [276].
First, research suggests n-3 PUFAs and EAAs from dietary protein can improve the
domains of SA via activation of the mammalian/mechanistic target of rapamycin (mTOR)
pathway. mTOR is a serine-threonine kinase that serves as a nutrient, growth factor, and energy
sensor and exists in two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex
2 (mTORC2) [277]. The complex mTORC1 is involved in the activation of protein synthesis in
skeletal muscle [278]. Leucine, a well-established regulator of protein synthesis [279], activates
mTORC1 [280-285] in tissues such as the brain [281] and skeletal muscle [282], through Sestrin
2 [286]. In addition, the mTORC1 pathway is a regulator of MPS [287], muscle regeneration and
repair [288], muscle protein breakdown (atrophy) [289], cerebral cellular survival [290], and is
activated following n-3 PUFAs supplementation combined with AA infusion [246, 261].
Furthermore, stimulation of mTORC1 is a suggested approach to prevent age-related fiber
atrophy, increase LBM, and improve physical function with advanced age [291, 292]. However,
the combined effect of n-3 PUFAs and AA dietary intake on mTORC1 activation is unknown.
Second, with respect to the cellular membrane, n-3 PUFAs may increase neurotransmitter
uptake and release. Acetylcholine is a neurotransmitter that supports muscle contraction, making
synaptic transmission quicker at the neuromuscular junction resulting in a quicker contractility as
well as improved cognitive function [276]. Moreover, acetylcholine interacts with additional
excitatory transmitters in the brain such as OXA [293]. Fadel et al. [293-295] have identified a
relationship between OXA and improved age-related cognitive decline, primarily via
hippocampal and hypothalamic regulation via the cholinergic system. However, the effect of
nutrients on the relationship between OXA, acetylcholine, and SA is largely unknown. Few
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studies, primarily animal studies, have investigated the effect of dietary protein and n-3 PUFAs
on OXA. Elliot et al. [296] delineated BCAA supplementation as a potential therapy to restore
glutamate density to orexin neurons in mice with traumatic brain injury. Furthermore, in a study
evaluating the effects of a high-protein diet in obese Zucker rats found that obese Zucker rats
receiving the higher protein diet had higher levels of plasma orexin compared to the other
treatments. [297]. Currently little research has investigated the effect of n-3 PUFAs on orexin
neurons. A study examining the effect of fish oils and vegetable oils (olive, sunflower, linseed,
and palm) found no effect on the presence or distribution of OXA, OXB, and OX2R in the
hypothalamus and gastrointestinal system in rainbow trout [298]. Animal studies have shown
dietary n-3 PUFAs to protect neurons from apoptosis by reducing oxidative stress [299] and
therefore may protect again the loss of orexin neurons with age, albeit further research is needed
to support or refute this theory.
In vitro analyses indicate OXA activates mTORC1 via extracellular calcium influx and
lysosome pathway involving Rag GTPases and Erk/Akt-independent pathways [300]. It is
probable that elevated OXA concentrations and protein and n-3 PUFA supplementation may
further stimulate mTORC1 with age, resulting in inhibition of catabolic pathways linked to agerelated decline in OXA, skeletal muscle, and well-being. Furthermore, n-3 PUFAs may enhanced
OX2R signaling via incorporation into cellular membranes [225]. Given that neuronal function
and anabolic signaling decline with advanced age, combined n-3 PUFA and protein
supplementation may be a potential interventional strategy to mitigate age-related decline.
However, further investigation of the mechanisms underlying the proposed effects are warranted.
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Conclusion
Age-related loss of skeletal muscle mass increases the likelihood of cardiometabolic risk,
loss of physical function, and poor well-being. These concerns continue to grow as the older
population increases in the U.S. On the basis of the reviewed evidence, we propose that
increased protein above the RDA and n-3 PUFAs above the DGA recommendations for middleaged and older adults is required for older people to maintain skeletal muscle mass and to
promote SA. Given that sarcopenia is, in part, underpinned by the reduced ability of dietary
protein to stimulate MPS, increasing amounts of protein coupled with increased incorporation of
n-3 PUFAs into cellular membranes may result in better preservation of muscle mass and
neuroregulation. However, more research is needed to establish an additive effect of protein and
n-3 PUFA on skeletal muscle mass, cardiometabolic risk, physical function, and well-being as a
possible strategy to promote SA. As part of a multimodal intervention, increasing dietary protein
and n-3 PUFA intakes may increase the prevalence of SA in middle-aged and older adults,
beyond muscle mass maintenance. However, more research is needed.
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CHAPTER 3. Beef and Nutrients Found in Beef Positively Impact Well-Being in Healthy
Adults ≥ 50 Years of Age: A Meta-Analysis and Systematic Review of Randomized
Controlled Trials

Abstract
Shifts in well-being occur as we age. Nutrients found in beef are associated with
outcomes of well-being such as physical and cognitive function, lean body mass, and mood.
However, it is unclear how beef and nutrients found in beef impact well-being in healthy adults ≥
50 years of age. The objective of this meta-analysis and systematic review was to evaluate the
available evidence of randomized controlled trials (RCTs) assessing the effect of beef and
nutrients found in beef on well-being in healthy adults ≥ 50 years of age. We hypothesized that
RCTs using beef, or nutrients found in beef, would improve well-being outcomes in healthy
adults > 50 years of age. PubMed, CINAHL, and Web of Science were searched up to September
30, 2019 for eligible RCTs. Nine RCTs with 55 effect sizes were included in the meta-analysis.
The random-effects model indicated an overall positive effect of beef and its nutrients on wellbeing (g = 0.20, 95% CI = [0.05, 0.34], p=0.01), with substantial heterogeneity. An overall
positive effect of amino acids (g=1.53, 95% CI: [1.04, 2.03], p<0.01) and protein (g=0.71, 95%
CI: [0.52, 0.92], p<0.01) was found on well-being outcomes with no effect of arginine, vitamin
B-12, leucine, and zinc. Physical function (g=0.83, 95% CI: [0.49, 1.17], p<0.01) was influenced
by beef and nutrients found in beef. This meta-analysis identified a need for further research
regarding the effect of beef and nutrients found in beef on defined functional outcomes of wellbeing in healthy adults ≥ 50 years of age. PROSPERO CRD42020145729
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Introduction
The older adult population in the United States is a segment of unprecedented growth [1].
Longer life spans and aging baby boomers will lead to nearly double the population of
Americans ≥ 65 years of age over the next thirty years. Aging increases the risk of developing
chronic diseases such as heart disease, cancer, and diabetes [2], which are responsible for the
majority of health care costs for older Americans [3]. People living with chronic disease often
experience diminished quality of life (QoL) due to gradual physiological and psychological
decline and disability [3, 4]. Shifts in characteristics of QoL, such as decreased grip strength and
cognitive function, begin prior to old age in the sixth decade of life [5-7]. However, advancing
age is not always associated with significant functional regression [8], and some individuals
maintain a successful aging trajectory [9, 10].
Successful aging is commonly defined as a multidimensional concept characterized by
facets of high levels of physiological functioning, active social and emotional engagement, and
beneficial extrinsic factors (e.g. improved nutrient intake and increased exercise) [9, 11-13].
Underlying the framework of successful aging is well-being [14]. Although a single definition
for well-being has yet to be solidified, well-being is defined by the Center for Disease Control
and Prevention (CDC) as positive emotions (presence of positive and absence of negative affect
states), life satisfaction and fulfillment, and positive functioning [15]. Results from
epidemiological studies demonstrate that well-being is associated with self-perceived health,
longevity, healthy behaviors, mental and physical health, social connectedness, and productivity
[16, 17]. In addition, data suggest that well-being is inversely associated with poor lifestyle
factors such as dysregulated sleep quality, low physical activity, decreased lean body mass
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(LBM), and poor diet [18]. However, few clinical trials have investigated the effect of nutrition
on outcomes of well-being prior to the development of disability and chronic disease [19].
Adequate nutrition is a key contributor to successful aging [20]. Diets rich in nutrients
found in high amounts in beef such as protein, essential amino acids, vitamins B-6, B-12, choline
and minerals zinc and iron are associated with improved markers of chronic disease [21-24].
Research has validated the importance of protein intake above the current Recommended Dietary
Allowance [25] of 0.8 grams per kilogram of body weight on strength and physical function for
older adults [26, 27]. High quality protein sources, such as unprocessed meat, are negatively
correlated with frailty [28], chronic disease, and muscle loss [29] in older adults. Beef is high in
nutrients relative to calories [30, 31] and is protein dense (i.e. gram of protein per gram of food
source) [32] when compared to alternative protein sources such as legumes, eggs, and dairy
[21]. For example, a 3-ounce (~84g) serving of lean beef accounts for a fraction of daily calorie
requirements (8.2%), ~25g of dietary protein, ~6.0 mg zinc (40 % daily value (%DV)), 2.2

g

B-12 (37 %DV), 0.4 mg B-6 (18 %DV), and 2.7 mg iron (15 %DV) [33].
Cross-sectional analyses have identified positive associations between unprocessed
beef/lean red meat, LBM, physical function, and nutrient status [34, 35]. However, randomized
controlled trials (RCTs) investigating the effect of beef alone are limited. A recent meta-analysis
and systematic review of clinical trials found beef protein to provide similar benefits to
commonly used whey protein isolate on LBM and exercise performance in adults [36]. In
observational studies, LBM is commonly associated with positive physical and cognitive
functioning, increased longevity, and improved QoL [37-39]. Furthermore, diets higher in
nutrients found in greater amounts in beef, such as vitamin B-6, vitamin B-12, choline, zinc, and
iron, are associated with improved markers of metabolic health [21, 22], but it is unclear how the
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combination of protein and these nutrients impact well-being and QoL in aging adults.
Nevertheless, studies of lean, red meat have reached contradictory conclusions in terms of health
effects, in part because lean meats are often grouped together with processed meats [40-42].
However, recent studies suggest that lean red meat intake, such as beef, is not associated with
increased risk of chronic disease [43-45].
RCTs have found positive benefits following beef consumption in adults when coupled
with weight-loss and exercise, or in the presence of chronic disease [36, 46, 47]. However, RCTs
investigating the effect of beef and nutrients found in beef under caloric maintenance in healthy,
older adults remain limited. Lean beef contributes ~18% and ~22% of the dietary reference
intakes for protein for males and females ≥ 51 years of age, respectively [48]. A recent metaanalysis revealed that beef consumption can promote LBM and exercise performance when
combined with exercise training but did not explore the effect of beef apart from exercise [36].
Other meta-analyses focused on protein [49], vitamin B [50], zinc [51], and iron [52]
supplementation focus on older adults with chronic disease, younger populations, multi-nutrient
supplements, or do not assess outcomes of QoL or well-being. To our knowledge, a metaanalysis of RCTs has yet to summarize the existing data on the effects of beef and nutrients
found in beef on markers of QoL and well-being in older adults.
Therefore, the objective of this meta-analysis and systematic review was to evaluate the
available evidence of RCTs assessing the effect of beef and nutrients found in beef on QoL and
well-being in healthy adults ≥ 50 years of age to promote successful aging. We hypothesized that
RCTs using beef, or nutrients found in beef, would improve the successful aging outcomes, QoL
and well-being, in healthy adults ≥ 50 years of age. We searched PubMed, CINAHL, and Web of
Science databases and the reference list of the selected articles or related reviews for potential
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trials up until September 30, 2019 by using key words such as older adults, beef, dietary protein,
essential amino acids (EAA), branched chain amino acids (BCAA), tryptophan, arginine,
cysteine, glycine, glutamate, vitamin B6, vitamin B12, choline, zinc, and iron. The QoL and
well-being concept included search terms such as “well-being”, “quality of life”, “depression”,
“cognitive function”, “mood”, “sleep”, “physical function”, “frailty”, and “strength”.

Materials and Methods
Approach. This systematic review and meta-analysis of randomized controlled trials was
performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidelines (PRISMA) [53]. The protocol for this meta-analysis was registered in PROSPERO
(CRD42020145729).
Search Methods for Study Identification. Using predesigned search strategies, we
systematically searched PubMed, CINAHL, and Web of Science databases for all RCTs up to
September 30, 2019 investigating the effect of beef and nutrients found in beef on QoL and wellbeing in healthy older adults (aged > 50 years). Three concepts were included in the search:
population, nutrients, and QoL and well-being. The population search terms were “aging adults”,
“older adults”, and “elderly”. The intervention search terms were “beef”, “red meat”, “animal
dietary protein”, “dietary protein”, “essential amino acids”, “branched chain amino acids”,
“leucine”, “tryptophan”, “arginine”, “cysteine”, “glycine”, “glutamate,” “vitamin B6”,
“pyridoxine”, “vitamin B12”, “cobalamin”, “choline”, “zinc”, and “iron”. The QoL and wellbeing concept included search terms as “well-being”, “wellbeing”, “quality of life”,
“depression”, “cognitive function”, “mood”, “sleep”, “physical function”, “frailty”, and
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“strength”. We also searched the reference list of the selected articles or related reviews for
potential RCTs.
Eligibility Criteria. We included RCTs that examined associations between QoL, wellbeing, and beef and nutrients found in beef among healthy older adults (aged ≥ 50 years).
Detailed inclusion and exclusion criteria can be found in Table 1.
Study Selection. Two reviewers independently reviewed the retrieved articles. All
abstracts and titles were screened according to the inclusion and exclusion criteria.
Disagreements were resolved by discussion to achieve consensus. Figure 1 depicts the flow of
information through the different study selection phases including the studies identified,
included, excluded, and the justifications for exclusions.
Study Extraction and Quality Assessment. Two investigators independently retrieved
data regarding the study design. Participant characteristics, supplementation regimens, followup duration, outcome measures, statistical model, and experimental design. We assessed the
quality of the RCTs using the National Heart, Lung, and Blood Institute website quality
assessment tool for Quality Assessment of Controlled Intervention Studies (Table 2) [54].
Outcomes Assessed. The primary outcome was well-being as defined by the RCTs.
Well-being was grouped into four categories: LBM, cognitive function, physical function, and
QoL. Studies were synthesized using effect sizes as the dependent variable and summary
measures [55]. An effect size was computed for each outcome of each included RCT. As a result,
nine articles yielded a total of 55 effect sizes for the meta-analysis. First, to calculate the effect
size Cohen’s d effect size [56], which quantifies the standardized mean difference between the
treatment (T) and baseline (B) groups (control), defined as:
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however, has been shown to overestimate the effect in small studies. Thus, the Hedges’ g [57]
effect size, a transformation of the Cohen’s d was used to correct for small sample bias. Hedges’
g was transformed from Cohen’s d as follows:
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A positive g indicates a benefit of the treatment group, and a negative g indicates a benefit of the
control group.
Heterogeneity Tests. The heterogeneity of effect sizes was evaluated using various
statistical measures. To examine the between-study heterogeneity, the Cochran’s Q statistic [58]
and Higgin’s and Thompson’s I2 [59] were used to assess the degree of heterogeneity. A
significant Q statistic indicates heterogeneity (effect sizes come from different populations),
whereas a non-significant Q statistic indicates homogeneity (effect sizes come from the same
population). The I2 represents the proportion of variability in effect sizes that is not accounted for
by sampling errors. The I2 of 25%, 50% and 75% indicates low, moderate and substantial
heterogeneity, respectively [60]. Subgroup analyses and meta-regression analyses were
conducted to investigate the possible sources of heterogeneity.
Publication Bias. Begg’s funnel plot and Egger’s test were used to statistically evaluate
asymmetry and potential publication bias [61].
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Statistical Analysis
Cohen’s d effect sizes were computed and then transformed to Hedge’s g. The overall
differences between the control and treatment groups were examined using both the fixed-effects
and random-effects models. The two common approaches for modeling effect sizes are 1) the
fixed-effects model that assumes a homogeneous population of effect sizes, and 2) the randomeffects model that assumes a distribution of true effect sizes [55]. More specifically, in a randomeffects model, the variability of the effect sizes comes from both the sampling errors and the
variation of true effects across studies [62]. The random-effects model provides wider
confidence intervals for the effect estimates. In this study, a random-effects model was used to
explore the overall variability of effect sizes and a mixed-effect model (random errors, fixed
moderator effects) was used to evaluate each moderator at a time. The analysis of effect sizes
was conducted using the computer program R [63], with the R packages meta [64] and dmetar
[65]. All statistical tests were 2-sided, and statistical significance was defined as P < 0.5.

Results
Study Characteristics. Nine RCTs fulfilled the inclusion criteria and were included in the
meta-analysis. The characteristics of the chosen studies are shown in Tables 3 and 4. The RCTs
had a total of 864 participants. The RCT sample size ranged from 14 to 249 participants. Six
studies recruited both male and female participants, one study recruited only male participants
and two studies recruited only female participants. The duration of each RCT ranged from 8 to
104 weeks with one acute response intervention lasting 100 minutes. The average length of RCT
was 33 weeks when excluding the acute study. The included RCT nutrients were consumed as a
liquid (n=2), pill (n=6) or whole foods containing beef (n=1). The publication years of the nine
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RCTs ranged from 2005 to 2018 and were sourced from 7 different journals. Outcomes
pertaining to well-being were identified and analyzed separately as physical function (n=17),
cognitive function/mood (n=36) and LBM (n=2) (Table 4). RCTs containing outcomes of QoL
did not meet the search criteria. Five RCTs included outcomes pertaining to physical function,
two RCTs included outcomes pertaining to LBM and physical function and four RCTs included
outcomes pertaining to cognitive function. In addition, there is an inverse relationship between
effect size and study characteristics of study duration, age, and BMI ( Figure 2).
Meta-regression (Table 5) was used to examine study and participant characteristics as
continuous moderators including age, BMI, study duration (time in weeks), and publication year.
Continuous moderators of age (g=-0.02, p=0.02), BMI (g=-0.30, p=0.01) and study length (g=0.01, p<0.01) were significant. There was no effect of BMI or publication year. There was a
significant effect of heterogeneity on all meta-regression factors for continuous moderators
(p<0.01 for all parameters).
Risk of Bias and Quality of Included Studies. The quality assessment score of the RCTs,
as measured by the National Heart, Lung, and Blood Institute website quality assessment tool for
Quality Assessment of Controlled Intervention Studies ranged from 11 to 13 out of a maximum
of 14, indicating that all studies were high quality (Table 2).
Overall Effect of Beef and Nutrients Found in Beef on Well-being. The overall effect of
beef and nutrients found in beef were modeled based on the 55 effect sizes computed from the
outcomes of 9 RCTs, summarized in Table 6. The fixed-effects model indicated an overall
positive effect of beef and nutrients found in beef on well-being in healthy, older adults (g =
0.08, 95% CI = [0.03, 0.13], p<0.01). The significant Q-statistic suggested statistical
heterogeneity among effect sizes (Q (62) = 270.97, p<0.01). This was also supported by the high
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I2 of 80.1%, which indicated 80.1% of the variability in effect sizes was beyond the sampling
errors. Due to the substantial heterogeneity of effect sizes, a random-effects model was fitted,
which estimated a wider confidence interval for each effect. The random-effects model provided
a greater overall effect estimate (g = 0.20, 95% CI = [0.05, 0.34], p=0.01) than the fixed-effects
model. A forest plot (Figure 3) identifies the largest significant positive effects were found in the
article of Scognamiglio et al [66]. An influence analysis [65] was conducted to identify the
influential cases (extremely small or large effects). Five effect sizes were identified to have
remarkably large effects; all came from Scognamiglio et al [66], consistent with what was
observed in the forest plot. These effect sizes largely contributed to the between-study
heterogeneity, and if being removed, the mean effect size g would drop to 0.02 (p=0.49).
Effect of Beef and Nutrients Found in Beef on Outcomes of Well-being. The results of
the subgroup analysis suggest that physical function (g=0.83, 95% CI: [0.49, 1.17], p<0.01) was
significantly influenced by beef and nutrients found in beef. The effect of physical function was
positive reflecting an overall improvement in physical function. There was no significant effect
of beef and nutrients found in beef on other outcomes of wellbeing including LBM or cognitive
function/mood. Sex had a significant impact on effect size. There was a significant positive
effect in studies including both men and women (g=0.22, 95% CI: [0.06, 0.38], p=0.01) with no
effect in females only or males only. The results of the intervention nutrient subgroup analysis
suggest a significant positive effect of amino acids (g=1.53, 95% CI: [1.04, 2.03], p<0.01) and
protein (g=0.71, 95% CI: [0.52, 0.92], p<0.01) with no effect of arginine, vitamin B-12, leucine,
and zinc. There was a significant negative effect of vitamin B-12 + vitamin B-6+ folic acid (FA)
(g=-0.14, 95% CI: [-0.22, -0.064], p<0.01). There was a significant effect of heterogeneity on all
subgroup analyses by moderator categories (p<0.05 for all parameters).
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Publication Bias. There was evidence of publication bias using Begg’s funnel plot and
Egger’s test of the intercept (p<0.01) (Figure 4) [61]. Caution should be taken when interpreting
the results on account of the possible publication bias.

Discussion
To our knowledge, this is the first meta-analysis and systematic review to synthesize
scientific literature regarding the impact of beef and nutrients found in beef on well-being in
healthy adults ≥ 50 years of age. The results suggest that interventions incorporating beef,
protein, and amino acids are potentially beneficial for outcomes of physical function in healthy
older adults. Surprisingly, only one RCT evaluated the effect of beef as a whole food [67] and
only two RCTs [67, 68] examined LBM, physical function, and multiple domains of well-being,
within the same trial.
In the present meta-analysis, only two RCTs evaluated the effect of beef and nutrients
found in beef on LBM and physical function. One RCT evaluated the effect of 7.5 g/d leucine
[68] and the other evaluated the effect of high protein whole foods including beef (1.1 g
protein·kilogram body weight-1·d -1) [67]. There was no effect of leucine or beef on LBM, which
is supported by a previous meta-analysis evaluating the effect of protein supplementation
sourced from non-beef protein sources on LBM [69]. In contrast to these findings, a metaanalysis and systematic review summarizing the effects of protein, not sourced from beef, on
body composition and physical function in older adults found protein significantly increased
LBM compared to the control group [70]. The lack of effect observed in the current metaanalysis, and contradictory findings throughout the literature, are likely attributed to the
inconsistencies in methodology. RCTs showing a beneficial effect of protein supplementation on
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LBM in healthy, older adults commonly use a supplementation period of at least 12-weeks [71,
72] and supplement with higher amounts of protein [73, 74] than what were used in the RCTs
included in this analysis.
Only five RCTs measuring physical function, using 11 different physical function
measurements, were analyzed in this study. These include gate speed/distance [66, 67, 75],
handgrip strength [66, 67, 76], sit-and-stand [67, 75], and 1 repetition maximum (1RM) knee
extensions [67, 68]. The diversity of physical function tests conducted within the five RCTs is
reflective of the substantial heterogeneity found in this meta-analysis. Verhoeven et al [68] and
Kim et al [67] found no effect of leucine supplementation or protein intake on strength and
physical function in healthy, older men. Consumption of beef improved 1RM knee extension
(kg) post-dietary intervention, although improvements were only observed when protein was
consumed evenly throughout the day [67]. The lack of significance among other physical
function tests may be due to the low protein amount or short duration. The largest effect sizes
found in this meta-analysis came from Scognamiglio et al. [66]. In this study, 12 weeks of daily
amino acid supplementation resulted in significant improvements in ambulatory function and
hand-grip strength compared to the control group. The robust effect of amino acids in this RCT
may be due to the older age of the participants (74 ± 5.5 years), the sedentary activity level of
participants, and/or the longer study duration of 12 weeks.
Observational studies suggest a positive role of protein dense foods on cognitive function
[77, 78]. However, in this meta-analysis there was no effect of either beef or nutrients found in
beef on cognitive function in healthy older adults. We examined RCTs investigating the effect of
nutrients found in beef, including vitamin B-12, B-6, folate, and zinc [79-81], on measures of
cognitive function and found no effect of these nutrients on cognitive function in healthy, older
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adults. This is supported by two recent meta-analyses which found no effect of B-vitamin intake,
individually or in combination with other nutrients, on cognitive function in middle-aged and
older adults [50, 82]. Dietary zinc is hypothesized to play a crucial role in regulating
neuroplasticity, cognitive function, and positive and negative affect states in older adults [83-85].
The RCT included in this meta-analysis measured the effects of 15 mg/d or 30 mg/d of zinc on
positive and negative affect states in healthy, older adults and found no effect compared to a
placebo control [86]. In contrast, observational studies report an association of dietary and
plasma zinc levels on positive and negative affect states [87, 88] and cognitive function in older
adults [87].
Very few RCTs have investigated the effect of beef and nutrients found in beef on wellbeing in healthy, older adults independent of weight loss and/or exercise interventions. However,
in the studies involving weight loss a beneficial effect of lean beef consumption on well-being
has been found [89, 90]. For example, a 6-month weight loss trial in obese, older adults ≥ 60
years of age found consumption of 30 g of high-quality protein per meal, predominantly sourced
from lean beef, reported an improvement in physical function when compared to a lower protein
control group [89]. Similarly, O’Connor et al [90] compared a Mediterranean diet plan with 200
grams or 500 grams of lean red meat (beef and pork) per week and reported positive effects on
outcomes of well-being including reduced physical limitations, improved mental health, and
reduced fatigue [90].
There are several limitations to this meta-analysis and systematic review. First, there was
a small and heterogenous set of studies which met the inclusion criteria for the meta-analysis.
Few studies shared the same quantitative estimate on the relationship between beef and nutrients
found in beef and a specific well-being outcome. In addition, beef and the nutrients studied in
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this meta-analysis were provided in different forms such as whole foods, pills or liquid, which
were not directly sourced from beef which may influence outcomes. Studies were conducted in
nine different countries with diverse samples of different size, age, and sex. Lastly, we aimed to
include a well-being domain of quality of life, albeit available RCTs did not meet our search
inclusion criteria. The small heterogenous set of studies included in this meta-analysis emphasize
a need for standardized measurements of well-being outcomes in future RCTs in healthy, older
adults.
In summary, the results of our meta-analysis suggest that compared with a control group,
protein and amino acids found in beef, may positively influence well-being through improved
physical function in healthy adults ≥ 50 years of age.

Recommendations for Future Research
There is an evident need for additional well-designed RCTs evaluating the efficacy of
beef and nutrients found in beef in healthy adults ≥ 50 years of age to promote well-being. Future
research should adopt a population representative sample of healthy older adults, absent of
chronic diseases, and examine the effect of lean beef on outcomes of well-being. For example,
RCTs should implement lean beef supplementation within a multidimensional approach with
homologous defined functional outcomes of LBM, cognitive function, physical function, and
QoL to advance research in the field of aging and nutrition. Moreover, future studies should
investigate the molecular mechanisms underlying the potential effect of beef consumption, apart
from exercise and weight-loss, on well-being in healthy older adults.
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Tables
Table 1. Study Selection Process: Inclusion and Exclusion Criteria
Criteria
Inclusion Criteria
Beef and Beef’s Nutrients Beef
Beef sourced protein
Zinc
Arginine
Vitamin B-6
Vitamin B-12
Folic Acid
Essential amino acids
(individually and as a
group)
Choline
Cysteine
Glycine
Glutamate
Study Design Randomized controlled
clinical trials
Registered clinical trial

99

Exclusion Criteria
Other sources of red meat
Non-beef sourced protein
Multivitamin supplements

Exercise
Method of nutrient
supplementation (e.g.
injection)
Review article
Meta-analysis
Longitudinal or crosssectional data
Epidemiological
Weight-loss
Non-human model

Table 1. Study Selection Process: Inclusion and Exclusion Criteria (Cont.)
Criteria
Inclusion Criteria
Exclusion Criteria
Outcomes
Well-being and Quality of
Mechanistic
Life (e.g. SF-36, SF12, EQ5D, HRQOL)
Strength (e.g. handgrip,
Appetite
1RM)
Physical function (e.g. gait,
Bone Health
walking speed, sit-stand test)
Cognitive function, Mood,
Fat mass
Depression (e.g. POMS,
MMSE)
Sleep (e.g. PSQI, Actigraph)
Lean body mass
Journal Characteristics
Peer-reviewed full text
Conference abstracts
English language
Non-English language
Statistics cannot be
quantified
Participant Characteristics Humans
Chronic disease
Healthy
Age not specified
>50 years of age
Cognitive
disorders/Dementia
Non-human model
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Table 2. Quality Assessment of Controlled Intervention Studies

101

Criteria
1. Was the study described as randomized, a randomized trial, a randomized
clinical trial, or an RCT?
2. Was the method of randomization adequate (i.e., use of randomly generated
assignment)?
3. Was the treatment allocation concealed (so that assignments could not be
predicted)?
4. Were study participants and providers blinded to treatment group
assignment?
5. Were the people assessing the outcomes blinded to the participants' group
assignments?
6. Were the groups similar at baseline on important characteristics that could
affect outcomes (e.g., demographics, risk factors, co-morbid conditions)?
7. Was the overall drop-out rate from the study at endpoint 20% or lower of
the number allocated to treatment?
8. Was the differential drop-out rate (between treatment groups) at endpoint 15
percentage points or lower?
9. Was there high adherence to the intervention protocols for each treatment
group?
10. Were other interventions avoided or similar in the groups (e.g., similar
background treatments)?
11. Were outcomes assessed using valid and reliable measures, implemented
consistently across all study participants?
12. Did the authors report that the sample size was sufficiently large to be able
to detect a difference in the main outcome between groups with at least 80%
power?
13. Were outcomes reported or subgroups analyzed prespecified (i.e.,
identified before analyses were conducted)?
14. Were all randomized participants analyzed in the group to which they were
originally assigned, i.e., did they use an intention-to-treat analysis?
Total Score

1 denotes Yes, 0 denotes N0, and X denotes not reported

Study ID (Reference number)
4
5
6
7
1
1
1
1

1
1

2
1

3
1

8
1

9
1

X

1

X

X
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X

1

X

1

1

1

1

1

1
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1

1

0
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1
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1

1

1

1

1

1

1
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1
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1

1

1

1

1

1

1

1

X

1

1

1

1

1

1

1

1

X

1

1

1

1

1

X

X

1

1

X

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

0

X

1

1

1

0

1

0

1

0

1

1

1

1

1

1

1

1

1

1

1

1

1

1

13

13

13

10

10

12

11

11

11

Table 3. Main characteristics of subjects in randomized controlled trials included for the meta-analysis
Study
ID

Primary Author
(Year)

Country

Sample Size
(Experimental)

Sample Size
(Control)

Age
(Years)

Age
(SD)

Sex

BMI

102

1

Aguiar, 2015
[73]

Brazil

10

10

71.6

6.1

F

26.6

2

Dangour, 2015
[77]

England

97

100

80.0

3.6

B

27.3

3

Eussen, 2006
[78]

Netherlands

50

53

82.0

5

B

NR

4

Fricke, 2008
[74]

Germany

11

12

53.9

4.3

F

5

Kim, 2018
[65]

United States

7

7

59.2

6.3

B

27.5

6

McMahon, 2006
[79]

New Zealand

125

124

73.5

5.8

B

26.8

7

Scognamiglio, 2005
[64]

Italy

48

47

74.0

5.5

B

25.3

8

Stewart-Knox, 2011
[84]

Ireland

62

62

68.1

4.1

B

NR

9

Verhoeven, 2009
[66]

Belgium

15

14

71.0

15.3

M

26.1

Int, intervention; M, male; F, female; B, both males and females; NR, not reported

23.5

Table 3. Main characteristics of subjects in randomized controlled trials included for the meta-analysis (Cont.)
Study ID

1
2
3
4
103

5
6
7
8

Primary Author
(Year)
Aguiar, 2015
[73]
Dangour, 2015
[77]
Eussen, 2006
[78]
Fricke, 2008
[74]
Kim, 2018
[65]
McMahon, 2006
[79]
Scognamiglio, 2005
[64]
Stewart-Knox, 2011 [84]

Int.
Duration

Statistical
Model

Attrition
Rate

Acute

Repeated measures
ANOVA

0%

52

ANCOVA
Logistic Regression

5.0%

24

ANOVA

16.9%

26

ANOVA

0%

8

ANCOVA

0%

104

Estimating equations w/
exchangeable correlation matrix

8.3%

12

Repeated measures ANOVA

5.0%

26

Mixed ANOVA

Not Reported

Verhoeven, 2009
12
Repeated Measures ANOVA
[66]
Int, intervention; M, male; F, female; B, both males and females; NR, not reported
9

3.6%

Table 4. Intervention arms, nutrients consumed, well-being measures, and results.
Study
ID

Intervention
Arms

1
[73]

Intervention: LArginine 8 g, liquid
form
Control:
Corn starch 8 g,
liquid form

Nutrient/diet
methodology

Well-being
parameter

Study Results Post-Intervention

Overall Conclusion

104

Supplements were
Physical
*Tandem gait: ARG:16.8±1.2 vs. Acute arginine
orally administered Function
PLA: *18.8±1.3s; (NS)
supplementation
in water in a double*Sit-stand:
does not
blind placebo*ARG:4.9±0.1. vs. PLA:
significantly effect
controlled
5.1±0.3s; (NS)
endothelial function
randomized design.
*Timed up and go
or muscle
Physical tests and
*ARG:7.2± 0.3 vs PLA: 7.4±0.4s; performance in
examinations were
(NS)
older women.
initiated 80 min
after
supplementation
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID
2
[77]

Intervention
Arms
Intervention:
Vitamin B-12
(cyanocobalamin)
1 mg
Control: 1 mg
control tablet
(nutrient not
reported)

Nutrient/diet
methodology

105

Participants had
moderate vitamin
B-12 deficiency in
the absence of
anemia and of
neurologic and
cognitive signs or
symptoms.
Supplements
administered as a
daily oral tablet for
12 months in a
double-blind
placebo-controlled
randomized
manner.

Well-being
parameter
Cognitive
Function/
Mood

Study Results Post-Intervention

Overall
Conclusion

30-item general health questionnaire
12-months of
Vit B-12: 2.4±0.5 vs PLA: 2.7±0.5; Adj
vitamin B-12
effect size and 95% CI -0.1(-1.3,1.1);
supplementation
California Verbal Learning Test: A Total does not
words correct in first 3 trials
significantly
Vit B-12: 23.9±0.7 vs PLA: 24.6±0.7;
effect
Adj effect size and 95% CI -1.4 (neurologic or
2.9,0.1)
cognitive
B
Words recalled at delayed recall
function.
Vit B-12 7.5±0.3 vs PLA:7.7±0.4 Adj
effect size and 95% CI -0.4 (-1.0,0.2)
Symbol letter modality, n correct
Vit B-12: 39.6±1.1 vs PLA: 4-.1±1.2;
Adj effect size and 95% CI -1.3 (3.2,0.6)
Simple-reaction time
Vit B-12: 0.3±0.01 vs PLA: 0.3±0.01;
Adj effect size and 95% CI 0.01 (0.02,0.04)
Choice-reaction time
Vit B-12: 0.7±0.01 vs. PLA: 0.7±0.02;
Adj effect size and 95% CI - 0.003 (0.03,0.02)
Verbal fluency
Vit B-12: 20.8±0.5 vs PLA 19.9±0.6; Adj
effect size and 95% CI 1.1(-0.01,0.22)
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
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1

Study
ID

Intervention
Arms

Nutrient/diet
methodology

3
[78]

Intervention
: Vitamin B12
(cyanocobal
amin) 1000
μg, tablet
Control:
AVICEL
PH102,
tablet

Participants had
moderate vitamin
B-12 deficiency
in the absence of
anemia and of
cognitive
impairment.
Supplements
administered as a
daily oral tablet
for 24 weeks in a
double-blind
placebo
controlled
randomized
manner.

Well-being
parameter
Cognitive
Function/
Mood

Study Results Post-Intervention

Overall
Conclusion

Construction: complex figure of Rey (pts)
Vit B-12: 30.0±7.5 vs PLA:29.2±7.0 (NS)
Attention: digit span forward-attention (pts)
Vit B-12: 7.5±1.7 vs PLA: 7.8±1.6 (NS)
Motor planning 2-sensomotor speed (millisecond)
Vit B-12: 647±265 vs PLA: 618±300 (NS)
Finger tapping-sensomotor speed (millisecond)
Vit B-12: 412±175 vs. PLA:389±168 (NS)
Trail making test-sensomotor speed [1]
Vit B-12: 77.5±52.3 vs PLA: 73.9±43.9 (NS)
15 word learning immediate recall-memory(pts)
Vit B-12: 35.2±12.1 vs PLA: 35.7±11.1 (NS)
15 word learning delayed recall-memory(pts)
VitB-12: 5.5±3.9 vs. PLA: 6.1±3.9 (NS)
15 word learning recognition-memory(pts)
Vit B-12: 26.6±3.7 vs PLA: 27.0±3.6 (P<0.05)
Complex figure of Rey, immediate recall-memory
(pts)
Vit B-12: 12.2±7.7 vs PLA: 12.7±7.4 (NS)
Complex figure of Rey delayed recall-memory
(pts)
Vit B-12: 11.4±7.0 vs PLA: 11.9±7.3 (NS)
Digit span backward-memory (pts)
Vit B-12: 4.6±1.6 vs PLA: 5.3±1.7 (P<0.05)

Oral
supplementati
on of vitamin
B-12 for 24
weeks does
not effect
cognitive
function.

All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
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1

Study
ID

Intervention
Arms

Nutrient/diet
methodology

3
[78]

Intervention
: Vitamin B12
(cyanocobal
amin) 1000
μg, tablet
Control:
AVICEL
PH102,
tablet

Participants had
moderate vitamin
B-12 deficiency in
the absence of
anemia and of
cognitive
impairment.
Supplements
administered as a
daily oral tablet for
24 weeks in a
double-blind
placebo controlled
randomized
manner.

Well-being
parameter
Cognitive
Function/
Mood

Study Results Post-Intervention

Overall
Conclusion

Motor planning 3-executive function
(millisecond)
Vit B-12: 863±376 vs PLA: 990±696 (NS)
Trail making test (part C/part A)-executive
function (millisecond)
Vit B-12: 2.8±1.2 vs PLA: 2.8±1.0 (NS)
Stroop test (part 3/part 2)-executive function
(millisecond)
Vit B-12: 2.2±0.9 vs PLA: 2.8±1.0 (NS)
Similarities WAIS-executive function (pts)
Vit B-12: 6.1±2.6 vs PLA: 5.4±2.8 (NS)
Raven-executive function (pts)
Vit B-12: 16.6±3.5 vs PLA: 16.5±3.9 (NS)
Word fluency animals-executive function (#onf)
Vit B-12: 17.6±5.5 vs PLA: 16.5±5.9 (NS)
Word fluency letter-executive function (#ofn)
VitB-12: 15.5±7.9 vs PLA: 17.5±8.8 (p<0.05)

Oral
supplementa
tion of
vitamin B12 for 24
weeks does
not effect
cognitive
function.

All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID

Intervention
Arms

Nutrient/diet
methodology

4
[74]

Intervention
: L-Arginine
hydrochlori
de 18 g and
14.8 g,
tablet LArginine/
daily
Control:
Dextrose,
tablet

Supplements
administered
orally for 26 weeks in a
double-blind
placebo
controlled
randomized
manner.
Secondary
analysis from
Baecker et al.,

Well-being
parameter
Physical
Function

Study Results Post-Intervention

Overall
Conclusion

Maximal isometric grip force (MIGF) of nondominant hand via Jamar dynamometer (Newton)
*ARG: 0.909±2.3: vs PLA: 1.167±2.368 (NS)

Oral
supplementati
on of LArginine for
26 weeks did
not
significantly
influence
MIGF in
postmenopaus
al women.
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1

All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
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Study
ID

Intervention
Arms

5
[65]

Intervention
: Even
Distribution
of high
protein beef
containing
foods
(33/33/33%)
Control:
Typical
American
distribution
of beef high
protein
containing
foods
(15/20/65%)
Protein
sources
including
beef, eggs,
and dairy

Nutrient/diet
methodology

Wellbeing
parameter
Lean body
mass

UNEVEN control
group consumed
1.1g protein/kg
body weight/day
Physical
in an uneven
Function
pattern
(15/20/65%)
comparable to the
traditional pattern
of meal intake in
the U.S for 8weeks. The
EVEN group
consumed an
equal amount of
protein with an
even pattern of
~33/33/33%
protein for 8weeks Diets were
configured to
maintain a stable
body weight via
Harris-Benedict
equation and level
of physical
activity.

Study Results Post-Intervention

Overall
Conclusion

DEXA Lean body mass (kg)
EVEN Pre: 50.5 ±2.7 vs, EVEN Post: 50.3±3.1 (NS)
UNEVEN Pre:47.7±4.2 vs UNEVEN: Post 46.9±4.1
(NS)
EVEN Post: 50.3±3.1 vs UNEVEN: Post 46.9±4.1
(NS)
1 RM knee extension, kg
EVEN Pre:59.2±5.6 vs, EVEN Post: 73.1±7.4 *
UNEVEN Pre: 45.8±6.1 vs UNEVEN: Post 52.3±8.7
(NS)
EVEN Post: 73.1±7.4 vs UNEVEN Post: 52.3±8.7
(NS)
Handgrip strength, kg
Even Pre: 37.5±3.8: vs EVEN Post: 40.7±4.5
Uneven Pre: 33.0±4.6 vs UNEVEN Post: 32.9±3.9
(NS)
EVEN Post: 40.7±4.5 vs UNEVEN Post: 32.9±3.9
(NS)
10 m gait speed, s
Even Pre:5.6±0.6 vs EVEN Post: 5.0±0.4 (NS)
Uneven Pre: 6.2±0.6 vs UNEVEN Post: 6.7±0.6
(NS)
EVEN Post: 5.0±0.4 vs UNEVEN Post: 6.7±0.6
(NS)
Sit/Stand 5 reps (s)
Even Pre:10.4 ±0.9 vs EVEN Post: 8.0±1.0 (NS)
Uneven Pre:10.5 ± 1.7 vs UNEVEN Post: 9.7±1.2
(NS)

8-week
interventio
n period of
an even or
uneven
distributio
n pattern
of mixed
meals does
not
significantl
y affect
muscle
strength or
functional
outcomes.

1

All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.
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Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
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Study
ID

Intervention
Arms

5
[65]

Intervention:
Even
Distribution of
high protein
beef containing
foods
(33/33/33%)
Control:
Typical
American
distribution of
beef high
protein
containing
foods
(15/20/65%)
Protein sources
including beef,
eggs, and dairy

Nutrient/diet
methodology

Well-being
parameter

Study Results Post-Intervention

Overall
Conclusion

UNEVEN control
Lean body mass Sit/Stand 5 reps (s)
8-week
group consumed 1.1g
Even Pre:10.4 ±0.9 vs EVEN Post:
intervention
protein/kg body
Physical
8.0±1.0 (NS)
period of an
weight/day in an
Function
Uneven Pre:10.5 ± 1.7 vs UNEVEN even or
uneven pattern
Post: 9.7±1.2 (NS)
uneven
(15/20/65%)
EVEN Post: 8.0±1.0 vs UNEVEN
distribution
comparable to the
Post: 9.7±1.2 (NS)
pattern of
traditional pattern of
Stair ascend power, Nm/s
mixed meals
meal intake in the
Even Pre: 347.9 ± 15.7 vs EVEN
does not
U.S for 8-weeks. The
Post:360.3±30.3 (NS)
significantly
EVEN group
UNEVEN Pre: 290.6 ± 46.6
affect muscle
consumed an equal
UNEVEN Post: 282.7±46.6 (NS)
strength or
amount of protein
EVEN Post:360.3±30.3 vs
functional
with an even pattern
UNEVEN Post: 282.7±46.6 (NS)
outcomes.
of ~33/33/33%
Stair descend power, Nm/s
protein for 8-weeks
Even Pre: 363.9 ± 16.8 vs EVEN
Diets were
Post: 401.1±32.7 (NS)
configured to
UNEVEN Pre: 300.8 ± 53.7
maintain a stable
UNEVEN Post: 304.6±58.1 (NS)
body weight via
EVEN Post: 401.1±32.7 vs
Harris-Benedict
UNEVEN Post: 304.6±58.1 (NS)
equation and level of
physical activity.
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID
6
[79]

Intervention
Arms
Intervention:
Folic acid:
1000 μg,
Vitamin B-12
(cobalamin)
500 μg,
Vitamin B-6
(pyridoxine)
10 mg, tablet
Control:
MGF, tablet

112

Nutrient/diet
Well-being
methodology
parameter
Participants had
Cognitive
high fasting
Function/
homocysteine
Mood
concentrations of
at least 13 μmol
per liter and were
otherwise healthy.
Participants orally
consumed a daily
treatment or
control capsule
for 2 years in a
double-blind,
placebocontrolled,
randomized
manner.

Study Results Post-Intervention

Overall
Conclusion
2-year oral
supplementation
of B-vitamins
does not
significantly
affect cognitive
performance.

Mini-Mental State Examination (pts.)
B-VIT: 29.29±1.41 vs PLA: 29.32±2.10
(NS)
Wechsler Paragraph Recall test (pts)
B-VIT:18.67±6.55 vs PLA:20.76±7.21
(NS)
Category Word Fluency test (# of words)
B-VIT: 65.72±14.96 vs PLA:68.78±13.71
(NS)
Rey Auditory Verbal Learning (# of
words)
B-VIT:43.90±9.70 vs PLA: 44.22±9.90
(NS)
Raven's Progressive Matrices (pts)
B-VIT: 11.60±2.92 vs PLA: 11.90±3.05
(NS)
Controlled Oral Word Association test (#
of words)
B-VIT: 40.11±14.08 vs PLA:
41.00±12.44(NS)
Part B of the Reitan Trail Making Test
(sec to completion)
B-VIT: 114.40±84.23 vs
PLA:98.96±40.75 (p=0.007)
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID
7
[64]

113

Intervention
Nutrient/diet
Well-being
Study Results Post-Intervention
Overall
Arms
methodology
parameter
Conclusion
Intervention: oral
Participants with
Physical
Ambulatory function: 6 min walk
3-months of
amino acid (AA)
reduced physical
Function
distance (m)
oral amino acid
mixture 12 g/day+
activity consumed
AA: 268.8±34.9 vs PLA: 212±40
mixture
12.21 g of glucose,
an oral amino acid
(p<0.001)
significantly
liquid
mixture or placebo
Self -reported ambulatory ability:
improved
Control: glucose
3-times daily for 3
distance (%)
ambulatory
12.21 g/day, liquid
months as snacks at
AA:68.3±12 vs PLA: 53±14.8
capacity,
AA
10:00am., 4:00p.m.,
(p<0.001)
maximal
Composition/day:
and 10:00 p.m. in a
Self -reported ambulatory ability:
isometric
L-leucine: 3.8 g
single-blind,
speed (%)
muscle strength,
L-lysine 2 g
placebo-controlled,
AA: 72.2±14.4 vs PLA: 52.8±12
and myocardial
L-isoleucine 1.9 g
randomized
(p<0.001)
ability in
L-valine 1.9 g
manner.
Self -reported ambulatory ability:
elderly subjects
L-threonine: 1.1 g
Participants were
stairs (%)
without
L-cystine: 0.4 g
instructed to reduce
AA: 98.2±24 vs PLA: 72.4±22
affecting tested
L-histidine: 0.4 g
their usual dietary
(p<0.001)
metabolic
L-phenylalanine: 0.3 intake by 450kcal
Maximal Isometric muscle strength; parameters.
g
per day to
Right hand (kg)
L-methionine: 0.2 g
compensate for the
AA: 20.2±2 vs PLA: 14.38
L-tyrosine: 0.1 g
supplements.
(p<0.001)
L-tryptophan 0.1 g
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID
8
[84]

Intervention
Arms
Intervention:
Zinc
gluconate 15
mg/d
Zinc
gluconate 30
mg/d
Control:
placebo pill

Nutrient/diet
methodology

114

Participants in
four European
centers
(Northern
Ireland,
ClermontFerrand, Rome,
Grenoble)
consumed
15mg, 30mg, or
a placebo pill
with breakfast
daily for 6
months in a
double-blind
placebocontrolled,
randomized
manner

Wellbeing
parameter
Cognitive
Function/
Mood

Study Results Post-Intervention

Overall
Conclusion

Positive and Negative Affect Scale (PANAS): 556-months of
70 yrs old/Coleraine and Clermont-Ferrand (pts)
oral zinc
Sum of 4 consecutive days (upon rising,
supplementati
breakfast, lunch, after dinner and before going to
on does not
bed)
significantly
Positive affect
affect mood in
Zn(15mg) 28.70±6.09 vs PLA: 26.86±5.20 (NS)
healthy
Zn (30mg): 29.06±5.54vs PLA 26.86±5.20 (NS)
elderly
Negative affect (pts)
European
Zn(15mg): 12.22±3.30 vs PLA 11.84±2.89 (NS)
adults
Zn (30mg): 11.22±1.95vs PLA 11.84±2.89 (NS)
Positive and Negative Affect Scale (PANAS): ≥ 70
yrs old/Rome and Grenoble
Sum of 4 consecutive days (upon rising,
breakfast, lunch, after dinner and before going to
bed)
Positive affect
Zn(15mg) 23.20±6.50 vs PLA: 24.36±9.02 (NS)
Zn (30mg): 23.59±7.68 vs PLA: 24.36±9.02 (NS)
Negative affect (pts)
Zn(15mg): 13.27±4.90 vs PLA 12.29±3.02 (NS)
Zn (30mg): 12.81±4.26.95vs PLA 12.29±3.02
(NS)
1
All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 4. Intervention arms, nutrients consumed, well-being measures, and results (Cont.)
Study
ID
9
[66]
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1

Intervention
Arms
Intervention
: Leucine
2.5 g/main
meal and
7.5 g/day,
tablet
Control:
Wheat flour:
2.5 g/main
meal and
7.5 g/day,
tablet

Nutrient/diet
Well-being
methodology
parameter
Participants
Physical
consumed 5
Function
capsules of
leucine or placebo Lean body mass
with each main
meal daily for 3months in a
double-blind
placebocontrolled
randomized
manner.

Study Results Post-Intervention
1RM leg press
*Leucine:170±8 vs Placebo:172±6
(NS)
*1RM leg extension
*Leucine: 85±3vs Placebo: 85±3 (NS)
*Lean Mass (Kg)
*Leucine: 55.0±1.5 Placebo: 56.2±1.1
(NS)

Overall
Conclusion
3-months of
leucine
supplementation
with each main
meal does
significantly
affect muscle
mass and strength
in healthy elderly
men

All values are means ± SDs unless indicated as * denoting SEMs. Non-significant p-values are denoted by NS; #ofn: number of
nouns; significant p-values are denoted by the given p-value, P=0.05
2
PLA, placebo.

Table 5. Meta-Regression Results for Continuous Moderators
Aggregation

n

Age

55

Estimate

SE

95 CI
Lower

Upper

p

Intercept

1.93

0.75

0.42

3.43

0.01

Age (slope)

-0.02

0.01

-0.04

-0.003

0.02

BMI

33

Intercept

8.43

3.17

1.96

14.90

0.01

BMI (slope)

-0.30

0.11

-0.55

-0.06

0.01
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Length of time in weeks

52

Intercept

0.46

0.11

0.24

0.68

<0.01

Length (slope)

-0.01

0.002

-0.01

-0.003

<0.01

Publication year
(centered at 2005)

55

Intercept

0.18

0.10

-0.02

0.38

0.07

Year (slope)

0.004

0.02

-0.03

0.04

0.82

Heterogeneity
Qb

df

p

260.24

53

<0.01

148.26

31

<0.01

219.51

50

<0.01

270.97

53

<0.01

Table 6. Modeling Results for Overall Effects and by Moderator Categories
Aggregation

n

Fixed effects
Random effects

55
55

Well-being Outcome
Lean body mass
Cognitive Function
Physical Function
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Sex
Female
Male
Both

1

Beef and Beef’s Nutrients
AA
Arginine
B-12
B-12 +B-6 +FA
Leucine
Protein/Beef
Zinc
FA, folic acid.

2
36
17
4
3
48
5
4
25
7
3
7
4

Effect Size
g
0.08
0.20

-0.06
-0.01
0.83
0.19
-0.11
0.22
1.53
0.19
0.01
-0.14
-0.11
0.71
0.21

SE
0.03
0.07

0.29
0.03
0.17
0.13
0.08
0.08
0.25
0.13
0.04
0.04
0.08
0.10
0.12

95 CI
Lower
0.03
0.05

-0.63
-0.07
0.49
-0.06
-0.28
0.06
1.04
-0.06
-0.07
-0.22
-0.28
0.52
-0.02

Upper
0.13
0.34

0.52
0.06
1.17
0.45
0.05
0.38
2.03
0.45
0.08
-0.06
0.05
0.90
0.44

p
<0.01
0.01

Heterogeneity
Qb
270.97
270.97

df
54
54

p
<0.01
<0.01

22.33

2

<0.01

9.32

2

0.01

106.06

6

<0.01

0.85
0.81
<0.01
0.13
0.16
0.01
<0.01
0.13
0.83
<0.01
0.16
<0.01
0.07

Figures

Identification

Records identified through database searching
(n = 23,821)
(PubMed =12.136) (Web of Science=5,131)
(CINAHL= 6,554)

Screening

Records after duplicates removed
(n = 9,772)

Records screened
(n = 9,772 )

Full-text articles excluded, with reasons
(n = 55)
Age= 7
Disease State: 4
Exercise/Physical activity: 8
Non-peered review=3
Statistical Analysis = 2
Inappropriate design = 16
Well-being/quality of life missing/can’t be
quantified = 2
Source of nutrient = 12
Methods paper/Abstract=1

Eligibility

Full-text articles assessed for
eligibility
(n =87)

Studies included for coding
(n = 32)

Coded articles excluded, with reasons
(n =22)
Age=1
Statistical Analysis = 11
Inappropriate design =2
Health= 4
Well-being/quality of life missing/can’t be
quantified = 2
Weight loss= 2

Studies included in qualitative
synthesis
Randomized control trials
(n = 9)
Included

Records excluded with justifications
(n =9,685)
Abstract/ non-peered review= 19
Age <50 years = 623
Animal/in-vitro = 49
Disease State = 1356
Duplicate = 73
Exercise= 780
Food/supplement Source= 385
Missing Well-being/Quality of Life Quantifiable
Outcomes = 577
Multi-vitamin/supplement= 34
Missing Beef/Nutrients of Beef= 262
Non-English= 2
Off Topic = 4,062
Review/meta-analysis/report/book chapter = 619
Study design = 863

Studies included in
quantitative synthesis (metaanalysis)
(n = 9)

Figure 1. Literature search: Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) flow diagram
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Figure 2. Scatterplots that display the relationship between the effect size and the continuous
moderator
Note: the bubble size is proportional to the sample size
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Figure 3. Forest plot for the random-effects mode

120

Figure 4. Funnel plot that displays publication bias
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Abstract
Background: Diets higher in protein have been reported to improve age-related changes
in body composition via increased energy expenditure, shifts in substrate oxidation, and
decreased appetite. However, how protein source (e.g. animal versus plant protein) impacts
energy expenditure, appetite and food intake as we age is unknown. Objective: The objective of
this study was to evaluate the effect of protein source as part of a high protein breakfast on
appetite, food intake, energy expenditure, and fat oxidation in young men compared to older
men. Methods: This study used a randomized, single-blinded crossover design, with a one-week
washout period between testing days. Fifteen young (YM; 25.2 ± 2.8 years) and fifteen older
(OM; 67.7 ± 4.5 years) healthy, adult men participated in the study. Participants arrived fasted
and consumed an isocaloric, volume-matched, high-protein (40g) test beverage made with either
an animal (whey protein isolate; WPI) or plant (pea protein isolate; PPI) protein isolate source.
Markers of appetite and energy expenditure were determined at baseline and over four hours
postprandial. Results: There was a significant effect of time, age, and protein source on appetite
(p < 0.05). There was no effect of protein source on plasma markers of appetite, food intake,
energy expenditure, and substrate oxidation. After controlling for body weight OM had
decreased energy expenditure (p < 0.05) and lower fat oxidation (p < 0.001) compared to YM.
Conclusions: This study indicates that a high protein breakfast containing WPI or PPI exerts
comparable effects on appetite, energy expenditure, and 24-hour energy intake in both young and
older healthy adult men. This trial was registered at clinical trials.gov as NCT0339981
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Introduction
Life expectancy continues to increase in the United States and adults 65 years of age and
older are projected to more than double from 600 million to 1.6 billion between 2015 and 2050
[1]. Successful aging is commonly defined by high levels of physiological function [2], which is
strongly associated with body composition, strength, and appetite [3, 4]. Skeletal muscle mass
and strength begin to decrease in the third decade of life and these losses are accelerated in the
sixth decade of life [5]. In the midst of skeletal muscle loss, older adults commonly experience
concurrent fat mass gain [6]. These shifts in body composition are often accompanied by
changes in energy homeostasis via decreased energy expenditure [7], shifts in substrate oxidation
[8], and decreases in appetite [9]. Age-related shifts in appetite contribute to energy imbalance
and altered body composition often observed with age [10]. Age-related decreases in appetite are
largely contributed to alterations in appetite hormones [11], changes in gastrointestinal motility
[12] and losses in lean body mass [13-15] . Research suggests nutritional strategies focused on
higher-protein diets containing high-quality proteins are a potential way to mitigate the decrease
in energy expenditure and body composition observed with age [6].
Dietary patterns promoting plant-based protein have gained significant attention in recent
years [16]. However, studies examining the effect of plant-based protein sources versus animalbased protein sources markers of appetite, energy expenditure and markers of metabolism offer
conflicting results [17-20] . For example, high-protein meals containing varying protein sources
have been shown to influence appetite differently [18, 21, 22], albeit previous work from our lab
did not see a difference in postprandial appetite responses in participants consuming an animal
protein- versus plant protein-based breakfast [17].
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Although research exists comparing the effects of protein source on appetite and energy
expenditure in healthy young adults, there is little data looking at the effect of animal and plant
protein sources on energy expenditure, appetite, and food intake in young versus older men.
Therefore, the primary objective of this study was to compare the acute effects of a high-protein
breakfast containing either animal protein or plant protein on energy expenditure, appetite, and
food intake young versus older men. Whey protein isolate (WPI) was used as the animal protein
source due to the high level of branched chain amino acids (leucine, isoleucine, and valine) and
its ability to increase satiety in response to a mixed meal [23]. Pea protein isolate (PPI) was used
as the plant protein source due to its complete amino acid profile and its potential to suppress
appetite compared to animal proteins [24].

Materials and Methods
Participants and Ethical Approval. From December 2017 to May 2018, young men
(YM) between 18-29 years of age and older men (OM) 60-85 years of age were recruited to
participate in this study. Participants were recruited from the Northwest Arkansas area via the
daily University of Arkansas digital newsletter, flyers throughout the community, word-ofmouth, and social media to participate in this study. The initial screening was carried out via
phone interview. Participants who consumed protein related supplements, did not regularly
consume breakfast (<5 times per week), smoked, had dietary restrictions, disliked chocolate,
were actively trying to lose weight, participated in vigorous activity for 4 hours a week or more,
were competitive athletes, had any pre-existing metabolic conditions (e.g. type 1 or 2 diabetes,
cancer, cardiovascular disease), were taking medications that would influence protein or energy
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metabolism, were claustrophobic and/or were uncomfortable with needles were excluded from
participating in the study.
Sixty-one men underwent an initial screening, 17 younger and 20 older men met the
screening criteria, and 15 young and 15 older men completed all study procedures (May 2018).
Of those who did not complete the study, participants dropped out due to claustrophobia under
the metabolic canopy hood, time constraints, and personal reasons. The total participant dropout
rate was 18.9%. Each individual agreed to participate by signing the study consent form,
completed two test days and an additional final body composition assessment. Written consent
was obtained from participants prior to starting the study. Ethical approval for the study protocol
was approved by the Office of Research Compliance Institutional Review Board of the
University of Arkansas (Fayetteville, AR, USA). This trial was registered at clinical trials.gov as
NCT03399812.
Study Design. The study was conducted as a single-blinded randomized cross-over
design study in which each participant was allocated to YM (18-29 years of age; n=15) or OM
(60-85 years of age; n=15) intervention group. Refer to Table 1 for participant characteristics.
On the two test days, the participants arrived fasted (10-12 hours) at the Center for Human
Nutrition at the University of Arkansas prior to 08:00. for data collection. Each participant
followed a randomized crossover comparison design as they received both breakfast beverages,
whey protein-based isolate (WPI) and pea protein-based isolate (PPI), on subsequent test days
with each participant serving as their own control. A one-week washout period separated the test
days. Refer to Figure 1 for study design.
Upon arrival, anthropometrics were recorded and an intravenous catheter was inserted
into an antecubital arm vein. Fasting measurements of subjective appetite via visual analogue
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scale [25], resting energy expenditure (REE) and substrate oxidation via indirect calorimetry
[26], and venous blood via an intravenous catheter were collected prior to the consumption of the
protein-based breakfast test beverage. Participants were then served one of two test breakfast
beverages. Each protein-based breakfast test beverage was served with a straw inserted into an
opaque disposable cup and lid to prevent visual and olfactory influence. Participants consumed
the protein-based breakfast test beverage during the next 10 minutes. The cups were evaluated by
research staff to confirm the contents were fully consumed. Subsequently, the participants
completed a VAS on subjective appetite and for the palatability of the protein-based breakfast
test beverage. Assessment of subjective appetite using a VAS was repeated at 30, 60, 90, 120,
180, and 240 minutes after the ingestion of the protein-based breakfast test beverage. Resting
energy expenditure (REE), thermic effect of food (TEF), and substrate oxidation (SO) via
indirect colorimetry were measured at 30, 60, 120, 180, and 240 minutes after the ingestion of
the protein-based breakfast test beverage. In addition, 10 ml of blood were collected via a
syringe from an intravenous catheter at 30, 60, 90, 120, and 240 minutes after the ingestion of
the protein-based breakfast test beverage. At the conclusion of the 4-hour test day, a 24-hour
food log was administered, and detailed instructions were given to participants to record their
food intake until 11:59 p.m.
Dietary Intervention. The protein-based breakfast test beverage contained 40 grams of
dietary supplementary chocolate WPI or chocolate PPI. The WPI (BiPRO; Davisco Foods
International. Le Sueur, MN) and PPI (NOW Foods Bloomingdale, IL, USA; sourced from
yellow peas (Lathyrus aphaca species) were commercially purchased. The test beverages were
isocaloric, volume matched, and macronutrient matched (refer to Table 2 for nutrient
composition of the test beverages). The amino acid profile of the test beverages is listed in
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Supplemental Table 1. Palatability of the test beverages was measured using visual analog
scales. Viscosity was measured using a Brookfield Synchro-Lectric Viscometer (Brookfield
Engineering Laboratories, INC, Stroughton, Massachusetts). Viscosity of the pea and whey
protein drinks were measured at ambient conditions in separate 16 oz. opaque serving containers.
Samples were thoroughly mixed immediately prior to measurement. The viscosity samples were
measured following the immersion of the spindle and a minimum of 5 revolutions. When the
motor was activated, the spindle rotated at a constant speed of 4 rpm. The palatability and
viscosity of the protein-based breakfast test beverages can be found in Table 2.
Anthropometric Measurements. Height was measured to the nearest 0.01 cm using a
standard stadiometer (Detecto, St. Louis, MO) without shoes, in the free-standing position. Body
weight was measured to the nearest 0.05 kg using a calibrated scale (Detecto, St. Louis, MO) in
the fasted state. Body composition was determined using duel energy X-ray absorptiometry
(DXA) analysis (Lunar Prodigy, GE Healthcare, Madison, WI, USA) at the Exercise Science
Research Center at the University of Arkansas.
Appetite Response. Subjective appetite and palatability were assessed using a traditional
100-mm VAS [25] with opposing anchors at 0, 15, 30, 60, 90, 120, 180, and 240 minutes
postprandial. Participants were asked to place an “X” on the 100-mm VAS that most accurately
reflected their perceived feeling of appetite according to a series of seven questions (e.g., “How
HUNGRY do you feel at this moment” and “How FULL do you feel at this moment”).
Dietary Records and Assessment. Participants completed a total of two 24-hour food
logs, one following each test day. The energy and macronutrient composition of the test
breakfast beverages and the remaining 24-hours of the test day were analyzed using the Genesis
R&D nutrient analysis software package (version 9.10.2, ESHA Research, Salem, OR, USA).
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Energy Expenditure and Substrate Oxidation. Resting energy expenditure (REE; kcal/min),
thermic effect of feeding (TEF; kcal/min), and substrate oxidation (SO; kcal/min) were measured
by indirect calorimetry using the validated [26] ventilated hood technique with the TrueOne
2400 metabolic cart (Parvo Medics, Sandy, Utah, USA; [27]).
Plasma Biomarkers. Six blood samples (10mL/sample, 60mL/testing day) were collected
following a 10-12 hour fast and during the four-hour postprandial meal time response period.
The samples were collected in EDTA vacutainer tubes. Samples were immediately centrifuged at
4ºC for 15 minutes at 1800 x g. The plasma was separated and stored at -80 ºC until analysis.
Plasma glucose (mg/dl), cholecystokinin (CCK) (pg/ml) and peptide YY (PYY) (pg/ml) levels
were determined via colorimetric (Cayman Chemical Company, Ann Arbor, MI, USA), and
Enzyme Immunoassay (RayBiotech, Inc) using commercially available kits per manufacture
instructions.

Statistical Analysis
Summary statistics were calculated for all data and data are expressed as means ±
standard deviation (SD). Two-sample independent t-tests were used to analyze baseline
measurements of participant characteristics and body composition. The two factor repeated
measures design was analyzed as a generalized linear mixed model with protein source and age
as fixed effects and subjects as a random effect nested within age categories. Appetite ratings,
REE, substrate oxidation, food intake, and metabolic biomarker levels (glucose, PYY and CCK),
that could only take on positive values were assumed to follow a gamma distribution. Thermic
effect of food was analyzed as a proportion and was assumed to follow a beta distribution. For
appetite ratings, energy expenditure, substrate oxidation, and plasma markers of glucose, PYY,
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and CCK there was a third main effect of time. In our model we analyzed main effects of time,
age, and protein source. Where appropriate, two-way and three-way interaction of age x protein
source, age x time, and protein source x time and age x protein source x time respectively were
tested for significance. Where appropriate, follow-up least squares mean comparisons for protein
source, age and time main effects were declared significantly different if the corresponding
analysis of variance F statistic was significant. For any significant interactions mean comparison
were carried using the protected least significant difference (LSD). Subjective rating of
palatability was analyzed as a generalized linear mixed model with protein source and age as
fixed effects and subjects as a random effect nested within age categories without repeated
measures. Viscosity of the test beverages were analyzed using independent t-tests. Net
incremental area under the curve (niAUC) was calculated for appetite ratings, REE, TEF, SO,
and metabolic biomarker levels. Where significance was found, follow-up least squares mean
comparisons for protein source and age categories. For any significant interactions mean
comparison were carried using the protected leas significant difference (LSD). Statistical
analyses involving generalized linear mixed models were performed using PROC GLIMMIX in
SAS version 9.4. All graphs were made using GraphPad Prism Software version 7.0 (GraphPad
Software, La Jolla, CA, USA). p < 0.05 was considered significant. To verify the
appropriateness of the sample sizes we carried out a post-hoc power analysis using the SAS
procedure PROC POWER with the paired t-test option. The observed sample means and
standard deviations were used to determine that 15 participants per group had a statistical power
of 0.987 (based on an overall level of significance of 0.05) to detect an accurate postprandial
difference in TEF after supplementation of WPI and PPI protein-based breakfast test beverages.
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Results
Participant Characteristics. The demographics and physical characteristics of the
participants who completed the study are presented in Table 1. The YM and OM had a mean age
of 25.2 ± 2.8 years and 67.7 ± 4.5 years, respectively (p < 0.0001). There were significant
differences in fat mass (FM; p < 0.01), body fat percentage (p < 0.05), and fat-to-lean ratio (p <
0.05) between groups with no significant differences in lean body mass (LBM) and fat free mass
(FFM).
Energy Expenditure and Substrate Oxidation. Results for energy expenditure and
substrate oxidation are presented in the line (individual time points) and bar graphs (niAUC) in
Figure 2. After controlling for body weight (kg), there was a significant effect of age (p <
0.0001) and time (p < 0.0001) on REE (kcal/min), TEF (kcal/min), and fat oxidation (kcal/min)
with no effect of protein source. There was an effect of age on REE, TEF, and fat oxidation with
YM having significantly higher REE (p < 0.0001), TEF (p < 0.05), and fat oxidation (p < 0.01)
compared to OM. There was a significant age x time interaction on TEF (kcal/min) (p < 0.01).
All other two- and three-way interactions of REE, TEF, and substrate oxidation were not
significant.
Subjective Appetite and Palatability. Results for perceived hunger, perceived fullness,
prospective food consumption (PFC), and perceived desire to eat are presented in Figure 3.
Fasting values of perceived hunger, fullness, prospective food consumption and desire to eat
were not significantly different between the YM and OM when consuming either protein-based
breakfast test beverages. There was a significant effect of time, age, and protein source on
subjective hunger (p < 0.01), fullness (p < 0.01), PFC (p < 0.01), desire to eat (p < 0.01) and
desire for a snack (p < 0.05). There was a significant interaction effect of age x time (p < 0.01)
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and protein source x time (p < 0.05) on desire for a snack. All other interactions of age x protein
source, age x time, protein source x time, and age x protein source x time were not significant.
There were no significant differences in the desire for something sweet on time, age, or protein
source (Supplemental Figure 1).
However, there was a significant effect of age on the desire for something salty (p < 0.001;
Supplemental Figure 1) and an age x time interaction (p < 0.01) with no significant interaction
effect of age x time x protein source. Palatability was higher for the WPI compared to the PPI
protein-based breakfast test beverage (p < 0.01) with no significant difference between age
groups (Table 2).
Plasma Biomarkers. The plasma glucose, CCK, and PYY responses to the test breakfast
beverage are depicted in Figure 4. There was an effect of age (p < 0.05), but not protein source,
with older men having higher concentrations of all tested biomarkers. There was a significant
time x age interaction on glucose ( p < 0.05) with no significant effect of age x time x protein
source. All other interactions of age x time, protein source x time, and age x protein source x
time interactions of plasma glucose, CCK, and PYY were not significant.
24-hour Dietary Assessment. Twenty-four-hour energy and macronutrient intake are shown in
Table 3. No significant differences were observed in 24-hour total food intake between either
protein source or age groups.

Discussion
To our knowledge, this is the first study to examine the short-term effect of a high-protein
breakfast from plant or animal derived protein sources on energy expenditure and appetite
response in healthy, young and older men. The present study tested the hypothesis that WPI,
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when compared to PPI, would have a greater effect on energy expenditure and appetite in OM
versus YM when supplemented as a 40-gram protein-based breakfast beverage. Collectively, the
results of this study suggest that age, not protein source, effects postprandial energy expenditure
and appetite responses.
A breakfast containing high-protein foods has been shown to increase energy expenditure
and fat oxidation in healthy, young adults [18, 27]. However, the impact of protein source as part
of a high-protein breakfast on energy expenditure and fat oxidation in aging adults still needs to
be established. For example, consumption of whey, casein, and soy protein-based beverages
compared to a carbohydrate-based control beverage increased TEF and fat oxidation in young
men over a five-hour period [18]. One likely mechanism for the increase in TEF could be due to
protein turnover and the favoring of protein synthesis or deamination and urea synthesis
associated with protein breakdown [28]. However, in this clinical trial, we did not observe any
differences between protein source with respect to energy expenditure and substrate oxidation.
This may have been due to the 40 grams of protein used in the test breakfast beverages which
was a larger dose compared to the doses used in other studies demonstrating differences in
energy metabolism between protein sources [18, 29].
The majority of clinical trials investigating the short-term effect of animal- and plantbased proteins on appetite and food intake use soy as the plant-based protein source [20, 30],
whey as the animal-based protein source [18, 31, 32], or a complete mixed meal [30, 33-35]. In
agreement with our study, fifteen grams of protein sourced from either whey-, pea-, or a
combination of whey and pea protein isolate on appetite, postprandial changes in satiety
hormones, and energy intake found that the pea protein resulted in a modest increase in satiety,
with no differences in energy intake [21]. In addition, a randomized single-blind cross-over study
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investigating the role of a meal preload of twenty grams of casein, whey, pea protein, egg
albumin, or maltodextrin compared to water found that casein and pea protein increased satiety
significantly more when compared to the other sources of protein [24]. In contrast, casein and
pea protein also lowered energy intake, albeit food intake was recorded 30 minutes following the
meal preload.
There are a limited number of studies investigating the differences in energy expenditure
and substrate oxidation between protein sources. In one study, three isoenergetic 30% protein
test meals using meat, dairy, and soy protein sources found no significant differences in energy
expenditure, carbohydrate oxidation, or fat oxidation between test meals [30], similar to the
results found in this study. In contrast, a second study tested three meals with 50% protein
coming from either whey, casein, or soy protein and found that TEF and fat oxidation were
greater after the consumption of the whey protein meal [18].
To our knowledge, this is the first short-term meal response study to demonstrate the
effect of whey protein isolate and pea protein isolate on energy expenditure and appetite in
young versus older men at breakfast. However, there are several limitations to this study. This
study had strict inclusion and exclusion criteria and we only recruited healthy young and older
men which could be the reason that there was no difference in lean or fat-free mass between the
younger and older men. Women were excluded from this study, which means the results may
not apply to the overall population. The sample size, although powered correctly, was small. The
breakfast test breakfast beverages varied in viscosity which may have contributed to differences
seen in participant appetite response [36]. The test beverages also varied in palatability despite
controlling for nutrient content and sensory properties of smell and sight, which may have
influenced appetite [37]. We also relied on self-reported 24-hour food intake for intake for the
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24-hour dietary assessment, which may provide inaccurate measurements of food intake [38]. In
addition, we did not provide the pea protein and whey protein in mixed-meal context. Therefore,
the results cannot be directly translated into a plant-based or animal-based protein complete diet.
Finally, there was a racial imbalance in the young compared to the older participants. The 15
older men were Caucasian as the younger men were Caucasian, Indian, and American
Asian/Asian. However, as this was a crossover design the racial imbalance was unlikely to
impact our primary outcomes.
In conclusion, an isocaloric, isovolumetric, macronutrient- and fiber-matched proteinbased breakfast beverages from an animal-based whey protein isolate and a plant-based pea
protein isolate exerts comparable effects on appetite, energy expenditure, and 24-hour energy
intake in both young and older healthy adult men.
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Tables
Table 1. Baseline characteristics of the study population by age group 1

Age, y

Young
(n=15)
25.2 ± 2.8

Older
(n=15)
67.65 ± 4.5

<0.0001****

Anthropometrics
Height, m

1.8 ± 0.1

1.81 ± 0.1

0.59

Weight, kg

78.4 ± 11.3

88.9 ± 10.4

0.01*

BMI, kg/m2

25.1 ± 3.3

27.9 ± 3.0

0.02*

Total body fat mass, kg

17.5 ± 6.4

26.3 ± 9.8

0.01**

Percent body Fat, %

23.5 ± 7.8

30.5 ± 9.7

0.04*

Total lean mass, kg

57.6 ± 11.1

58.3 ± 7.0

0.84

Total fat-free mass, kg

60.9 ± 11.6

58.0 ± 16.6

0.59

0.32 ± 0.1

0.46 ± 0.2

0.03*

American Asian/Asian

4/15

-

Indian

1/15

-

Caucasian

10/15

15/15

p-value

DXA

Fat-to-Lean ratio, (total
fat
mass/ total lean mass)
Ethnicity 2

1

Data are expressed as means + SDs. Significant differences denoted by ****p<0.0001; **p<0.01;
* p<0.05.
2
Ethnicity is expressed as number of participants within age group.
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Table 2. Ingredient composition and nutrient profile of breakfast test beverages
Macronutrient Profile, Palatibility, and Viscosity of Breakfast Test Beverages1
WPI

PPI

Protein isolate, g

50.00

73.33

Cane sugar, g

13.00

-

Canola oil, g

0.75

-

Inulin, g

3.60

-

350.00

350.00

Calories, kcal

265.8

263.8

Protein, g

40.0

40.0

Carbohydrate, g

15.0

15.0

Fiber, g

3.6

3.3

Fat, g

4.4

4.2

56.2 ± 16.6

37.9 ± 17.9*

Ingredient composition

Water, mL
Nutrient profile

Palatability, mm2

Viscosity, cP
62.5
10,500.0*
Whey protein isolate, WPI; Pea protein isolate, PPI; Centipoise, cP.
2
Palatability is expressed as means + SDs. Palatability measurements were collected from
participants at time point 15 minutes. Significant differences denoted by * p<0.05.
1
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Table 3. 24-hour energy and macronutrient intake post-consumption of test breakfast beverages 1
Young
WPI
(n=15)

PPI
(n=15)

WPI
(n=15)

PPI
(n=15)

2248.6 ± 703.0

2328.6 ± 903.7

2078.0 ± 542.3

2120.7 ± 850.1

Protein, g

129.4 ± 44.9

141.4 ± 51.4

117.9 ± 26.3

115.7 ± 29.5

Fat, g

88.7 ± 40.1

87.1 ± 53.8

80.1 ± 31.2

80.0 ± 43.7

Carbohydrate
,g

236.5 ± 73.1

244.9 ± 82.7

217.7 ± 87.1

2058.0 ± 92.0

Sugar, g

73.5 ± 26.7

64.0 ± 26.7

94.5 ± 52.2

64.5 ± 40.4

Fiber, g

21.4 ± 7.6

22.3 ± 9.2

19.5 ± 5.3

21.1 ± 11.1

3934.3 ± 1937.8

3895.0 ± 1482.4

3611.3 ± 1976.9

Protein, %

23.2 ± 1

24.97 ± 1

2577.3 ±
1329.8
23.40 ± 1

Carbohydrate
,%
Fat, %

43.3 ± 1

43.9 ± 1

41.3 ± 1

40.0 ± 1

34.1 ± 1

32.3 ± 1

34.5± 1

32.9± 0

Calories, kcal

Sodium, mg

1

Older

24.1 ± 1

Data are expressed as means + SDs. Whey protein isolate, WPI; Pea protein isolate, PPI.
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Figures

Figure 1. Schematic of randomized, controlled, single-blinded study design
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Figure 2. Energy expenditure and substrate oxidation following ingestion of either a whey
protein isolate (WPI)-based or pea protein isolate (PPI)-based breakfast test beverage in young
(YM, n=15) or older (OM, n=15) men using indirect calorimetry. Data are expressed as means ±
SD. Data is controlled for body weight in kilograms (kg). (A) Resting energy expenditure (REE)
over time and net incremental area under the curve (niAUC). (B) Postprandial energy
expenditure (TEF) over time and niAUC. (C) Fat oxidation over time and niAUC. Data is
expressed as means ± SD. Means not sharing the same letter are significantly different (p <
0.05).
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Figure 3. Ratings of perceived appetite assessment following ingestion of either whey protein
isolate (WPI)-based or pea protein isolate (PPI)-based breakfast test beverage in young (YM,
n=15) or older (OM, n=15) men using visual analog scales. (A) Perceived hunger over time and
net incremental area under the curve (niAUC). (B) Perceived fullness over time and niAUC. (C)
Perceived prospective food consumption over time and niAUC. (D) Perceived desire to eat over
time and niAUC per age and protein source. Data are expressed as means ± SD. Means not
sharing the same letter are significantly different (p < 0.05).
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Figure 4. Postprandial peptide YY (PYY), and cholecystokinin (CCK) response following
ingestion of either whey protein isolate (WPI)-based or pea protein isolate (PPI)-based breakfast
test beverage in young (YM, n=15) or older (OM, n=15) men. (A) CCK response over time and
net incremental area under the curve (niAUC). (B) PYYbresponse over time and niAUC. Data is
expressed as means ± SD. Means not sharing the same letter are significantly different (p <
0.05).
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Appendix
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Supplemental Figure 1: Ratings of perceived desire for a snack and food cravings Ratings of
perceived appetite assessment following ingestion of either whey protein isolate (WPI)-based or
pea protein isolate (PPI)-based breakfast test beverage in young (YM, n=15) or older (OM,
n=15) men using visual analog scales. Line graphs represent perceived appetite over time and bar
graphs represent net incremental area under the curve (niAUC) per age and protein source group
(A) Perceived desire to eat; (B) Perceived desire for a snack; (C) Perceived desire for something
salty; (D) Perceived desire for something sweet. Data are expressed as means ± SDs. Means not
sharing the same letter are significantly different (p < 0.05).
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Supplemental Figure 2. Carbohydrate oxidation following ingestion of either whey protein
isolate (WPI)-based or pea protein isolate (PPI)-based breakfast test beverage in young (YM,
n=15) or older (OM, n=15) men using indirect calorimetry. Data is controlled for body weight in
kilograms (kg). The line graph represents Carbohydrate (CHO) oxidation over time and the bar
graph represents net incremental area under the curve (niAUC). Data is expressed as means ±
SDs. Means not sharing the same letter are significantly different (p < 0.05)
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Supplemental Figure 3. Postprandial glucose response following ingestion of either whey
protein isolate (WPI)-based or pea protein isolate (PPI)-based breakfast test beverage in young
(YM, n=15) or older (OM, n=15) men. The line graph represents the plasma glucose postprandial
response over time and the bar graph represents net incremental area under the curve (niAUC).
Data is expressed as means ± SDs. Means not sharing the same letter are significantly different
(p < 0.05).
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Supplemental Table 1. Amino acid composition per serving of breakfast test beverages
WPI

PPI

Alanine

2.00

1.62

Arginine

1.00

3.38

Aspartic Acid

4.60

4.70

Cysteine

1.20

0.60

Glutamic acid

6.40

7.14

Glycine

0.60

1.64

Histidine

0.80

0.98

Isoleucine

2.20

1.82

Leucine

5.00

3.35

Lysine

4.00

3.00

Methionine

1.00

0.35

Phenylalanine

1.40

2.20

Proline

1.80

1.74

Serine

1.40

2.08

Threonine

1.80

1.56

Tryptophan

1.20

0.35

Tyrosine

1.40

1.49

Valine
2.20
1.86
The amino acid composition of 40 grams of protein in the WPI and PPI breakfast test beverages.
WPI, whey protein isolate; PPI, pea protein isolate.
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CHAPTER 5. The Effect of Whey Protein Isolate and Omega-3 Fatty Acid
Supplementation on Markers of Cardiometabolic Health, Sleep, and Mood in PostMenopausal Women: A 16-Week Randomized, Controlled Trial

Abstract
Background: Post-menopausal women are at an increased risk for negative health
outcomes including cardiometabolic disease, sleep disturbances, and depression. Individual
supplementation of protein and omega-3 polyunsaturated fatty acids (n-3 PUFAs) has been
shown to mitigate age-related physiological decline with little evidence on well-being. In
addition, the combined effect of protein and n-3 PUFAs on successful aging (SA) is unknown.
Objective: The objective of this study was to determine the effect of protein and n-3 PUFA
supplementation individually and in combination on body composition, cardiometabolic risk,
strength, sleep and mood states in postmenopausal women to promote SA. We hypothesized that
concomitant protein and n-3 PUFA supplementation would improve body composition, decrease
cardiometabolic risk, and increase strength, indexes of sleep, and mood states compared to
individual supplementation and would be accompanied by increases in orexin-A (OXA)
concentrations. Methods: Thirty-nine postmenopausal women (age: 61.3 ± 8.7 years; BMI: 27.6
± 6.6 kg/m2) were randomly allocated to one of 5 groups: 1) control (CON; no intervention freeliving; n=6), 2) whey protein isolate (PRO; 25 g/d; n=7), 3) n-3 PUFA (DHA/EPA; 4.3 g/d;
n=10), 4) PRO + placebo soybean oil (PRO + PLA; 4.1 g/d; n=7), or 5) PRO + n-3 PUFAs
(n=9). Outcome measures of body composition, energy metabolism, metabolic health, sleep, and
mood states were assessed every four weeks and compared across all five groups at 0, 4, 8, 12,
and 16 weeks, except objective sleep, which was assessed at 0, 8, and 16 weeks, and body
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composition and hand-grip strength (HGS) which were assessed at 0 and 16 weeks only.
Results: We did not observe a significant treatment effect on anthropometrics, body composition,
HGS, resting energy expenditure, mood states, nor subjective or objective sleep quality. We
observed a significant treatment effect on OXA ( P < 0.05). OXA increased significantly in PRO
+ n-3 PUFA compared to all other groups (P < 0.05). Conclusions: Although not significant, the
data suggests individual and combined supplementation of protein and n-3 PUFAs have the
potential to improve outcomes of SA including cardiometabolic health, mood states, subjective
sleep, and OXA levels in postmenopausal women. NCT0303041

Introduction
The older adult population in the United States (U.S.) is a segment of unprecedented
growth [1]. This robust shift in demographics emphasizes the importance of independence,
quality of life, and health across the lifespan to promote successful aging (SA) [2]. SA can be
defined by low cardiometabolic risk, preservation of physical function, and a positive state of
well-being, which are strongly associated with body composition [3-9]. Age-related deleterious
shifts in body composition, one of the major threats to SA, can lead to sarcopenia, which is the
age-related loss of muscle mass, strength, and function [10]. Furthermore, declines in
endogenous estrogen production during the menopausal transition are associated with muscle
mass loss and increased central adiposity, putting postmenopausal women at increased risk for
negative health outcomes such as cardiovascular disease and type-2 diabetes mellitus [11-13]. In
addition to cardiometabolic risk, age- and menopause-related reduction in muscle mass and
function is associated with decreased well-being such as depression [14] and poor sleep quality
[15]. Research suggests nutritional strategies focused on the incorporation of high-quality protein
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and omega-3 polyunsaturated fatty acids (n-3 PUFAs) are potential methods to mitigate agerelated decline in skeletal muscle mass and gain in fat mass, decreases in metabolic health, sleep,
and mood in postmenopausal women to promote SA [16, 17].
Protein is a dietary focal point for SA as the constituent amino acids (AA) are the
essential building blocks necessary to sustain life [17]. The benefits of dietary protein intake for
older adults above the current recommended dietary allowance (RDA) of 0.8g/kg/day is well
established [17, 18], and experts generally recommend a dietary protein intake between 1.2 and
2.0 g/kg/day or higher and ~30 g of high-quality protein per meal to promote skeletal muscle
mass and function in older adults [18-25]. A recent cross-sectional analysis found
postmenopausal women who consumed ≥ 1.3 g/kg/day had a significantly higher skeletal muscle
mass index (appendicular lean mass / BMI) and significantly lower body fat percentage and
waist circumference when compared to women who consumed 0.94-1.29 g/kg/day [26].
n-3 PUFAs, eicosapentaenoic acid (EPA; 20:5 n-3), and docosahexaenoic acid (DHA;
22:6 n-3) are also associated with SA [27]. High doses of EPA and DHA (3-4 g/day) [28, 29]
may mitigate deleterious characteristics of aging via suppression of chronic inflammation,
incorporation into cellular membranes, and via stimulation of muscle growth through the same
mechanistic pathway, mechanistic target of rapamycin complex 1 (mTORC1), as dietary protein
[30]. Smith et al, demonstrated n-3 PUFAs (in the presence of AA infusion) increased wholebody protein synthesis [30] and that supplementation of 4g/d of n-3 PUFAs for six months
increased muscle mass and function in healthy older adult men and women [31]. Similarly,
postmenopausal women who consume a diet high in fish rich in EPA and DHA, such as the
Mediterranean diet, tend to have higher lean body mass than their counterparts [32] . However,
NHANES data demonstrates daily EPA and DHA intake from foods and supplements is well
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below recommendations with only ~10% of U.S. adults ≥ 55 years meeting or exceeding the
American Heart Association’s recommendations of 500 mg/day of EPA and DHA [33].
Approximately 30% of adults ≥ 50 years of age suffer from poor sleep quality and the
prevalence of sleep disruption is notably higher in postmenopausal women, with 35 to 60%
reporting significant sleep disruptions [34]. Sleep deprivation and low sleep quality are
associated with increased energy intake [35], insulin resistance, elevated glucose [36, 37], mood
disturbances (e.g., stress, cortisol, and depression) [38, 39], and poor body composition [40, 41].
Cross-sectional studies have found both dietary protein and n-3 PUFAs to independently
improve sleep and mood [42-44]. Yet, apart from weight-loss and exercise interventions, few
RCTs have investigated the effect of protein or n-3 PUFAs on sleep and mood in adults.
Therefore, further research is needed to investigate dietary protein and n-3 PUFAs as moderators
of indexes of sleep and mood as well as to further investigate possible mechanisms.
Orexin-A (OXA) and orexin-B (OXB), also known as hypocretin-1 and hypocretin-2, are
excitatory neuropeptides solely synthesized in the hypothalamus [45, 46] and project throughout
the brain and spinal cord where G-coupled protein receptors, orexin receptor 1 (OXR1) and
orexin receptor 2 (OXR2) are located [46, 47]. OXA is a “multi-tasking” neuron and regulates a
broad range of physiological functions such as sleep/wake states (rapid eye movement), energy
homeostasis (increase in O2 consumption), excitatory motivational behavior, cognitive function,
and affect states [48-50] and has been proposed as a possible mechanism of SA [51]. A lack or
deficiency of OXA is associated with daytime sleepiness and nighttime wakefulness (REM
disruption), decreased energy expenditure, increased adiposity, decreased mood/motivation [52],
decreased motor neuron signaling, and inflammation [46, 47, 53] . Current literature suggests
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OXA is a unique endogenous factor that influences SA [51], albeit nutrition-based human
research is limited.
The objective of the current randomized, controlled dietary intervention was to assess the
individual and combined effect of protein and n-3 PUFAs on body composition, cardiometabolic
health, indexes of sleep, and mood states in postmenopausal women to promote SA. This study
was also designed to assess the effect of protein and n-3 PUFAs on OXA as a proposed
biomarker of SA. We hypothesized that concomitant protein and n-3 PUFA supplementation
would improve body composition, metabolic health, indexes of sleep, and mood states compared
to individual supplementation and would be accompanied by increases in OXA concentrations.

Materials and Methods
Participant Recruitment and Ethical Approval. From July 2018 to April 2020,
postmenopausal women (≥ 12 consecutive months without menstruation) were recruited to
participate in this clinical trial. Due to the onset of the COVID-19 pandemic recruitment and
enrollment were terminated earlier than expected. Participants were recruited from the Northwest
Arkansas area via the daily University of Arkansas digital newsletter, flyers throughout the
community, word-of-mouth, and social media to participate in this study. The initial screening
was carried out via phone interview. Participants who consumed protein and or n-3 PUFA
supplements, consumed fatty fish ≥ two times per week, did not regularly consume breakfast (<5
times/week), smoked, had dietary restrictions, food allergies, were actively trying to lose weight,
participated in vigorous activity for ≥4 h/week, had any pre-existing metabolic conditions (e.g.,
type 1 or 2 diabetes, cancer, cardiovascular disease), were taking hormone replacement therapy
and/or medications that would influence protein, n-3 PUFA, or energy metabolism, were
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claustrophobic, and/or were uncomfortable with needles, or were unavailable due to travel or
work schedule were excluded from participating in the study. At the conclusion of the phone
screening participants completed the Pittsburgh Sleep Quality Index (PSQI).
Participants who met all exclusion criteria and scored >5 via the PSQI global score or slept < 7
hours a night qualified for participation in this clinical trial. One hundred seventy women
underwent an initial phone screening and 39 eligible women completed all study procedures
(July 2020). Written consent was obtained from participants prior to starting the study. Ethical
approval for the study protocol was approved by the Office of Research Compliance Institutional
Review Board of the University of Arkansas (Fayetteville, AR, USA). This trial was registered at
clinical trials.gov as NCT0303041.
Study Design. The study and all measurements were conducted at the Center for Human
Nutrition at the University of Arkansas unless otherwise stated. The study was conducted as a
randomized parallel design study with one control and four dietary intervention arms via excel
complete double randomization of treatment groups and treatment code with an allocation ratio
of 1:1. The dietary intervention groups were as follows; 1) control (no intervention, free-living;
CON; n=6), 2) whey protein isolate (WPI; 25 g; n=7), 3) n-3 PUFAs, EPA and DHA (n-3 PUFA;
4,300 mg; n=10), 4) WPI + placebo fat (PRO+PLA; 25 g WPI +4,140 g soybean oil; n=7), and
5) WPI + n-3 PUFAs (WPI+n-3 PUFA; 25 g WPI + 4,300 mg of n-3 PUFA; n=9). Refer to
Table 1 for participant demographics and baseline anthropometrics for each treatment group. On
the basis of previous estimates of variance in triglyceride assessment, we originally aimed to
recruit 80 participants as 80 participants (n=16 per dietary intervention) provide 80% power at P
< 0.05 for detection of a 17.7 mg/dl change in fasting triglycerides. However, to test the
appropriateness of the of the forced sample size (due to COVID-19 ending recruitment early) we
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carried out two post-hoc power analyses using the SAS procedure PROC POWER with a oneway ANOVA. First, using the observed sample means and standard deviations we determined 11
participants were needed to reach a statistical power of 0.86 (based on an overall level of
significance of 0.05) to detect an accurate 16-week difference in fasting plasma triglyceride
concentration. Next, we determined the power of the obtained sample size of 6, 7, 10, 7, and 9
had a statistical power of 0.722.
In this 16-week supplementation intervention all nutritional supplements were consumed
daily for 16 weeks. To ensure compliance, participants returned empty containers every four
weeks. n-3 PUFA and soybean capsules were stored in pill boxes with AM and PM dividers and
WPI was received in 28 individual one-serving bags. At the initial visit, participants signed the
consent form and body composition was determined using dual energy X-ray absorptiometry
(DXA) analysis (Lunar Prodigy, GE Healthcare, Madison, WI, USA) at the Exercise Science
Research Center at the University of Arkansas. Participants also received an ActiGraph sleep
monitor (ActiGraph, LLC, Pensacola, FL, USA), sleep diary, and 3-day food records to return at
their first clinical test day and the following study materials: a breakfast recipe book with or
without the addition of WPI, food scales, measuring cups and spoons, and a Blender Bottle
(Blender Bottle Company, Lehi, UT) for protein consumption.
Outcome measures were assessed every four weeks and compared across the four
intervention and one control group at 0, 4, 8, 12, and 16 weeks, except objective sleep at 0, 8,
and 16 weeks and body composition and strength which was assessed at 0 and 16 weeks only.
On the five clinical test days, the participants arrived fasted (10–12 h) at the Center for Human
Nutrition at the University of Arkansas at or before 08:00 for data collection. Compliance was
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assessed via capsule and empty WPI bag count, completion of weighed food records, and verbal
participant confirmation of supplement consumption, and time of consumption.
Dietary Intervention. The n-3 PUFA and placebo soft gels and were supplied by “Nordic
Naturals” (94 Hangar Way, Watsonville CA, 95076) and stored in the refrigerator at 4 °C.
During the 16-week intervention, participants were instructed to swallow two soft gels
containing either n-3 PUFA or placebo fat twice daily with the breakfast and dinner meal. One
dose of n-3 PUFAs, two soft gels, contained 1125 mg of EPA and 875 mg of DHA for a daily
dose of 4.0 g/day and ratio of 1.3 EPA: DHA. The n-3 PUFAs were sourced from anchovies and
sardines. All capsules contained a lemon oil to mask differences in taste and were identical in
color and shape. n-3 PUFAs and PLA (4.14 g/d) were administered in a single-blinded manner.
The daily supplement of protein contained 25 g unflavored WPI (BiPRO; Davisco Foods
International). The WPI was allocated into 28 separate small bags and participants received a
new batch every four weeks. Each WPI bag contained one serving of unflavored protein powder
and was consumed daily prior to 10:00 am with breakfast. Each daily serving provided 106 kcal,
25 g protein, 3.6 g leucine, 1.6 g isoleucine, 1.5 g valine, 0.4 g fat and 0 grams of carbohydrates.
Refer to Table 2 for the nutritional composition of the dietary supplements. Participants were
instructed to continue their habitual dietary and physical activity routines for the duration of the
clinical trial.
Body Composition and Anthropometrics. Height, weight, and waist-to-hip ratio (WHR)
were measured in the fasted state. Body weight was measured to the nearest 0.05 kg using a
calibrated scale (Detecto, St. Louis, MO). Height was measured to the nearest 0.01 cm via a
standard stadiometer (Detecto, St. Louis, MO) following the removal of shoes and layered
clothing, in the free-standing position. Waist circumference measurements were measured by
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research personnel at the level of the umbilicus with a 150 cm soft tape measure snug, but no
constricting, around the participant’s body. Participants were instructed to take normal breaths
and relax with their hands at their side, feet positioned closely together, and weight evenly
distributed. The measurements were taken at the end of normal expiration or at functional
residual capacity, duplicated, and averaged [54]. Body composition was determined via dualenergy X-ray absorptiometry (DXA) analysis (Lunar Prodigy, GE Healthcare) at the Exercise
Science Research Center at the University of Arkansas.
Strength Measurements. Isometric grip strength (kg) was measured using a standard
hand-grip dynamometer (Takei Scientific Instruments, Niigata-City, Japan). Participants
observed a demonstration by the researcher and were properly fitted to the dynamometer so that
their middle finger was at a 90-degree angle. In the standing position, participants were
instructed to squeeze maximally for 3-seconds. Three trials were completed on each hand,
beginning with the dominant hand, with a 60-seconds rest period between trials according to the
NHANES Muscle Strength Procedures Manual [55]. Handgrip strength was quantified by the
maximal grip force of the dominant hand. Grip strength relative to body weight and lean body
mass (LBM) was calculated by dividing grip force by the body mass (kg) and LBM (kg)
respectively of the participant at each timepoint.
Energy Expenditure and Substrate Oxidation. Resting energy expenditure (REE;
kcal/min) and substrate oxidation (SO; kcal/min) were measured in the fasted state via indirect
calorimetry (PARVO Medics, TrueMax 2400 metabolic cart) using the validated ventilated hood
technique [56]. A detailed methodology description has been published by Neumann et al [57].
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Sleep Assessment. Sleep quality and duration were assessed objectively via an ActiGraph
triaxial wrist accelerometer GT3X+, a validated method of sleep assessment [58]. Each
participant wore an ActiGraph monitor on the non-dominant wrist for 24-hour per day for seven
days (except when bathing or involved in water activities) prior to the start of the intervention, 8, and 16-weeks. Actigraph monitors were fitted securely on each participants wrist. Participants
received sleep diaries to define “time in bed” and “time out of bed”. Researchers used the
indicated “start” and “end” points to define a sleep region to be analyzed within the ActiGraph
software. Sleep outcomes were calculated based on epoch-to-epoch sleep/wake algorithms
within the defined sleep period. Data were processed by using the ActiLife Version 6.9.2
software (Pensacola, FL, USA) and sleep was scored via the Cole-Kripke algorithm [59]. The
following data was sleep outcomes were recorded: sleep latency (time between lights out and
first minute algorithm scores as sleep); sleep efficiency % (total sleep time/total time in bed);
total sleep time (TST; total number of minutes scored asleep); time in bed (TIB; total number of
minutes in bed); wake after sleep onset (WASO; total minutes awake after sleep onset);
awakenings (total and average}; Sleep Fragmentation Index (SFI; degree of sleep
fragmentation). A seven-day average was calculated for each sleep outcome.
A subjective measure of sleep quality was assed via the Pittsburgh Sleep Quality Index
(PSQI) questionnaire [60]. The 19-item PSQI questionnaire addressed seven components of
subjective sleep quality: subjective sleep quality, sleep latency, sleep duration, habitual sleep
efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction. In scoring the
PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty).
The component scores are summed to produce a global sleeping score (GSS) with a range of 0 to
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21. Higher scores indicate worse sleep quality. A compiled global score of the seven scored
components distinguishes good sleepers (≤ 5) from poor sleepers (>5) [61] .
Positive and Negative Affect States. The Profile of Mood States (POMS) questionnaire
consists of 65 questions containing a one-word adjective of mood to measure and identify six
affective states. The six identifiable mood/affective states are tension-anxiety, depressiondejection, anger-hostility, vigor-activity, fatigue/-inertia, and confusion-bewilderment.
Participants were instructed to define their mood on a 5-point Likert scale ranging from 0 to 4.
The numbers refer to the following descriptive phrases: 0 = Not at all, 1 = A little, 2 =
Moderately, 3 = Quite a bit, 4 = Extremely. Prior to the start of the questionnaire each participant
was read the following directions: Describe how you have been feeling during the past week
including today by circling the number that best describes your present mood with 0 indicating
“Not at all,” and 4 indicating “Extremely”. A researcher was readily available to answer
questions regarding the meaning of a word. POMS was administered in the fasted state at
baseline, 4-, 8-, 12- and 16- weeks. To obtain the score for reach identifiable mood/affective
state subscale, the sum of the responses for each adjective is calculated. The subscale scores
range from 0 up to 36, 60, 48, 32, 28, and 28 for tension-anxiety depression-dejection, angerhostility, vigor-activity, fatigue/-inertia, and confusion-bewilderment respectively. Higher
subscale scores for all affect states, but the vigor domain represent poorer mood. Two adjectives
relaxed and efficient were inversely scored from 4 to 0 rather than 0 to 4. Total Mood
Disturbance Score (TMD) is calculated by summing the scores across all six factors (weighting
vigor negatively). The total mood disturbance (TMD) is calculated by the following equation:
TMD = (Tension-Anxiety) + (Depression-Dejection) + (Anger-Hostility) + (Fatigue-Inertia) +
(Confusion-Bewilderment) – (Vigor-Activity).
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The TMD score is the most reliable outcome of POMS because of the intercorrelations among
the six affective factors and ranges from -32 (best possible TMD score) to 200 (worst possible
TMD score). The POMS questionnaire has been validated in postmenopausal women [62].
Plasma Biomarkers. Two blood samples (10 mL/sample, 20 mL/testing day) were
collected after a 10- to 12-h fast at baseline, 4-, 8-, 12-, and 16-weeks. The samples were
collected in EDTA-coated vacutainer tubes. Samples were immediately centrifuged at 4°C for 15
min at 1800 × g. The plasma was separated and stored at −80°C until analysis. Plasma glucose
(catalog #: 10009582; mg/dL), triglycerides (TG ; catalog #: 10010303mg/dl), C-reactive protein
(CRP; catalog #: 10011236; pg/mL), free-fatty acids (FFA; catalog #: 700310; uM), total
cholesterol (catalog #: 10007640, mg/dl), insulin (catalog #: 26619, uUI/mL) concentrations
were determined via commercially available kits (Cayman Chemical Company, Ann Arbor, MI,
USA). Plasma cortisol (EIA-CORT, ng/mL) and brain-derived neurotrophic factor (BDNF;
ELH-BDNF, ng/mL) concentrations were determined via commercially available kits
(RayBiotech, Inc, Norcross, GA, USA). Human orexin-A (OXA; LS-F4072; pg/mL)
concentrations was determined via commercially available kit (LifeSpan Biosciences, Inc,
Seattle, WA, USA). Creatine kinase M (CKM; Ab185988, U/mL) concentrations were
determined via commercially available kits (Abcam Cambridge, UK). All kits were performed
per the manufacturer’s instructions.
Dietary Records and Assessment. Participants completed a five self-administered 3-day
weighed food record prior to the intervention and at 4, 8, 12, and 16 weeks (two weekdays and
one weekend). Each participant was trained to accurately record quantities of food using a
provided food scales (Greater Goods, LLC) and beverages. Participants were instructed to
include brand names and methods of food preparation. The 3-day food records were reviewed
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with participants on each test day to ensure food intake was properly recorded in detail. The
energy, macronutrient, and micronutrient composition of the 3-day food records analyzed using
the Nutrition Data System for Research software (NDSR; NDS version 2018, Nutrition
Coordinating Center, University of Minnesota, Minneapolis, MN).

Statistical Analysis
Summary statistics were calculated for all data and data are expressed as mean ± SD.
One-way ANOVA was used to analyze baseline measurements of participant characteristics and
body composition. The one factor repeated measures design was analyzed as a generalized linear
mixed model with treatment group and time as fixed factors with time treated as a repeated
measures and subjects as random nested within treatment group. Number of levels of time
depended on the variable being tested which included 2, 3, and 5 time points. Initially, age and
BMI were considered as covariates. BMI was not considered as a covariate when measured as a
response or when analyzing body composition variables. All of the response variables, if they
could only take on only a positive value and were non-proportion values, were assumed to follow
a gamma distribution. Responses that were percentages were converted to proportions and
analyzed as a beta distribution. PSQI global score was assumed to follow a Poisson distribution.
POMS TMD was assumed to follow a gaussian distribution as TMD includes a range of positive
and negative scores. The treatment effect was tested when variables were converted to 16-week
change, by subtracting out baseline values (week-16 – baseline) they could take on positive or
negative value and were assumed to follow a gaussian distribution.
Where appropriate, follow-up least-squares mean (LS-mean) comparisons for treatment
and time main effects were declared significantly different if the corresponding ANOVA F
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statistic was significant. For any significant and interaction trends (P <0.1), mean comparisons
were carried out using the least significant difference (LSD). Statistical analyses involving
generalized linear mixed models were performed using PROC GLIMMIX in SAS version 9.4
(SAS Institute inc., Cary, NC). All graphs were made using GraphPad Prism Software version
7.0 (GraphPad Software, San Diego, CA). P < 0.05 was considered significant. As previously
mentioned, post-hoc power analyses using the SAS procedure PROC POWER with a one-way
ANOVA determined the observed sample means, standard deviations, and sample size of 6, 7,
10, 7, and 9 had a statistical power of 0.722. Therefore, as type-2 error is high trends will be
addressed in the subsequent sections.

Results
Subject Flow Chart, Characteristics, and Compliance. Of the 45 women eligible for the
study, 39 completed the study resulting in a 13.33 % attrition rate as shown in Figure 1. Reasons
for subject withdrawal can be found in Figure 1. Baseline characteristics (sex, age, baseline
anthropometrics, and baseline PSQI GSS) of subjects in the four treatment and control groups
who completed the study were not statistically different (Table 1). The average compliance of
subjects who completed the study in a dietary intervention group, as judged by the leftover
capsule and bag count was as follows: PRO: 99.4 ± 0.01%; n-3 PUFA: 98.6 ± 0.02%; PRO +
PLA: 98.8 ± 0.02%; and PRO + n-3 PUFA: 99.0 ± 0.02%. 16-weeks of dietary interventions did
not significantly affect anthropometric measurements of body weight, BMI, waist circumference,
hip circumference, or the waist to hip ratio (Table 3 and Table 4).
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Body Composition and Handgrip Strength. The differences in outcomes of body
composition and handgrip strength as a result of the dietary intervention are outlined in Table 4.
We observed a decreased trend for a group-by-time interaction effect for android fat % (P =
0.07) over the 16-week period. After applying LS-means, the CON and PRO groups had a
significant increase and decrease in % android fat from week 1 to week 16 respectively (P <
0.05) with no significant differences between treatment groups. A decreased trend for the
treatment effect (16wk – baseline) was observed for android fat % (P = 0.07). Following LSmeans, we found android fat % in PRO (-2.5 ± 2.2 %), n-3 PUFA ( -0.2 ± 3.2 %), and PRO + n-3
PUFA (-0.1 ± 3.0 %) significantly decreased when compared to the CON group (+2.8 ± 1.8 %)
(P < 0.05) with no differences when compared to PRO + PLA (0.2 ± 4.2 %). Although nonsignificant, we observed a trend towards greater % increase in the treatment effect on total fat
mass (kg) in the CON (+4.6 ± 3.6 %) compared to the PRO (-2.4 ± 5.2 %), n-3 PUFA (-0.7 ± 8.6
%), PRO + PLA (+1.3 ± 10.2 %), and PRO + n-3 PUFA (+2.0 ± 6.7 %). Similarly, we observed
a non-significant trend in the CON group towards a greater % decrease in FFM (-0.65 ± 2.06 %)
compared to PRO (+0.82 ± 1.19 %), n-3 PUFA (+1.25 ± 2.82 %), PRO and PRO + n-3 PUFA
(+0.36 ± 3.62) with similar losses compared to PRO + PLA (-0.98 ± 2.93 %). We did not
observe any significant effects of the 16-week dietary intervention on FFM, LBM, ALM, Total
FM, whole body fat %, android fat %, gynoid fat %, fat-to-lean ratio, or BMD.
We observed an increased trend of treatment effect on high HGS, over the 16-week
intervention (P = 0.08). PRO + PLA and PRO + n-3 PUFA supplementation resulted in
increases in high HGS by 7.9% and 5.2% compared to 0.3% increase in the control group (P <
0.05).
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Energy Expenditure and Substrate Oxidation. The effects of the 16-week
supplementation intervention on energy expenditure and substrate oxidation controlled for FFM
can be found in Table 5. After controlling for FFM, there was a significant effect of group on fat
oxidation (kcal/min), carbohydrate oxidation (kcal/min) and REE (kcal/day). Following LSmean we observed no significant differences between treatment groups in carbohydrate oxidation
nor REE. However, fat oxidation increased in n-3 PUFAs and PRO + n-3 PUFAs from baseline
to 16 weeks (P < 0.05). After controlling for baseline, an increased trend for fat oxidation
treatment effect was observed (P = 0.06). Following LS-means n-3 PUFA (+34.6 %; P < 0.05)
and PRO + n-3 PUFA (+55.6 %; P < 0.05) had significantly higher fat oxidation at 16 weeks
compared to baseline and PRO had significantly lower fat oxidation (-37.8%; P < 0.05)
compared to differences in all other treatment groups from baseline to 16 weeks.
Objective and Subjective Sleep. The effects of the 16-week supplementation intervention
on objective sleep duration and quality can be found in Table 6. We observed a significant
treatment effect (P < 0.05) for time in bed with PRO + n-3 PUFA significantly decreasing their
bedtime (-42 ± 62.4 min) when compared to n-3 PUFA (+0.6 ± 36.6 min) and PRO (+32.4 ± 18
min). Contrarily, PRO and n-3 PUFAs had a significant increase in bedtime compared to CON (15 ± 25.8 min). We observed a significant group (P < 0.05), but not a treatment effect for
WASO and sleep fragmentation with n-3 PUFA displaying a significant increase in WASO and
the sleep fragmentation index compared to all other groups. PRO had significantly lower WASO
and sleep fragmentation index at baseline (P < 0.05) and n-3 PUFA group had significantly
higher sleep latency (P < 0.05). We found no significant treatment effects of time out of bed,
sleep latency, sleep efficiency, sleep duration, nor number of awakenings.
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The effects of the 16-week intervention on subjective sleep duration and quality can be
found in Figure 2, and seven component scores in Table 7. We observed a significant time effect
(P < 0.05) on PSQI global scores with no differences between groups, but a significant decrease
in GSS from week 1 to 16 (P < 0.05). Although not significant, a greater % decrease was
observed in PRO (30.3%), n-3 PUFA (23.3%), PRO + PLA (20.2%), and PRO + n-3 PUFA
(26.4%) when compared to CON (-17.9%).
Profile of Mood States. The effects of the 16-week intervention on POMS TMD and sixaffect state subcomponent scores can be found in Table 8. No significant treatment, group, time,
nor group x time main effects were observed for POMS TMD score or subcomponents of
depression, anger, and fatigue over the 16-week intervention. However, a significant group and
group x time effect was observed for vigor (P < 0.05). At week-16 vigor scores were
significantly higher following PRO (20.6 ± 9.1) and n-3 PUFA (18.1 ± 8.0) supplementation
compared to CON (12.3± 6.4) with no differences compared to PRO + PLA (16.4 ± 6.2) and
PRO + n-3 PUFAs (16.3 ± 5.0).
Biomarkers of Metabolic Health and Well-being. The effects of the 16-week
intervention on biomarkers of cardiometabolic risk can be found in Table 9. We observed a
significant time or group X time effect of the 16-week supplementation intervention on insulin
(time: P < 0.05), FFA (time: P < 0.05), and cholesterol (group X time: P < 0.05) with a trend for
HOMA-IR (time: P = 0.09) and TG (group: P = 0.05). Following LS-means we found insulin,
HOMA-IR, FFA, cholesterol, and triglycerides decreased over time regardless of group (P <
0.05). A significant treatment effect was observed in cholesterol alone (P < 0.05) with significant
decreases in PRO by -7.3%, n-3 PUFA by -7.9%, PRO + PLA by -1.8% and PRO+n-3 PUFA by
-20.6% compared to an increase in CON by +17.8%. Although a treatment effect was not

168

observed, the percent decrease in triglycerides in n-3 PUFA + PRO was at least -16% greater
when compared to subsequent groups. No effect of 16-week intervention was observed on CRP
concentrations.
The effects of the 16-week intervention on biomarkers of well-being can be found in
Figure 3. We observed a significant effect of time BDNF (P < 0.05) and cortisol (P < 0.05) with
a trend on OXA (P = 0.07). However, we observed a significant treatment effect for OXA (P <
0.05). After applying LS-means we observed a significant increase in OXA concentration in
PRO + n-3 PUFA (Wk16: 28.4 ± 17.5; Δ Wk16: 8.6 ± 9.3 pg/mL) compared to PRO (Wk16:
19.2 ± 9.5; Δ Wk16 : -1.3 ± 7.0 pg/mL), n-3 PUFA (Wk16: 15.7 ± 11.2; Δ Wk16: -0.8 ± 5.9
pg/mL) , PRO +PLA (Wk16: 25.0 ± 16.8; Δ Wk16: 1.5 ± 8.1 pg/mL) , and CON (Wk16: 19.2 ±
10.7; Δ Wk16: 0.8 ± 3.3 pg/mL). Overall, the percent OXA increase in n-3 PUFA + PRO was at
least 19.4 % greater than subsequent study groups. We did not observe a treatment effect for
CKM, BDNF, or cortisol. OXA, BDNF, CKM, and cortisol raw values can be found in Table 10.
Dietary Intake. The effects of the 16-week intervention on dietary intake of energy and
macronutrients, AAs, and lipids can be found in Table 11, Table 12, and Table 13 respectively.
We observed no differences in energy intake (kcal/d) at baseline nor a group, time, group X time,
or treatment effect. We did not observe a significant treatment effect on total energy (kcal/day)
intake, macronutrients total (g/d and % energy), nor protein g/kg/bw. However, at baseline PRO
+ n-3 PUFA and PRO had a significantly higher protein intake g/day compared to CON (P <
0.05). We observed a significant time effect on carbohydrates (P < 0.05). Following LS-means
total carbohydrates significantly decreased in all groups from week 1 to week 16 (P < 0.05) with
no significant differences between groups.
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We observed a significant increase in EPA (mg/d), DHA (mg/d), % n-3 PUFAs of total
energy, and decreased n-6 PUFA: n-3 PUFA ratio (P < 0.05) in n-3 PUFA and PRO + n-3
PUFA. We observed a significant treatment effect of cholesterol (mg/d) (P < 0.05), but not
saturated fat (g/d), with lower cholesterol dietary intake in PRO + n-3 PUFA compared to
subsequent groups. PRO + PLA had a significantly lower cholesterol intake at baseline (P <
0.05) compared to subsequent groups. No differences in AA intake were observed at baseline.
We observed a significant time, group, time X group on total essential amino acids, branchedchain amino acids, tryptophan, and cysteine with increases in the PRO and PRO + n-3 PUFA
groups (P < 0.05). We observed a significant treatment effect on tryptophan (P < 0.05) with an
increased trend on total essential amino acids (P = 0.07), branched-chain amino acids (P = 0.05),
and cysteine with increases in the PRO and PRO + n-3 PUFA groups (P = 0.08).

Discussion
To our knowledge, this is the first RCT to examine the effect of 16-weeks of dietary
protein and/or n-3 PUFA supplementation on body composition, cardiometabolic risk, and wellbeing effect of in postmenopausal women. The present study tested the hypothesis that combined
dietary protein and n-3 PUFA supplementation would have a greater effect on body composition,
cardiometabolic risk, and indexes of sleep and mood states in postmenopausal women when
supplemented in combination as WPI and n-3 PUFA compared to individual supplementation.
Collectively, the results of this study suggest protein and n-3 PUFA combined supplementation
when compared to individual supplementation for 16-weeks does not provide additional benefits
on body composition, cardiometabolic health, and well-being. However, the results of this study
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indicate a trend that individual protein and n-3 PUFA improve different outcomes of SA
compared to free-living postmenopausal women.
Diets rich in high-quality protein and n-3 PUFAs, EPA and DHA, are positively
correlated with body composition, cardiometabolic health, and well-being in middle-aged and
older adults [27, 63, 64]. To our knowledge, RCTs examining the effect of dietary protein and n3 PUFA combined supplementation have solely been conducted in the context of a multi-nutrient
supplement or in combination with caloric restriction or exercise [65-67]. When consumed bidaily for 6-weeks a multi-nutrient supplement containing WPI, EPA, and DHA increased LBM
and strength in older adults [66]. Although not significant, the present study found an increased
trend in handgrip strength following PRO + PLA (2.1 ± 2.5) and PRO + n-3 PUFA (1.2 ± 2.5 kg)
supplementation with a decrease in CON (-0.3 ± 2.1) from baseline. The observed increases may
be functionally relevant as HGS is reflective of physical performance [68]. For example, in older
women every 1-kg increase in HGS is associated with a 0.13-s decrease in 3-minute walk time
and 1% decrease in chair rise time [69]. Similarly, in the present study non-significant increases
in FFM, were found following supplementation with PRO by 0.82%, n-3 PUFAs by 1.25%, and
protein + n-3 PUFAs by 0.35% compared to decreases in the control, free-living group by -0.65
%. Although, not statistically significant, in adults ≥50 years of age skeletal muscle begins to
significantly decline [70] and annual skeletal muscle loss is estimated to be approximately ~0.5
to 1% which emphasizes the physiological importance for even a small enhancement of FFM
preservation [71, 72]. The protective effect of protein and n-3 PUFAs on FFM/LBM is further
supported in longitudinal prospective studies in older adults [73, 74], which demonstrates a
longer supplementation period may be required to observe changes LBM. Furthermore, a caloric
restriction intervention in combination with a high-protein meal replacement (25 g) and fish oil
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(2,130 mg) reduced percent of android fat and the prevalence of metabolic syndrome by almost
twofold in comparison to caloric restriction alone (>40 years of age) [67]. In the present study
we observed a trend for individual PRO supplementation alone to reduce central adiposity.
Overall, the results do not indicate a significant effect of supplementation on body composition
nor HGS in post-menopausal women.
Protein and n-3 PUFAs may increase whole body REE and fatty acid oxidation, but the
results to date are varied. Dietary protein supplementation has been shown to increase REE by
preserving LBM primarily under caloric-restriction conditions [75]. When protein is consumed
within the AMDR, REE rarely increases after controlling for FFM [76]. For example, a weightmaintenance study following 12-weeks of energy restriction in adults (34-65 y) observed no
effect of a high-protein (27% dietary protein) compared to a lower protein (16%) diet [76].
Conflicting results are present in the literature regarding the influence of n-3 PUFAs on REE and
substrate oxidation and are conducted primarily in young adults [77-80]. For example, Noreen et
al. found six-weeks of fish oil supplementation (1,600mg EPA + 800mg DHA) did not influence
REE in adult men and women (34 ± 13 y) [78] and an alternative RCT found 3 g/day EPA and
DHA improved REE, but not fat oxidation, over a 12-week supplementation period in young
men [77]. However, a seminal study by Couet et al. found supplementation of 6 g/day of fish oil
for 3 weeks significantly increased fat oxidation, but not REE after controlling for LBM in
young men [79]. More recently, Logen et al. supplemented n-3 PUFAs (2 g EPA, 1 g DHA) for
12-weeks in healthy older women (66 ± 1 y) and found a significant increase in both REE (14%)
and fat oxidation (19%) [80]. Our study found no effect of supplementation on REE, but n-3
PUFAs and n-3 PUFAs combined with protein increased fat oxidation over the 16-week
intervention by ~34.6 % and ~55.6% respectively after controlling for FFM. Several theories
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have been proposed to explain the mechanisms of n-3 PUFAs and protein supplementation on
REE and substrate oxidation, although the precise mechanisms are yet to be fully elucidated. A
few likely theories include preservation/increases in skeletal muscle mass [81], EPA and DHA
incorporation into the phospholipid and mitochondrial membrane [82, 83], and altered gene
expression of enzymes involved in fatty acid oxidation [84] and energy metabolism [85] .
Poor well-being characterized by decreased sleep quantity, quality, and mood is
independently associated with an increased risk of obesity, sarcopenia, cardiometabolic disease,
and functional decline in middle-aged and post-menopausal women [86]. Over the past decade,
sleep duration and quality has decreased, and depression has increased in the US. Postmenopausal women report worse sleep quality and higher total mood disturbances compared to
the U.S. average [62, 87]. However, a link between diet, sleep, and mood remains inconsistent.
Our study results did not indicate a significant effect of supplementation of protein or n-3 PUFAs
on indexes of subjective or objective sleep or mood states compared to the free-living control
group. Interestingly, we observed improvements in perceived sleep quality and mood states in all
arms of the intervention over time. However, as the observed improvements were not
significantly greater than the control free-living group benefits cannot be attributed to one or
both of the supplemented nutrients. Contrarily, we did not observe an increasing trend in
objective sleep quality. In support of our findings, a PSQI validation study identified affect
states, opposed to actigraphy sleep parameters as correlates due to the influence of depression
and positive outlook on perceived sleep quality [88]. In agreement with the current literature,
biomarkers associated with mood states, BDNF and cortisol, increased and decreased
respectively with improvements in mood scores [89, 90] . Decreases in cortisol concentrations
are reflective of down-regulation of the hypothalamic-pituitary adrenal axis and subsequently
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decreases in cardiometabolic health [91]. Collectively we observed improvements in HOMA-IR
and decreases in triglycerides, FFA, and cholesterol among treatment groups over time. Similar
to our findings, intervention investigating dietary protein and n-3 PUFAs found no effect on
mood (POMS), cognitive function [92] or indexes of sleep (accelerometry) [93]. Furthermore,
recent meta-analyses concluded n-3 PUFAs decrease depression and anxiety in older adults with,
but not without clinical depression [94] and anxiety [95]. Although RCTs have suggested
dietary protein and n-3 PUFAs as potential modulators of sleep and mood [96] further data is
needed to support these findings.
The orexin system has recently been suggested as “The Key for a Healthy Life” [51].
OXA has an identified role in emotion regulation, energy homeostasis, and sleep and
wakefulness [46, 48, 50, 97-99]. However, the effect of nutrients on OXA in humans is largely
unknown. Although, open-label, medication clinical trials and cross-sectional analyses have
observed a positive association between improvements in metabolic health and psychological
outcomes and OXA concentrations [97, 100]. For example, anti-hyperglycemic treatment in
type-2 diabetics via metformin improved glycemic control and increased OXA concentration by
26% [97]. Similarly, our results showed that protein and n-3 PUFAs increased OXA
concentrations by ~23.9% with <6% change in additional study arms. To our knowledge,
comparable dietary interventions have yet to be conducted and a mechanism of action of OXA in
cardiometabolic health, physical, and cognitive function, and well-being is yet to be elucidated in
humans. Moreover, data from our lab indicate obese Zucker rats assigned a high-protein (40%
energy) diet had reduced liver and skeletal muscle lipid deposition, and higher OXA
concentrations compared to obese Zucker rats consuming a moderate-protein (20% energy) diet
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for 12-weeks [101]. Therefore, there is a need to further assess the effect of dietary protein and
n-3 PUFA intake on OXA in post-menopausal women.
There are multiple limitations in the present study. First, only women were included in
our study sample to control for sex‐specific differences in well-being [102, 103], body
composition [104], and strength [105]. Second, in our study, all arms including the control, were
associated with significant improvements in sleep quality and duration via the PSQI GSS. The
improvements in all groups, despite no changes in objective sleep quality, may be attributed to
the placebo effect. The mechanisms of the placebo effect have not been directly established.
However, participant expectancy and optimism are significant mediators of subjective outcomes
of well-being [106, 107]. To avoid bias, future clinical trials evaluating subjective components of
well-being should consider evaluation of expectancy of outcomes post-randomization (e.g.,
Credibility and Expectance scale) [108]. Third, although we screened for dietary protein
supplementation, we did not screen for baseline dietary protein intake. Fourth, a group of
participants completed the trial during the COVID-19 pandemic. Although, all supplements were
supplied we cannot verify how COVID-19 may have affected food availability, sleep, and stress
levels. Lastly, the findings of this clinical trial are based off of a lower than anticipated sample
size and may not translate to all post-menopausal women.
The results of this study indicate that concomitant compared to individual
supplementation of protein and n-3 PUFAs does not provide significant additional benefits on
body composition, cardiometabolic risk, and well-being in post-menopausal women. However,
protein and n-3 PUFA have the potential to reduce abdominal adiposity, increase strength,
enhance fatty acid oxidation, and to improve subjective mood states and sleep. In addition, a
potential additive effect on OXA concentration warrants further investigation. Future research
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should evaluate the efficacy of combined protein and n-3 PUFA supplementation over a longer
duration and investigate the mechanisms underlying the suggested improvements in
cardiometabolic risk, well-being, and OXA to promote SA.
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Tables
Table 1. Demographic and baseline anthropometric characteristics of the study population by treatment group

Age, y
Anthropometrics1
Height, m
Weight, kg
2

BMI, kg/m
Waist, cm
188

Hip, cm
WHR

CON
(n=6)
63.0 ± 8.9

PRO
(n=7)
61.6 ± 8.4

n-3 PUFA
(n=10)
58.5 ± 12.0

PRO + PLA
(n=7)
61.2 ± 2.6

PRO + n-3 PUFA
(n=9)
63.3 ± 8.4

1.62 ±
0.08
72.4 ±
15.2
27.4 ± 4.6

1.63 ± 0.06

1.62 ± 0.05

1.64 ± 0.10

1.65 ± 0.08

0.70

73.4 ± 18.1

76.7 ± 20.3

70.0 ± 19.6

72.8 ± 22.4

0.97

27.4 ± 4.8

29.5 ± 8.4

25.9 ± 6.0

27.0 ± 8.1

0.86

91.4 ±
10.1
107.3 ±
9.6
0.85 ±
0.05

92.8 ± 17.2

98.0 ±18.0

89.8 ±15.6

89.1 ± 18.8

0.80

108.5 ± 12.1

111.6 ± 17.4

106.2 ± 16.4

110.1 ± 18.0

0.96

0.85 ± 0.07

0.88 ± 0.06

0.84 ± 0.04

0.81 ± 0.06

0.80

P-value
0.81

PSQI
0.56
GSS, AU
8.3 ± 3.0
6.7 ± 1.6
7.8 ± 2.7
7.7 ± 2.5
8.9 ± 2.8
2
Ethnicity
American Asian/Asian,
1 (10.0)
n (%)
Hispanic, n (%)
2 (28.6)
1 (14.3)
Caucasian, n (%)
6 (100)
5 (71.4)
9 (90.0)
6 (85.7)
8 (89.9)
Other, n (%)
1 (11.1)
1
Data are expressed as mean ± SD unless otherwise indicated. Significant differences: * P < 0.05. Control, no intervention, free
living; whey protein isolate, PRO; omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA;

whey protein isolate + placebo soybean oil, PRO + PLA; whey protein isolate + omega-3 polyunsaturated fatty acids,
eicosapentaenoic acid + docosahexaenoic acid, PRO + n-3 PUFA; Waist to hip ratio, WHR; Pittsburgh Sleep Quality Index, PSQI;
global sleeping score, GSS.
2
Ethnicity is expressed in terms of frequency (n) with percentage of participants within treatment group (%).
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Table 2. Nutrient composition of dietary supplements1
PRO

n-3 PUFAs

PRO + PLA

PRO + n-3 PUFA

Energy content, kcal

106.4

50

143.7

156.4

Protein, g

25.5

-

25.5

25.5

Leucine, g

3.6

-

3.6

3.6

Isoleucine, g

1.6

1.6

1.6

Valine, g

1.5

1.5

1.5

Fat, g
190
1

0.4

5

4.14

5

Total n-3 PUFA

-

4,300

284

4,300

EPA, mg

-

2,250

-

2,250

DHA, mg

-

1,750

-

1,750

Other, mg

-

300

284

300

Carbohydrates, g

-

-

-

-

The PRO represents a single dose of whey protein isolate which participants consumed prior to 10:00 AM with breakfast daily. The
n-3 PUFAs and PLA represent a combination of two daily doses. Two capsules of n-3 PUFAs or two capsules of PLAs were
consumed with breakfast and with dinner daily. Whey protein isolate, PRO; omega-3 polyunsaturated fatty acids, eicosapentaenoic
acid + docosahexaenoic acid, n-3 PUFA; whey protein isolate + placebo soybean oil, PRO + PLA; whey protein isolate + omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, PRO + n-3 PUFA; soybean placebo, PLA;
eicosapentaenoic acid, EPA; docosahexaenoic acid, DHA.

Table 3. Effects of a 16-week supplementation intervention on anthropometrics in dietary intervention and control groups1
Treatment effect2

Weeks of Intervention
Anthropometri
cs

0

4

8

12

16

Δ 16 wk

Weight, kg
72.4 ± 15.2

72.7 ± 15.2

73.0 ± 14.2

73.1 ± 14.2

73.0 ± 14.1

0.57 ± 2.01

PRO

73.4 ± 18.1

73.3 ± 18.2

73.0 ± 18.4

73.4 ± 19.1

73.2 ± 18.8

-0.23 ± 1.42

n-3 PUFA

76.7 ± 20.3

76.3 ± 20.9

77.3 ± 20.8

76.9 ± 20.8

76.7 ± 20.8

-0.01 ± 2.52

PRO + PLA

70.0 ± 19.6

69.7 ± 19.8

70.2 ± 19.3

70.4 ± 19.5

70.2 ± 19.7

0.23 ± 2.06

72.8 ± 22.4

73.2 ± 22.4

73.2 ± 21.6

73.8 ± 21.6

74.2 ± 21.7

1.28 ± 2.27
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CON

27.4 ± 4.6

27.6 ± 4.3

27.7 ± 4.3

27.8 ± 4.2

27.7 ± 4.0

0.30 ± 0.79

PRO

27.4 ± 4.8

27.4 ± 5.0

27.2 ± 4.9

27.3 ± 5.2

27.3 ± 4.9

-0.12 ± 0.52

n-3 PUFA

29.5 ± 8.4

29.3 ± 8.6

29.6 ± 8.5

29.6 ± 8.6

29.4 ± 8.6

-0.07 ± 0.92

PRO + PLA

25.9 ± 6.0

25.6 ± 6.1

25.8 ± 5.8

25.9 ± 5.9

25.8 ± 6.1

-0.05 ± 0.89

27.0 ± 8.1

27.0 ± 8.2

26.9 ± 8.0

27.3 ± 8.0

27.5 ± 7.9

0.49 ± 0.82

CON

91.4 ± 10.1

91.9 ± 8.3

92.7 ± 8.5

93.2 ± 8.4

92.8 ± 8.6

1.4 ± 3.14

PRO

92.8 ± 17.2

92.1 ± 16.7

91.9 ± 16.3

91.4 ± 17.1

91.0 ± 16.4

-1.8 ± 3.35

n-3 PUFA

98.0 ± 18.0

97.7 ± 18.5

98.0 ± 17.2

96.3 ± 16.8

97.1 ± 16.9

-0.8 ± 3.91

PRO + PLA

89.8 ± 15.6

90.5 ± 16.4

90.4 ± 15.7

88.7 ± 16.8

87.5 ± 15.7

-2.3 ± 3.41

89.1 ± 18.8

90.6 ± 18.7

91.8 ± 17.1

91.3 ± 19.2

90.2 ± 18.9

1.0 ± 5.93

PRO + n-3
PUFA
Waist, cm

PRO + n-3
PUFA
1

0.64

CON

PRO + n-3
PUFA
BMI, kg/m2

P

ANCOVA P3
Grou
Group Time p X
time
0.97
0.11
0.70

0.46

0.86

0.12

0.58

0.36

0.85

0.18

0.42

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean

oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different from
control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 3. Effects of a 16-week supplementation intervention on anthropometrics in dietary intervention and control groups1(Cont.)
Weeks of Intervention
Anthropometrics

0

4

8

12

16

Treatment
effect2
Δ 16
P
wk

Hip, cm
CON
PRO
n-3 PUFA
PRO + PLA
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PRO + n-3
PUFA
WHR
CON

107.3 ±
9.6
108.5 ±
12.1
111.6 ±
17.4
106.2 ±
16.4
110.1 ±
18.0

107.2 ±
7.0
108.2 ±
12.5
111.3 ±
16.9
105.3 ±
16.7
111.3 ±
17.8

107.2 ±
9.1
107.8 ±
13.0
112.6 ±
16.2
106.3 ±
14.0
110.5 ±
17.2

107.8 ±
9.2
108.6 ±
12.4
111.6 ±
17.4
105.9 ±
17.4
110.5 ±
16.7

107.4 ±
10.3
108.4 ±
12.5
111.6 ±
16.5
106.1 ±
15.3
110.6 ±
17.5

ANCOVA P3
Group

Time

Group
X time

0.99

0.94

0.97

0.94

0.39

0.34

0.13

0.41

0.08 ±
1.46
-0.18
± 2.12
-0.01
± 3.44
-0.02
± 3.52
0.51 ±
3.17

0.85 ±
0.86 ±
0.87 ±
0.86 ±
0.86 ±
0.01 ±
0.05
0.04
0.06
0.04
0.04
0.02
PRO
0.85 ±
0.85 ±
0.85 ±
0.84 ±
0.84 ±
-0.01
0.08
0.05
0.05
0.08
0.08
± 0.03
n-3 PUFA
0.88 ±
0.88 ±
0.87 ±
0.86 ±
0.87 ±
-0.01
0.06
0.07
0.06
0.04
0.05
± 0.03
PRO + PLA
0.84 ±
0.85 ±
0.84 ±
0.82 ±
-0.02
0.86 ± 0.5
0.04
0.06
0.06
0.07
± 0.04
PRO + n-3
0.81 ±
0.81 ±
0.83 ±
0.82 ±
0.81 ±
0.01 ±
PUFA
0.06
0.08
0.07
0.08
0.08
0.04
1
Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.

2

Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different from
control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 4. Effects of a 16-week supplementation intervention on anthropometrics, body composition and handgrip strength in dietary
intervention and control groups1
1
Weeks of intervention
Treatment effect2
ANCOVA P3
Body Composition
0
16
Δ 16 wk
P
Group Time2
Group X time
Weight, kg
0.64
0.97
0.11
0.70
CON
72.4 ± 15.2
73.0 ± 14.1
0.57 ± 2.01
PRO
73.4 ± 18.1
73.2 ± 18.8
-0.23 ± 1.42
n-3 PUFA
76.7 ± 20.3
76.7 ± 20.8
-0.01 ± 2.52
PRO + PLA
70.0 ± 19.6
70.2 ± 19.7
0.23 ± 2.06
PRO + n-3 PUFA 72.8 ± 22.4
74.2 ± 21.7
1.28 ± 2.27
Waist, cm
0.36
0.85
0.18
0.42
CON
91.4 ± 10.1
92.8 ± 8.6
1.4 ± 3.14
PRO
92.8 ± 17.2
91.0 ± 16.4
-1.8 ± 3.35
n-3 PUFA
98.0 ± 18.0
97.1 ± 16.9
-0.8 ± 3.91
PRO + PLA
89.8 ± 15.6
87.5 ± 15.7
-2.3 ± 3.41
PRO + n-3 PUFA 89.1 ± 18.8
90.2 ± 18.9
1.0 ± 5.93
WHR
0.39
0.34
0.13
0.41
CON
0.85 ± 0.05
0.86 ± 0.04
0.01 ± 0.02
PRO
0.85 ± 0.08
0.84 ± 0.08
-0.01 ± 0.03
n-3 PUFA
0.88 ± 0.06
0.87 ± 0.05
-0.01 ± 0.03
PRO + PLA
0.84 ± 0.04
0.82 ± 0.07
-0.02 ± 0.04
PRO + n-3 PUFA 0.81 ± 0.06
0.81 ± 0.08
0.01 ± 0.04
LBM, kg
0.57
0.99
0.41
0.54
CON
40.3 ± 8.1
40.1 ± 8.8
-0.17 ± 0.99
PRO
40.2 ± 6.7
40.8 ± 7.5
0.42 ± 0.55
n-3 PUFA
39.3 ± 5.4
39.9 ± 6.4
0.64 ± 1.46
PRO + PLA
38.7 ± 6.1
38.6 ± 5.9
-0.13 ± 0.91
PRO + n-3 PUFA
41.5 ± 7.9
41.8 ± 7.9
0.31 ± 1.25
Values are mean ± SD. There were no significant differences between groups at baseline test by one-way ANOVA. Waist-to-hip ratio,
WHR; lean body mass, LBM; appendicular lean mass, ALM; fat-free mass, FFM; fat mass, FM; bone mineral density, BMD;
handgrip strength, HGS. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=7; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean

oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different
between groups within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 4. Effects of a 16-week supplementation intervention on anthropometrics, body composition and handgrip strength in dietary
intervention and control groups1 (Cont.)
Body Composition

Weeks of intervention
0
16

Treatment effect2
Δ 16 wk
P

ANCOVA P3
Group
Time2 Group X
time
0.90
0.14
0.59

1
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ALM, kg
0.73
CON
17.0 ± 3.6
17.4 ± 3.7
0.40 ± 0.63
PRO
17.2 ± 3.5
17.4 ± 3.7
0.09 ± 0.44
n-3 PUFA
16.7 ± 2.8
16.7 ± 3.1
0.03 ± 0.66
PRO + PLA
16.2 ± 2.2
16.3 ± 2.7
0.09 ± 1.26
PRO + n-3 PUFA
17.6 ± 4.0
18.1 ± 4.0
0.45 ± 0.81
FFM, kg
0.47
0.99
0.94
0.60
CON
42.8 ± 8.4
42.6 ± 9.0
-0.17 ± 0.93
PRO
42.5 ± 7.0
43.1 ± 7.9
0.37 ± 0.51
n-3 PUFA
41.6 ± 5.5
42.2 ± 6.5
0.61 ± 1.40
PRO + PLA
41.1 ± 6.3
40.7 ± 6.5
-0.38 ± 1.16
PRO + n-3 PUFA
43.6 ± 8.3
43.8 ± 8.3
0.16 ± 1.37
Total FM, kg
0.80
0.89
0.57
0.45
CON
28.4 ±8.8
29.7 ± 9.6
1.32 ± 1.31
PRO
30.7 ± 11.4
29.5 ± 12.6
-0.75 ± 1.67
n-3 PUFA
34.5 ±15.9
33.7 ± 14.7
-0.78 ± 2.67
PRO + PLA
28.6 ± 15.1
28.6 ±14.9
-0.01 ± 1.57
PRO + n-3 PUFA
29.1 ±16.3
29.5 ± 15.3
0.42 ± 2.09
Body fat, %
0.80
0.84
0.61
0.21
CON
41.1 ± 9.5
42.3 ± 9.4
0.48 ± 1.74
PRO
42.1 ± 6.2
40.5 ± 6.2
-0.39 ± 1.30
n-3 PUFA
44.8 ± 8.3
44.3 ± 7.4
-0.50 ± 2.08
PRO + PLA
40.4 ± 10.0
40.6 ± 9.2
0.17 ± 2.21
PRO + n-3 PUFA
39. 2 ± 10.0
39.5 ± 9.6
0.26 ± 1.72
Values are mean ± SD. There were no significant differences between groups at baseline test by one-way ANOVA. Waist-to-hip ratio,
WHR; lean body mass, LBM; appendicular lean mass, ALM; fat-free mass, FFM; fat mass, FM; bone mineral density, BMD;
handgrip strength, HGS. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=7; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean

oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different
between groups within time point following LS-means; $ significantly different compared to baseline follow LS-means
.
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Table 4. Effects of a 16-week supplementation intervention on anthropometrics, body composition and handgrip strength in dietary
intervention and control groups1 (Cont.)

Body Composition
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Android fat, %
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Gynoid fat, %
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Fat-to-lean ratio
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
BMD, g/cm2
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

Weeks of intervention
0
16

Treatment effect2
Δ 16 wk
P
0.06

43.5 ± 11.9
44.5 ± 9.7
49.0 ± 9.0
43.8 ± 12.0
38.8 ± 14.2

46.3 ± 10.6
40.3 ± 9.7
48.8 ± 8.3
44.1 ± 10.7
38.7 ± 14.2

2.78 ± 1.82
-2.47 ± 2.24
-0.24 ± 3.15
0.24 ± 4.15
-0.10 ± 3.03

46.7 ± 9.1
49.7 ± 4.1
49.7 ± 7.7
47.5 ± 7.9
46.4 ± 6.7

47.4 ± 7.8
47.9 ± 5.7
50.3 ± 5.6
46.8 ± 8.0
46.5 ± 6.7

0.75 ± 3.79
-1.94 ± 1.65
0.57 ± 3.10
-0.66 ± 3.55
0.08 ± 2.35

0.73 ± 0.3
0.75 ± 0.2
0. 85 ± 0.3
0.72 ± 0.3
0.68 ±0.3

0.77 ± 0.3
0.70 ± 0.2
0.82 ± 0.2
0.72 ± 0.3
0.69 ± 0.3

0.04 ± 0.02
-0.03 ± 0.05
-0.03 ± 0.07
0.00 ± 0.05
0.01 ± 0.05

1.17 ± 0.07
1.09 ± 0.08
1.11 ± 0.10
1.12 ± 0.11
1.07 ± 0.10

1.19 ± 0.08
1.09 ± 0.11
1.12 ± 0.10
1.13 ± 0.11
1.07 ± 0.10

ANCOVA P3
Group
Time2
Group X
time
0.41
0.94
0.07

0.42

0.75

0.67

0.44

0.14

0.68

0.83

0.22

0.79

0.28

0.61

0.67

0.02 ± 0.03
-0.01 ± 0.02
0.01 ± 0.02
0.01 ± 0.03
-0.01 ± 0.09

Values are mean ± SD. There were no significant differences between groups at baseline test by one-way ANOVA. Waist-to-hip
ratio, WHR; lean body mass, LBM; appendicular lean mass, ALM; fat-free mass, FFM; fat mass, FM; bone mineral density, BMD;
handgrip strength, HGS. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=7; omega-3

polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different
between groups within time point following LS-means; $ significantly different compared to baseline follow LS-mean
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Table 4. Effects of a 16-week supplementation intervention on anthropometrics, body composition and handgrip strength in dietary
intervention and control groups1 (Cont.).
Body Composition

Weeks of intervention
0
16

Treatment effect2
Δ 16 wk
P

High HGS, kg
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
1

0.08
28.2 ± 8.1
27.4 ± 3.8
25.7 ± 4.2
28.1 ± 4.9
25.8 ± 4.6

27.9 ± 7.0
27.5 ± 3.1
25.8 ± 4.3
30.2 ± 4.6
27.0 ± 4.6

ANCOVA P3
Group
Time2
Group X
time
0.65
0.14
0.59

-0.3 ± 2.1
-1.5 ± 2.3
0.1 ± 3.3
2.1 ± 2.5
1.2 ± 2.5
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Values are mean ± SD. There were no significant differences between groups at baseline test by one-way ANOVA. Waist-to-hip
ratio, WHR; lean body mass, LBM; appendicular lean mass, ALM; fat-free mass, FFM; fat mass, FM; bone mineral density, BMD;
handgrip strength, HGS. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=7; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age as a covariate. P-values are indicated for main effects
of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly different
between groups within time point following LS-means; $ significantly different compared to baseline follow LS-means.

Table 5. Effects of a 16-week supplementation intervention on energy expenditure and substrate oxidation controlled for FFM in
dietary intervention and control groups1
Treatment effect2

Weeks of Intervention
REE and SO

0

4

8

12

16

Δ 16 wk

REE, Kcal/min
CON
PRO
n-3 PUFA
PRO + PLA
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PRO + n-3
PUFA
KFAT, Kcal/min
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
1

0.022 ±
0.002
0.024 ±
0.003
0.023 ±
0.002
0.022 ±
0.002
0.022 ±
0.002
0.012 ±
0.004
0.019 ±
0.004
0.015 ±
0.003
0.016 ±
0.001
0.014 ±
0.005

0.024 ±
0.005
0.023 ±
0.003
0.023 ±
0.002
0.023 ±
0.003
0.022 ±
0.002
0.014 ±
0.002
0.016 ±
0.005
0.013 ±
0.004
0.013 ±
0.008
0.014 ±
0.003

0.021 ±
0.004
0.024 ±
0.003
0.023 ±
0.002
0.023 ±
0.002
0.022 ±
0.002
0.010 ±
0.004
0.016 ±
0.007#
0.014 ±
0.006#
0.017 ±
0.004#
0.017 ±
0.003#

0.023 ±
0.003
0.024 ±
0.002
0.023 ±
0.003
0.022 ±
0.004
0.022 ±
0.002
0.010 ±
0.004
0.016 ±
0.004#
0.017 ±
0.005#
0.013 ±
0.006#
0.016 ±
0.002#

0.022 ±
0.003
0.024 ±
0.002
0.024 ±
0.003
0.023 ±
0.002
0.022 ±
0.003
0.012 ±
0.009
0.012 ±
0.009$
0.020 ±
0.008$#
0.019 ±
0.005
0.018 ±
0.005$

ANCOVA P 3

P

Group

Time

0.81

0.76

0.18

Group
X time
0.40

0.06

0.09

0.21

0.03*

0.002 ±
0.003
0.000 ±
0.004
0.001 ±
0.002
0.001 ±
0.001
0.001 ±
0.002
0.001 ±
0.007
-0.006 ±
0.007*
0.005 ±
0.007
0.002 ±
0.006
0.004 ±
0.009

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9; rate of fat oxidation (kilocalories per minute), KFAT; rate of carbohydrate oxidation (kilocalories per minute),
KCHO.

2

Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 5. Effects of a 16-week supplementation intervention on energy expenditure and substrate oxidation controlled for FFM in the
dietary intervention and control groups1 (Cont.)
Treatment effect2

Weeks of Intervention
REE and SO

0

4

8

12

16

Δ 16 wk

KCHO,
kcal/min
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1

CON

0.010 ±
0.004

0.010 ±
0.005

0.011 ±
0.005

0.013 ±
0.003

0.010 ±
0.007

-0.004
±0.004

PRO

0.005 ±
0.003

0.007 ±
0.004

0.008 ±
0.006

0.008 ±
0.005

0.009 ±
0.009

0.004 ±
0.009

n-3 PUFA

0.008 ±
0.003

0.010 ±
0.003

0.009 ±
0.004

0.006 ±
0.003

0.004 ±
0.006

-0.004 ±
0.006

PRO +
PLA

0.006 ±
0.002

0.009 ±
0.008

0.006 ±
0.004

0.009 ±
0.003

0.005 ±
0.005

-0.001 ±
0.004

PRO + n3 PUFA

0.008 ±
0.005

0.008 ±
0.003

0.005 ±
0.002

0.006 ±
0.003

0.004 ±
0.003

-0.003 ±
0.007

ANCOVA P 3

P

Group

Time

Group X
time

0.22

0.04*

0.28

.50

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9; rate of fat oxidation (kilocalories per minute), KFAT; rate of carbohydrate oxidation (kilocalories per minute),
KCHO.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05

3

Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 6. Effects of the 16-week dietary supplementation intervention on objective sleep duration and quality in the dietary
intervention and control group1
0

206

7-day ActiGraph
Time in bed
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Time out of bed
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Sleep latency, min
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Sleep efficiency, %
` CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

Weeks of intervention
8

23.1 ± 1.3
22.6 ± 0.8
23.2 ± 0.7
23.0 ± 0.7
22.7 ± 1.0
6.8 ± 1.2
6.0 ± 1.2
6.4 ± 1.1
6.8 ± 0.8
6.2 ± 1.4
3.9 ± 3.5
2.0 ± 1.2
8.5 ± 6.9$
3.9 ± 2.1
4.4 ± 1.8
85.8 ± 4.5
92.6 ± 1.1
88.7.1 ± 4.4
87.0 ± 4.2
86.0 ± 5.2

$

22.6 ± 1.4
22.8 ± 1.1
23.0 ± 0.4
23.1 ± 1.0
22.2 ± 0.7$
5.7 ± 2.2
6.2 ± 1.0
6.4 ± 1.2
6.8 ± 0.7
6.0 ± 1.3
3.7 ± 1.6
2.4 ± 1.3
4.2 ± 3.7
3.8 ± 2.2
6.3 ± 3.3
87.6 ± 4.2
91.5 ± 3.7
86.8 ± 4.4
88.9 ± 2.3
84.8 ± 5.9

16

22.8 ± 1.3
23.1 ± 1.0$
23.3 ± 0.8
22.9 ± 0.9
22.0 ± 0.8$
6.2 ± 1.0
6.1 ± 1.1
6.7 ± 1.4
6.8 ± 1.0
6.0 ± 1.4
3.5 ± 2.0
2.9 ± 2.1
9.0 ± 11.5
5.9 ± 1.6
4.1 ± 3.3
88.7 ± 3.4
92.0 ± 3.1
87.7 ± 5.8
88.3 ± 1.7
87.0 ± 5.8

Treatment effect2
Δ 16 wk
P

ANCOVA P3
Group
Time
Group
X time

0.03*

0.21

0.21

0.047*

0.18

0.74

0.31

0.21

0.95

< 0.01*

0.42

0.33

0.31

0.46

0.98

0.41

-0.25 ± 0.43
0.54 ± 0.65*
0.14 ± 0.61*
-0.15 ± 0.30
-0.70 ± 1.04
-0.57 ± 0.51
0.12 ± 0.51
0.30 ± 0.93
-0.11 ± 0.45
-0.21 ± 0.31
-0.41 ± 4.78
0.92 ± 2.97
0.46 ± 13.14
2.14 ± 2.96
-0.39 ± 3.27
2.91 ± 2.89
-0.54 ± 2.96
-0.95 ± 6.82
1.23 ± 3.61
0.97 ± 2.13

All baseline, 8, and 16-week values are means ± SD. Control, no intervention and free living, CON, n=5; whey protein isolate, PRO,
n=7; omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate +
placebo soybean oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid +
docosahexaenoic acid, PRO + n-3 PUFA, n=8. “Time in bed” denotes time from “lights out” to “got up” as indicated by participants in
their sleep diary. Time is expressed as hours followed by the proportion of an hour in minutes. “Sleep period” denotes time from “fell

asleep” to “woke up”; “Sleep duration” denotes time spent asleep within sleep period, excluding wake time; WASO denotes time from
sleeping to first period of wakefulness; “Sleep latency” denotes time from “lights out” to “fell asleep”; “Sleep duration” (%) denotes
the proportion of time spent asleep in the sleep period; “Sleep efficiency” (%) denotes the proportion of time spent asleep of time in
bed (100% × sleep duration/the time between bed time and get up time). “Sleep fragmentation index” denotes the number of
interruptions of sleep by physical movement calculated as 100 × the number of groups of consecutive mobile 60‐s epochs/by the total
number of immobile epochs. H:mm, hours: minutes; TST, total sleep time; WASO, wake after sleep onset; SFI, sleep fragmentation
index.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 6. Effects of the 16-week dietary supplementation intervention on objective sleep duration and quality in the dietary
intervention and control group1 (Cont.)
0

208

7-day ActiGraph
TST, min
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Awakenings, #
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
WASO
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
SFI
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

Weeks of intervention
8

16

Treatment effect2
Δ 16 wk
P

395.3 ± 38.1
414.6 ± 47.4
381.3 ± 53.9
400.6 ± 35.5
384.1 ± 45.2

405.0 ± 25.6
377.9 ± 97.8
389.5 ± 57.6
424.4 ± 75.3
386.9 ± 56.2

392.3 ± 38.3
388.1 ± 46.2
390.3 ± 53.6
409.8 ± 59.6
408.6 ± 63.1

-2.94 ± 39.73
-26.47 ± 19.92
9.01 ± 37.70
4.06 ± 36.16
24.47 ± 56.30

15.9 ± 4.3
10.5 ± 2.8
12.6 ± 6.0
16.0 ± 4.1
13.4 ± 6.0

15.3 ± 6.1
8.9 ± 2.2
16.1 ± 6.0
16.9 ± 2.5
14.6 ± 7.6

14.0 ± 4.1
9.4 ± 2.6
13.5 ± 6.1
17.0 ± 5.2
14.9 ± 7.9

-1.92 ± 2.13
-1.15 ± 1.58
0.89 ± 3.77
0.35 ± 3.77
1.54 ± 2.81

61.6 ± 14.7
31.9 ± 4.0
40.9 ± 18.8
58.5 ± 25.5
58.1 ± 23.3

54.0 ± 19.5
32.4 ± 16.4
56.8 ± 20.6
49.7 ± 16.6
62.8 ± 31.2

45.7 ± 15.8
31.0 ± 11.6
49.7 ± 26.3
48.0 ± 12.9
59.3 ± 34.5

-15.88 ± 7.47
-0.93 ± 13.22
8.75 ± 24.01
-10.35 ± 19.53
1.23 ± 18.64

27.3 ± 4.7
16.6 ± 4.4 $
23.6 ± 6.7
27.9 ± 7.3
24.2 ± 7.9

24.2 ± 4.1
19.5 ± 6.6
25.5 ± 6.2
26.0 ± 4.8
26.0 ± 7.1

22.2 ± 7.4
19.7 ± 6.7
27.7 ± 10.4
25.5 ± 5.3
22.0 ± 8.4

-5.06 ± 4.72
3.01 ± 3.57
4.18 ± 11.69
-2.48 ± 4.69
-2.23 ± 6.79

ANCOVA P3
Group
Time
Group
X time

0.22

0.46

0.98

0.42

0.24

0.02*

0.87

0.32

0.09

0.05

0.76

0.42

0.10

0.03*

0.96

0.12

All baseline, 8, and 16-week values are means ± SD. Control, no intervention and free living, CON, n=5; whey protein isolate, PRO,
n=7; omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate +
placebo soybean oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid +
docosahexaenoic acid, PRO + n-3 PUFA, n=8. “Time in bed” denotes time from “lights out” to “got up” as indicated by participants in
their sleep diary. Time is expressed as hours followed by the proportion of an hour in minutes. “Sleep period” denotes time from “fell
asleep” to “woke up”; “Sleep duration” denotes time spent asleep within sleep period, excluding wake time; WASO denotes time from

sleeping to first period of wakefulness; “Sleep latency” denotes time from “lights out” to “fell asleep”; “Sleep duration” (%) denotes
the proportion of time spent asleep in the sleep period; “Sleep efficiency” (%) denotes the proportion of time spent asleep of time in
bed (100% × sleep duration/the time between bed time and get up time). “Sleep fragmentation index” denotes the number of
interruptions of sleep by physical movement calculated as 100 × the number of groups of consecutive mobile 60‐s epochs/by the total
number of immobile epochs. H:mm, hours: minutes; TST, total sleep time; WASO, wake after sleep onset; SFI, sleep fragmentation
index.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means
.
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Table 7. Mean ± SD are presented from the 16-week supplementation intervention on ratings of subjective sleep quality and duration
via the Pittsburg Sleep Quality Index seven subcomponents and GSS in dietary intervention and control groups1.
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Weeks of Intervention
Treatment effect
PSQI
0
4
8
12
16
Δ 16 wk
Component 1: Sleep
Quality
CON
1.5 ± 0.5
0.8 ± 0.4
1.5 ± 0.8
1.3 ± 0.5
1.0 ± 0.6
-0.5 ± 0.1
PRO
1.3 ± 0.5
0.9 ± 0.4
1.1 ± 0.7
0.9 ± 0.9
0.7 ± 0.8
-0.6 ± 0.3
n-3 PUFA
1.3 ± 0.5
1.2 ± 0.8
0.9 ± 0.3
0.9 ± 0.7
0.8 ± 0.4
-0.5 ± -0.1
PRO + PLA
1.1 ± 0.7
1.0 ± 0.6
0.9 ± 0.4
0.9 ± 0.7
0.9 ± 0.4
-0.3 ± -0.3
PRO + n-3 PUFA
1.4 ± 0.5
0.9 ± 0.6
1.3 ± 0.5
0.9 ± 0.6
0.9 ± 0.6
-0.6 ± 0.1
Component 2: Latency
CON
1.2 ± 0.8
1.2 ± 0.8
1.0 ± 1.1
1.5 ± 1.0
1.5 ± 0.5
0.3 ± -0.2
PRO
1.1 ± 0.9
1.1 ± 0.9
1.1 ± 0.9
1.1 ± 1.1
0.9 ± 1.1
-0.3 ± 0.2
n-3 PUFA
1.4 ± 1.3
1.2 ± 1.1
0.9 ± 0.9
1.2 ± 0.6
1.2 ± 0.9
-0.2 ± -0.3
PRO + PLA
1.3 ± 0.8
1.4 ± 1.0
1.1 ± 1.1
1.1 ± 0.7
1.1 ± 0.9
-0.1 ± 0.1
PRO + n-3 PUFA
1.4 ± 0.7
1.2 ± 0.7
1.1 ± 0.6
1.3 ± 0.9
1.3 ± 1.0
-0.1 ± 0.3
Component 3: Duration
CON
1.3 ± 0.5
1.0 ± 0.6
1.5 ± 0.5
1.2 ± 0.4
1.2 ± 0.8
-0.2 ± 0.2
PRO
0.9 ± 0.7
0.7 ± 0.5
0.7 ± 0.8
0.6 ± 0.5
0.9 ± 0.7
0.0 ± 0.0
n-3 PUFA
1.6 ± 0.8
1.3 ± 0.9
1.3 ± 0.9
1.2 ± 0.9
1.2 ± 0.9
-0.4 ± 0.1
PRO + PLA
0.9 ± 0.9
1.0 ± 0.8
0.9 ± 0.7
0.6 ± 0.5
0.7 ± 0.5
-0.1 ± -0.4
PRO + n-3 PUFA
1.3 ± 1.1
1.1 ± 0.8
0.9 ± 0.8
0.8 ± 0.8
0.7 ± 0.7
-0.7 ± -0.4
Component 4: Sleep
Efficiency
CON
0.8 ± 0.4
0.3 ± 0.5
0.7 ± 0.8
0.2 ± 0.4
0.2 ± 0.4
-0.7 ± 0.0
PRO
0.6 ± 0.5
0.3 ± 0.5
0.1 ± 0.4
0.7 ± 1.0
0.4 ± 0.5
-0.1 ± 0.0
n-3 PUFA
0.6 ± 0.8
0.5 ± 0.8
0.6 ± 0.7
0.5 ± 0.8
0.5 ± 1.1
-0.1 ± 0.2
PRO + PLA
0.7 ± 1.1
0.6 ± 0.8
0.3 ± 0.5
0.3 ± 0.5
0.3 ± 0.5
-0.4 ± -0.6
PRO + n-3 PUFA
1.1 ± 0.9
0.7 ± 0.9
1.0 ± 1.0
0.6 ± 0.9
0.6 ± 0.5
-0.6 ± -0.4
1
Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean

oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9. Pittsburgh sleep quality index, PSQI; global sleeping score . GSS.
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Table 7. Mean ± SD are presented from the 16-week supplementation intervention on ratings of subjective sleep quality and duration
via the Pittsburg Sleep Quality Index seven subcomponents and GSS in dietary intervention and control groups1 (Cont.)
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PSQI
Component 5: Disturbances
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Component 6: Medications
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Component 7: Daytime
Dysfunction
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Compiled GSS
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

0

4

Weeks of Intervention
8

12

16

Treatment effect
Δ 16 wk

1.5 ± 0.8
1.6 ± 0.5
1.7 ± 0.5
1.6 ± 0.5
1.8 ± 0.4

1.2 ± 0.8
1.4 ± 0.5
1.5 ± 0.5
1.3 ± 0.5
1.4 ± 0.5

1.3 ± 0.5
1.3 ± 0.8
1.3 ± 0.5
1.3 ± 0.5
1.6 ± 0.5

1.3 ± 0.5
1.1 ± 0.7
1.1 ± 0.3
1.1 ± 0.4
1.6 ± 0.5

1.3 ± 0.5
1.0 ± 0.6
1.3 ± 0.5
1.3 ± 0.5
1.6 ± 0.5

-0.2 ± -0.3
-0.6 ± 0.0
-0.4 ± 0.0
-0.3 ± 0.0
-0.2 ± 0.1

1.2 ± 1.2
0.3 ± 0.5
0.4 ± 1.0
1.0 ± 1.2
1.0 ± 1.3

1.2 ± 1.2
0.1 ± 0.4
03 ± 0.9
1.1 ± 1.2
0.8 ± 1.3

1.3 ± 1.0
0.7 ± 1.3
0.3 ± 0.9
0.6 ± 0.8
0.8 ± 1.3

1.2 ± 1.2
0.3 ± 0.8
0.2 ± 0.6
0.9 ± 0.9
0.8 ± 1.1

0.8 ± 1.0
0.1 ± 0.4
0.4 ± 1.0
1.0 ± 1.2
0.8 ± 1.3

-0.3 ± -0.2
-0.1 ± -0.1
0.0 ± 0.0
0.0 ± 0.0
-0.2 ± 0.0

0.8 ± 0.8
1.0 ± 0.8
0.8 ± 0.6
0.9 ± 0.4
0.8 ± 0.4

1.2 ± 1.0
0.7 ± 0.5
1.1 ± 0.9
1.0 ± 0.0
0.8 ± 0.4

1.0 ± 1.1
0.6 ± 0.5
1.1 ± 0.7
0.9 ± 0.4
0.9 ± 0.6

1.0 ± 1.1
0.7 ± 0.8
0.9 ± 0.6
0.9 ± 0.7
0.9 ± 0.6

0.8 ± 1.0
0.6 ± 0.5
1.1 ± 0.6
1.0 ± 0.0
0.9 ± 0.6

0.0 ± 0.2
-0.4 ± -0.3
0.3 ± -0.1
0.1 ± -0.4
0.1 ± 0.2

8.3 ± 3.0
6.7 ± 1.6
7.8 ± 2.7
7.7 ± 2.5
8.9 ± 2.8

6.8 ± 2.9
5.3 ± 1.8
7.1 ± 4.5
7.4 ± 2.5
6.9 ± 2.7

8.3 ± 3.6
5.7 ± 3.7
6.4 ± 3.2
5.9 ± 2.5
7.6 ± 3.2

7.7 ± 3.5
5.4 ± 4.1
6.0 ± 2.4
5.7 ± 1.4
6.8 ± 3.3

6.8 ± 3.2
4.6 ± 2.2
6.5 ± 2.8
6.3 ± 2.1
6.7 ± 3.6

-1.5 ± 0.2
-2.1 ± 0.6
-1.3 ± 0.1
-1.4 ± -0.4
-2.2 ± 0.8

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9. Pittsburgh sleep quality index, PSQI; global sleeping score . GSS.

Table 8. Effects of the 16-week dietary supplementation interventions on negative and positive affect states in the dietary intervention
and control groups1.
Treatment effect2

Weeks of Intervention
POMS

213

Tension/Anxiety
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Depression
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Anger
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Fatigue
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

0

4

8

12

16

Δ 16 wk

4.0 ± 3.3
8.7 ± 6.9
6.7 ± 5.0
6.9 ± 3.4
8.0 ± 6.9

5.8 ± 7.8
5.6 ± 3.8
3.8 ± 4.0
4.9 ± 2.4
6.0 ± 3.1

3.7 ± 3.9
7.0 ± 6.4
5.1 ± 4.3
6.3 ± 4.5
7.4 ± 5.5

4.8 ± 4.4
8.0 ± 5.5
4.0 ± 3.9
5.7 ± 4.2
6.9 ± 3.8

4.0 ± 3.8
6.4 ± 5.5
6.3 ± 7.0
6.3 ± 3.1
5.8 ± 3.8

0.0 ± 1.9
-2.3 ± 6.5
-0.4 ± 7.6
-0.6 ± 2.6
-2.2 ± 5.6

3.0 ± 3.0
7.4 ± 8.3
4.1 ± 4.9
4.1 ± 4.3
6.7 ±
12.4

7.7 ± 13.6
5.7 ± 5.3
2.7 ± 2.7
3.4 ± 3.0

2.7 ± 2.7
6.7 ± 9.8
3.1 ± 3.6
2.3 ± 2.2

5.8 ± 5.8
7.3 ± 8.0
2.7 ± 2.9
2.7 ± 1.9

3.7 ± 4.0

5.9 ± 4.9

7.0 ± 6.5

2.3 ± 2.4 -0.7 ± 0.8
8.1 ± 8.4 0.7 ± 7.3
2.3 ± 3.4 -1.8 ± 3.6
4.6 ± 3.2 0.4 ± 4.4
-0.1 ±
6.6 ± 5.2
12.1

3.8 ± 5.5
5.0 ± 3.4
4.1 ± 5.1
3.0 ± 1.6
4.7 ± 5.7

6.7 ± 7.6
3.0 ± 3.5
3.2 ± 3.4
1.9 ± 1.3
2.6 ± 2.4

1.5 ± 2.5
5.9 ± 10.4
3.7 ± 4.6
1.1 ± 1.3
5.2 ± 4.3

4.8 ± 6.5
5.3 ± 8.2
1.8 ± 3.4
2.6 ± 2.9
4.8 ± 6.7

P
0.83

6.5 ± 8.8
9.1 ± 7.2
5.9 ± 5.0
5.6 ± 4.4
7.8 ± 3.8

9.3 ± 12.3
7.4 ± 4.9
7.1 ± 5.5
6.7 ± 5.0
9.1 ± 5.9

6.7 ± 6.1
8.0 ± 6.1
5.7 ± 3.8
5.7 ± 4.2
8.1 ± 5.9

11.7 ± 8.0
6.4 ± 5.5
4.0 ± 3.6
6.6 ± 3.2
6.0 ± 5.7

3.0 ± 4.0
4.4 ± 7.9
1.7 ± 2.1
2.7 ± 2.1
3.1 ± 3.6
8.5 ± 8.1
4.9 ± 4.5
3.9 ± 3.9
5.0 ± 2.9
6.2 ± 2.2

-0.8 ± 5.3
-0.6 ± 6.7
-2.4 ± 4.5
-0.3 ± 2.0
-1.6 ± 5.2

ANCOVA P 3
Group
Group Time
X time
0.58
0.28
0.79

0.87

0.20

0.84

0.50

0.89

0.65

0.56

0.12

0.42

0.43

0.14

0.41

2.0 ± 4.6
-4.3 ± 4.6
-2.0 ± 5.3
-0.6 ± 4.4
-1.6 ± 4.7

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,

PRO + n-3 PUFA, n=9. POMS: TMD = (Sum of all subscales except Vigor) minus Vigor, TMD score range (−32) to 200. All
subscales are positive.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 8. Effects of the 16-week dietary supplementation interventions on negative and positive affect states in the dietary intervention
and control groups1 (Cont.)
Treatment effect2

Weeks of Intervention

215
1

POMS

0

4

8

12

16

Δ 16 wk

CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
Vigor
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
TMD
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA

5.3 ± 3.0
6.6 ± 4.5
5.0 ± 2.7
4.4 ± 1.7

5.8 ± 4.6
4.7 ± 3.8
4.4 ± 3.2
5.7 ± 2.0

5.2 ± 3.8
6.1 ± 4.1
5.3 ± 3.2
4.1 ± 1.3

7.5 ± 6.6
5.0 ± 4.5
4.2 ± 2.6
5.1 ± 1.5

5.7 ± 4.3
3.6 ± 3.9
5.6 ± 4.2
4.3 ± 2.1

0.3 ± 2.0
-3.0 ± 3.7
0.6 ± 4.1
-0.1 ± 2.5

5.7 ± 3.2

5.2 ± 2.8

5.6 ± 4.1

4.8 ± 3.4

5.9 ± 4.3

0.2 ± 3.9

16.3 ± 2.3
18.6 ± 6.9
17.4 ± 6.1
17.6 ± 5.3

17.2 ± 5.5
22.0 ± 5.5
18.2 ± 6.3
15.6 ± 6.4

15.8 ± 5.5
23.0 ± 7.3
17.7 ± 7.7
18.0 ± 5.1

11 ± 7.4
19.7 ± 9.5
18.9 ± 8.3
15.7 ± 5.3

12.3 ± 6.4
20.6 ± 9.1*
18.1 ± 8.0*
16.4 ± 6.2

-4.0 ± 5.9
2.0 ± 6.5
0.7 ± 4.7
-1.1 ± 4.9

15.8 ± 6.3

16.3 ± 5.0

15.2 ± 7.1

16.9 ± 4.7

16.3 ± 5.0

0.6 ± 4.3

6.3 ± 19.5
18.3 ± 33.0
8.4 ± 20.7
-0.4 ± 9.1

18.2 ± 45.5
4.4 ± 22.4
3.0 ± 19.4
7.0 ± 9.1

3.8 ± 18.1
10.7 ± 37.8
5.2 ± 21.1
1.6 ± 12.4

23.7 ± 33.4
12.3 ± 34.4
-2.2 ± 18.4
7.0 ± 11.5

11.2 ± 23.4
6.9 ± 32.6
1.7 ± 20.2
6.4 ± 10.8

4.8 ± 15.6
-11.4 ± 26.1
-6.7 ± 18.2
6.9 ± 12.0

17.0 ± 31.7

10.2 ± 16.2

17.0 ± 17.4

12.6 ± 15.6

11.2 ± 19.4

-5.8 ± 29.0

ANCOVA P 3

P

Group

Time

Group
X
time

0.17

0.01

0.21

0.046

0.71

0.71

0.73

0.11

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9. POMS: TMD = (Sum of all subscales except Vigor) minus Vigor, TMD score range (−32) to 200. All
subscales are positive.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05

3

Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 9. Effects of the 16-week dietary interventions on fasting plasma concentrations of cardiometabolic risk in the dietary
intervention groups and control group1
Treatment effect2

Weeks of Intervention
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Metabolic
Biomarkers
Glucose. mg/dl
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Insulin, uUI/mL
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
HOMA-IR, AU
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
FFA, uM
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

0

8

16

Δ 16 wk

90.1 ± 15.9
92.6 ± 11.0
93.3 ± 13.2
88.8 ± 9.6
83.7 ± 12.6

98.4 ± 17.1
91.7 ± 6.9
93.4 ± 12.4
88.1 ± 12.4
86.6 ± 13.4

91.5 ± 14.9
88.2 ± 6.6
92.0 ± 11.8
89.9 ± 7.8
81.8 ± 5.5

1.5 ± 6.4
-4.4 ± 8.6
-1.3 ± 13.5
1.1 ± 4.8
-1.9 ± 9.0

10.6 ± 4.1
13.8 ± 9.3
22.0 ± 27.1
10.6 ± 8.8
9.6 ± 5.8

12.8 ± 9.2
11.9 ± 6.9
16.2 ± 13.1
12.8 ± 8.9
11.2 ± 4.7

7.5 ± 3.5
11.7 ± 10.4
22.4 ± 21.3
10.1 6.4
8.8 ± 4.8

-3.2 ± 4.6
-2.0 ± 8.0
0.4 ± 9.5
-0.5 ± 4.3
-0.8 ± 6.5

2.4 ± 1.0
3.3 ± 2.5
5.2 ± 6.1
2.5 ± 2.4
2.1 ± 1.6

3.3 ± 2.6
2.7 ± 1.6
4.0 ± 3.7
3.0 ± 2.5
2.3 ± 1.6

1.7 ±1.0
2.6 ± 2.4
5.0 ± 4.2
2.3 ± 1.6
1.8 ± 1.0

-0.6 ± 0.9
-0.7 ± 1.9
-0.2 ± 3.2
-0.2 ± 1.1
-0.3 ± 1.5

131.5 ± 24.7
186.5 ± 36.8
187.8 ± 54.2
175.8 ± 48.2
162.9 ± 71.9

144.2 ± 47.2
154.9 ± 33.4
164.5 ± 68.0
135.7 ± 54.3
126.1 ± 50.7

161.3 ± 42.2
147.0 ± 33.4
175.4 ± 48.9
156.8 ± 60.6
137.0 ± 47.0

29.7 ± 22.5
-39.5 ± 25.1
-12.4 ± 38.2
-19.1 ± 63.4
-26.0 ± 63.0

P
0.78

ANCOVA P3
Time Group X
Group1
2
Time3
0.34
0.22
0.72

0.89

0.38

0.07

0.32

0.98

0.32

0.09

0.54

0.12

0.48

0.02*

0.37

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10 *Wk8:n=9; whey protein isolate +
placebo soybean oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid +
docosahexaenoic acid, PRO + n-3 PUFA, n=9. Homeostatic Model Assessment of Insulin Resistance, HOMA-IR; free-fatty acids,
FFA; c-reactive protein. CRP.

2

Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 9. Effects of the 16-week dietary interventions on fasting plasma concentrations of cardiometabolic risk in the dietary
intervention groups and control group1 (Cont.)
Treatment effect2

Weeks of Intervention
Metabolic Biomarkers

219

Cholesterol, mg/dl
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Triglycerides, mg/dl
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
CRP, u/L
CON
PRO
O3FA
PRO + PLA
PRO + O3FA
1

0

8

16

Δ 16 wk

179.5 ± 33.0
190.4 ± 30.4
197.5 ± 23.0
206.8 ± 19.6
196.5 ± 28.4

200.5 ± 18.1
200.0 ± 29.4
212.6 ± 20.9
194.4 ± 20.5
178.0 ± 33.7$

219.0 ± 24.5$
178.7 ± 22.9
186.0 ± 32.5
204.9 ± 24.7
171.4 ± 38.2$

39.5 ± 30.4
-11.8 ± 30.8*
-11.4 ± 24.1*
-1.9 ± 24.8*
-25. 1 ± 43.6*

78.1 ± 23.8
118.9 ± 46.2
105.8 ± 44.5
80.4 ± 32.8
102.3 ± 36.6

66.8 ± 24.6
110.0 ± 51.0
92.0 ± 36.0
74.6 ± 22.2
84.0 ± 35.4

66.6 ± 16.4
103.5 ± 31.2
89.5 ± 36.4
89.8 ± 29.6
76.8 ± 32.8

-11.5 ± 26.1
-15.4 ± 32.7
-16.4 ± 29.1
9.4 ± 42.5
-25.5 ± 17.0

.72 ± .43
1.29 ± .60
1.07 ± .58
.81 ± .62
1.02 ± 1.09

.70 ± .45
1.11 ± .61
1.28 ± .65
.94 ± .61
.82 ± .68

.85 ± .53
1.02 ± .72
1.00 ± .43
1.01 ± .76
1.04 ± 1.14

0.13 ± .42
-0.27 ± .90
-0.07 ± .47
0.20 ± .33
0.01 ± .33

P
0.01*

ANCOVA P3
Group X
Group1 Time2
Time3
0.34
0.58
0.01*

0.25

0.05

0.13

0.71

0.48

0.88

0.99

0.24

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10 *Wk8:n=9; whey protein isolate +
placebo soybean oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid +
docosahexaenoic acid, PRO + n-3 PUFA, n=9. Homeostatic Model Assessment of Insulin Resistance, HOMA-IR; free-fatty acids,
FFA; c-reactive protein. CRP.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.

Table 10. Effects of the 16-week dietary interventions on fasting plasma concentrations of well-being biomarkers the dietary
intervention groups and control group1
Biomarkers
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OXA, pg/mL
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
BDNF, ng/m:
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
CKM, U/mL
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA
Cortisol, ng/mL
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3
PUFA

0

Weeks of Intervention
8

16

Treatment effect 2
Δ 16 wk
P
0.046

18.4 ± 10.5
20.5 ± 15.3
16.6 ± 13.6
23.5 ± 15.7
19.8 ± 11.8

17.8 ± 10.3
23.6 ± 13.2
15.5 ± 9.5
24.6 ± 18.5
25.0 ± 14.0

19.2 ± 10.7
19.2 ± 9.5
15.7 ± 11.2
25.0 ± 16.8
28.4 ± 17.5$

562.9 419.9
485.0 ± 148.3
528.0 ± 126.7
540.9 ± 241.3
513.6 ± 200.1

460.4 101.3
449.8 ± 134.1
502.3 ± 142.4
528.0 ± 254.2
400.0 ± 133.2

30.6 ± 16.2
27.4 ± 11.6
30.5 ± 8.6
40.8 ± 13.8
39.6 ± 17.4

29.4 ± 7.9
34.5 ± 17.9
31.1 ± 17.5
40.1 ± 20.0
40.7 ± 18.9

33.5 ± 15.0
32.5 ± 18.0
35.7 ± 15.7
37.6 ± 16.6
43.7 ± 20.0

2.9 ± 11.1
5.1 ± 8.6
5.1 ± 10.0
-3.2 ± 6.5
4.2 ± 5.7

27.7 ± 18.8
26.0 ± 17.8
14.4 ± 6.1
17.3 ± 6.0
15.9 ± 3.1

22.0 ± 14.6
26.0 ± 13.5
19.4 ± 7.8
16.5 ± 7.4
15.7 ± 3.1

24.5 ± 22.2
18.7 ± 13.4
15.1 ± 9.9
14.4 ± 4.0
15.2 ± 2.7

-3.17 ± 12.57
-7.31 ± 15.33
0.69 ± 6.30
-2.88 ± 4.85
-0.70 ± 2.48

ANCOVA P3
Group Time
Group X
time
0.39
0.08
0.27

0.8 ± 3.3
-1.3 ± 7.0
-0.8 ± 5.9
1.5 ± 8.1
8.6 ± 9.3*
0.39

0.67

0.01*

0.53

0.32

0.57

0.28

0.40

0.47

0.47

0.02

0.16

667.7 ± 306.9 104.7 ± 1819.8
452.0 ± 100.7 -32.9 ± 106.0
621.1 ± 201.5 93.1 ± 173.6
611.9 ± 342.1
71 ± 189.9
499.5 ± 179.6 -14.1 ± 1788

1

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10 *Wk8:n=9; whey protein isolate +
placebo soybean oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid +
docosahexaenoic acid, PRO + n-3 PUFA, n=9. Orexin A, OXA; brain-derived neurotrophic factor, BDNF; creatine kinase M-type,
CKM.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 11. Effects of a 16-week supplementation intervention on energy and macronutrient intake in dietary intervention and control
groups1
Weeks of Intervention
Treatment effect2
ANCOVA P 3
Energy &
Group
0
8
16
Δ 16 wk
P
Group Time
Macronutrients
X time
Energy, kcal/d
0.27
0.60
0.73
0.84
CON
1963.3 ±
1844.6 ±
1757.3 ± 573.5
87.3 ± 170.8
858.3
490.9
PRO
2193.9 ±
1560.9 ±
1560.2 ±
-124.5 ± 409.9
1403.0
447.1
332.1
n-3 PUFA
1726.5 ±
1709.6 ±
2091.7 ± 848.2
-106.2 ± 680.1
500.1
854.9
PRO + PLA
1737.0 ±
1641.4 ±
1988.1 ± 798.8
-320.7 ± 851.1
619.9
469.4
PRO + n-3 PUFA
2006.8 ±
1799.5 ±
1881.6 ± 604.5
115.7 ± 597.8
886.1
886.0
Protein, g/day
0.51 <0.01* 0.04*
0.12
CON
71.3 ± 18.6
69.9 ± 16.2
72.7 ± 19.7
1.4 ± 18.7
PRO
87.1 ± 35.9$
90.8 ± 32.8
93.9 ± 31.5
6.8 ± 36.5
n-3 PUFA
76.5 ± 28.2
67.5 ± 21.0
74.3 ± 32.9
-0.9 ± 19.5
PRO + PLA
73.3 ± 30.6
92.5 ± 29.4
95.2 ± 30.3
25.7 ± 21.6
PRO + n-3 PUFA
93.2 ± 20.3 $
112.6 ± 45.3
95.9 ± 21.1
12.6 ± 30.2
Protein, %
CON
16.2 ± 1.6
15.4 ± 2.1
16.1 ± 3.2
0.29 <0.01* <0.01 <0.01*
-0.07 ± 4.22
*
$#
$#
PRO
18.9 ± 6.7
26.6 ± 9.0
23.6 ± 4.2
4.70 ± 6.13
n-3 PUFA
15.2 ± 4.1
15.8 ± 3.1
18.7 ± 6.4
1.14 ± 7.85
$#
$#
PRO + PLA
15.6 ± 4.9
22.5 ± 5.3
24.1 ± 6.6
9.15 ± 7.02
PRO + n-3 PUFA
20.8 ± 5.7
23.8 ± 5.0$#
23.9 ± 6.7#
2.64 ± 3.97
1
Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.

2

Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 11. Effects of a 16-week supplementation intervention on energy and macronutrient intake in dietary intervention and control
groups1 (Cont.)
Weeks of Intervention
Treatment effect2
ANCOVA P 3
Energy &
Group
0
8
16
Δ 16 wk
P
Group
Time
Macronutrients
X time
Protein, g/kg/bw
0.14
0.01
0.05
0.14
CON
0.99 ± 0.23
1.00 ± 0.27
1.01 ± 0.29
0.018 ± 0.274
PRO
1.23 ± 0.54
1.32 ± 0.62
1.6 ± 0.54
0.128 ± 0.548
n-3 PUFA
0.92 ± 0.33
0.79 ± 0.21
0.86 ± 0.24
-0.040 ± 0.256
PRO + PLA
1.00 ± 0.24
1.28 ± 0.18
1.32 ± 0.23
0.417 ± 0.287
PRO + n-3
1.27 ± 0.26$
1.56 ± 0.61
1.35 ± 0.50
0.206 ± 0.442
PUFA
CHO, g/d
0.71
0.98
0.03*
0.49
CON
183.8 ± 70.3
204.6 ± 75.1 194.2 ± 46.3
10.3 ± 21.7
PRO
272.3 ± 202.7 178.2 ± 45.7 175.8 ± 42.3
-96.5 ± 192.8
n-3 PUFA
242.6 ± 100.2 185.3 ± 85.2 180.4 ± 98.1
-15.4 ± 120.7
PRO + PLA
235.3 ± 112.5 174.5 ± 83.4 158.9 ± 72.0
-71.9 ± 115.8
PRO + n-3
208.7 ± 92.9
167.8 ± 51.3 190.7 ± 92.2
-17.3 ± 49.8
PUFA
CHO, %
0.29
0.72
0.15
0.27
CON
41.4 ± 6.1
42.3 ± 3.7
41.8 ± 9.9
0.36 ± 11.89
PRO
45.8 ± 11.4
44.5 ± 8.7
47.6 ± 7.3
1.79 ± 6.11
n-3 PUFA
46.1 ± 7.1
42.7 ± 11.3
41.6 ± 13.7
-0.09 ± 13.63
PRO + PLA
46.4 ± 10.4
39.6 ± 12.9
37.8 ± 12.2
-7.61 ± 6.25
PRO + n-3
42.4 ± 6.2
35.1 ± 5.4
42.9 ± 4.0
-3.07 ± 8.62
PUFA
1
Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05

3

Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 11. Effects of a 16-week supplementation intervention on energy and macronutrient intake in dietary intervention and control
groups1 (Cont.)
Weeks of Intervention
Treatment effect2
ANCOVA P 3
Energy &
0
8
16
Δ 16 wk
P
Group Time Group X
Macronutrients
time
Fat, g
0.79
0.65
0.27
0.14
CON
79.0 ± 30.7
83.1 ± 35.7
83.6 ± 33.8
4.6 ± 11.2
PRO
89.3 ± 64.0
55.8 ± 22.8
55.6 ± 17.6
-33.8 ± 60.4
n-3 PUFA
93.3 ± 45.2
81.8 ± 26.4
78.6 ± 46.4
-4.2 ± 25.8
PRO + PLA
81.0 ± 42.5
76.2 ± 32.9
70.2 ± 23.6
-11.2 ± 39.7
PRO + n-3 PUFA
76.7 ± 25.7
100.4 ± 56.8
76.0 ± 38.4
6.6 ± 28.7
Fat, %
0.79
0.05
0.38
0.27
CON
39.0 ± 8.3$
40.0 ± 5.3
38.2 ±8.3
-0.82 ± 10.87
PRO
34.8 ± 6.5
30.0 ± 7.2
30.4 ± 4.6
-4.40 ± 3.89
n-3 PUFA
34.4 ± 8.2
42.8 ± 8.5
40.6 ± 9.9
2.60 ± 6.81
PRO + PLA
33.9 ± 6.7
38.6 ± 6.6
38.4 ± 5.4
3.37 ± 6.84
PRO + n-3 PUFA
36.5 ± 7.8
42.4 ± 7.1
37.8 ± 12.6
1.68 ± 8.15
1

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.

Table 12. Effects of a 16-week supplementation intervention on dietary lipid profile in dietary intervention and control groups1
Dietary Lipid Profile
n-3 PUFA s
ALA, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
EPA, mg/d

2.0 ± 1.0
1.9 ±1.4
1.7 ± 1.1
1.9 ± 0.9
1.6 ± 0.5
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CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
DHA, mg/d

11.0 ± 5.9
61.9 ± 88.3
40.5 ± 96.3
10.2 ± 6.3
27.6 ± 23.5

CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Total n-3 PUFA, g/d

26.2 ± 14.1
104.0 ± 115.6
94.6 ± 202.5
30.8 ± 19.0
67.6 ± 56.8

CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

0

2.2 ± 0.9
2.2 ± 1.3
1.9 ± 1.2
2.1 ± 1.2
1.9 ± 0.6

Weeks of Intervention
8

1.79 ± 0.6
1.55 ± 1.0
1.50 ± 0.6
1.36 ± 0.8
1.97 ± 1.3
19.6 ± 12.5
55.1 ± 87.1
2267.0 ± 21.9#$
39.5 ± 72.6
2326.5 ± 131.7#$
46.6 ± 31.5
44.9 ± 50.9
1784.1 ± 40.6#$
89.9 ± 157.1
1923.2 ± 291.8#$
2.1 ± 1.0
1.8 ± 1.0
6.0 ± 0.6#$
1.8 ± 1.1
6.0 ± 0.8#$

16

2.04 ± 0.9
1.39 ± 1.2
1.47 ± 1.1
1.12 ± 0.5
1.49 ± 1.3
52.3 ± 101.8
8.6 ± 7.8
2356.5 ± 314.7#$
16.5 ± 19.4
2308.8 ± 107.4#$
133.4 ± 247.7
34.0 ± 25.2
1801.5 ± 71.6#$
37.0 ± 37.4
1938.9 ± 330.2#$
2.5 ± 0.7
1.5 ± 1.2
5.9 ± 1.1#$
1.2 ± 0.5
5.8 ± 1.3#$

Treatment effect2
Δ 16 wk
P

ANCOVA P3
Group Time Group
X time

0.82

0.82

0.19

0.77

<0.01

<0.01

<0.0
1

<0.01

<0.01

<0.01

<0.0
1

<0.01

<0.01

<0.01

<0.0
1

<0.01

0.01 ± 1.0
-0.49 ± 1.5
-0.25 ± 1.5
-0.79 ± 1.2
-0.08 ± 1.4
41.2 ± 102.6
-53.3 ± 81.9
2316.0 ± 340.5*
6.3 ± 17.7
2281.2 ± 1134.0*
107.2 ± 238.4
-123.8 ± 209.6*
1706.9 ± 214.5*
6.2 ± 40.9
1871.2 ± 338.5*
0.3 ± 0.9
-0.7 ± 1.3
3.9 ± 1.5*
-0.9 ± 1.5
3.9 ± 1.7*

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean

oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 12. Effects of a 16-week supplementation intervention on dietary lipid profile in dietary intervention and control groups1
(Cont.)
Dietary Lipid Profile
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n-3 PUFA, %
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
n-6 PUFA / n-3
PUFA Ratio
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Cholesterol, mg/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Saturated fat, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

0

Weeks of Intervention
8

16

Treatment effect2
Δ 16 wk
P

1.33 ± 1.03
1.16 ± 0.69
1.03 ± 0.69
0.93 ± 0.24
1.04 ± 0.61

1.08 ± 0.67
0.98 ± 0.41
3.59 ± 1.05
0.90 ± 0.52
2.86 ± 0.83

1.24 ± 0.35
0.79 ± 0.60
3.35 ± 0.68
0.66 ± 0.20
2.91 ± 0.87

-0.09 ± 0.77
-0.36 ± 0.70
2.33 ± 0.93*
-0.27 ± 0.36
1.87 ± 0.80*

10.5 ± 4.4
10.1 ± 2.7
9.7 ± 3.3
9.3 ± 1.1
9.2 ± 3.8

9.6 ± 2.8
8.1 ±2.6
2.9 ± 0.7#$
10.4 ± 3.8
3.5 ± 2.8#$

14.9 ± 5.3
12.4 ± 8.5
2.6 ± 0.9#$
10.7 ± 1.0
2.7 ± 2.0#$

4.5 ± 2.8
2.3 ± 7.9
-7.1 ± 3.4*
1.5 ± 1.9
-6.5 ± 3.7*

281.7 ± 169.7
287.9 ± 157.5
273.8 ± 107.8
188.3 ± 106.1#
300.8 ± 99.4

268.2 ± 71.5
252.1 ± 139.0
211.8 ± 120.2
300.7 ± 187.6
280.0 ± 240.0$

263.7 ± 158.6
247.0 ± 181.9
341.3 ± 191.1#
245.8 ± 118.3$
182.1 ± 145.3$

-18.1 ± 171.3
-40.9 ± 132.9
67.5 ± 167.6
57.5 ± 92.9
-118.7 ± 160.0

29.3 ± 6.4
29.0 ± 25.3
26.4 ± 14.2
25.4 ± 15.1
24.3 ± 9.7

38.4 ± 19.6
19.0 ± 6.8
20.3 ± 7.7
25.5 ± 10.2
32.3 ± 22.2

26.5 ± 11.5
16.4 ± 6.5
21.5 ± 8.4
21.0 ± 7.6
28.0 ± 18.5

-2.9 ± 12.8
-12.6 ± 24.3
-4.9 ± 8.3
-4.4 ± 13.7
3.6 ± 20.0

<0.01

ANCOVA P3
Group
Time
Group
X time
<0.01
<0.01
<0.01

<0.01

<0.01

<0.01

<0.01

0.05

0.96

0.51

0.02

0.79

0.79

0.08

0.56

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.

3

Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 13. Effects of a 16-week supplementation intervention on dietary amino acid profile in dietary intervention and control groups1

Amino Acid Profile

0

Weeks of Intervention
8

16

Treatment effect2
Δ 16 wk 2
P

ANCOVA P3
Group Time Group X
time
<0.01 <0.01
<0.01
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Leucine, g/d
<0.01
CON
5.41 ± 1.40
5.58 ± 1.55
5.64 ± 1.56
0.23 ± 1.54
PRO
6.72 ± 2.38
8.70 ± 2.47#$ 8.80 ± 2.54#$ 2.08 ± 2.96*
n-3 PUFA
5.40 ± 2.00
4.65 ± 1.57
5.49 ± 2.26
0.09 ± 1.57
PRO + PLA
5.20 ± 2.39
8.65 ± 2.19#$ 8.93 ± 1.83#$ 3.74 ± 1.81 *
PRO + n-3 PUFA
6.57 ± 1.72
9.17 ± 3.92#$ 9.10 ± 2.04#$ 2.53 ± 2.54 *
Total BCAAs, g/d
0.05 <0.01 <0.01
<0.05
CON
12.07 ± 3.08
12.48 ± 3.40
12.54 ± 3.54
0.47 ± 3.26
PRO
15.04 ± 5.38
18.14 ± 5.65
18.38 ± 5.74
3.33 ± 6.75
n-3 PUFA
12.10 ± 4.44
10.39 ± 3.48
12.08 ± 5.06
-0.03 ± 3.59
PRO + PLA
11.61 ± 5.40 17.87 ± 4.75#$ 18.38 ± 3.67#$ 6.77 ± 4.29
PRO + n-3 PUFA
14.82 ± 3.75 19.59 ± 8.54#$ 19.14 ± 4.34#$ 4.32 ± 5.49
Tryptophan, g/d
<0.01 <0.01 <0.01
<0.01
CON
0.83 ± 0.16
0.83 ± 0.21
0.89 ± 0.23
0.06 ± 0.20
PRO
1.03 ± 0.37
1.58 ± 0.45#$ 1.64 ± 0.41#$ 0.61 ± 0.46 *
n-3 PUFA
0.80 ± 0.29
0.70 ± 0.19
0.84 ± 0.30
0.04 ± 0.23
#$
#$
PRO + PLA
0.75 ± 0.34
1.55 ± 0.31
1.63 ± 0.32
0.88 ± 0.29 *
PRO + n-3 PUFA
1.05 ± 0.25
1.60 ± 0.77#$ 1.67 ± 0.34#$ 0.62 ± 0.37 *
Methionine, g/d
0.15 <0.05
0.16
0.12
CON
1.75 ± 0.72
1.59 ± 0.40
1.61 ± 0.49
-0.15 ± 0.70
PRO
2.02 ± 0.80
2.19 ± 0.85#$ 2.23 ± 0.86#$
0.21 ± 0.92
n-3 PUFA
1.58 ± 0.56
1.33 ± 0.47
1.53 ± 0.69
-0.05 ± 0.48
PRO + PLA
1.49 ± 0.82
2.10 ± 0.73#$ 2.23 ± 0.69#$
0.75 ± 0.61
#$
#$
PRO + n-3 PUFA
1.93 ± 0.52
2.33 ± 1.00
2.24 ± 0.56
0.31 ± 0.80
1
Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.

2

Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 13.. Effects of a 16-week supplementation intervention on dietary amino acid profile in dietary intervention and control groups1
(Cont.)
Amino Acid Profile
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Total EAAs, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Arginine, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Tyrosine, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Cysteine, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

Treatment effect2
Δ 16 wk 2
P

0

Weeks of Intervention
8

16

27.03 ± 7.12
34.26 ± 11.73
26.96 ± 10.13
25.74 ± 12.46
32.86 ± 8.34

27.09 ± 7.20
39.58 ± 13.31
22.88 ± 7.88
38.58 ± 11.05#$
42.29 ± 18.24#$

27.65 ± 7.99
40.48 ± 13.73
26.73 ± 11.64
40.22 ± 9.26#$
41.42 ± 9.23#$

0.62 ± 7.70
6.22 ± 15.53
-0.23 ± 8.07
14.48 ± 9.52
8.56 ± 12.20

3.98 ± 1.16
4.65 ± 1.85
3.75 ± 1.57
3.96 ± 1.76
4.45 ± 1.12

3.70 ± 0.90
4.27 ± 1.93
3.21 ± 1.36
4.10 ± 1.55
4.90 ± 1.67

3.93 ± 1.11
4.40 ± 1.97
3.63 ± 1.58
4.46 ± 1.68
4.76 ± 1.65

-0.05 ± 1.62
-0.25 ± 2.00
-0.12 ± 1.10
0.51 ± 1.32
0.32 ± 2.35

2.57 ± 0.75
3.01 ± 1.04
2.41 ± 0.86
2.27 ± 1.05
2.96 ± 0.82

2.55 ± 0.70
3.29 ± 1.11
2.09 ± 0.68
3.30 ± 1.01
3.76 ± 1.82

2.52 ± 0.75
3.31 ± 1.11
2.42 ± 0.93
3.42 ± 0.86
3.50 ± 0.90

-0.05 ± 0.68
0.30 ± 1.30
0.02 ± 0.65
1.15 ± 0.82
0.54 ± 1.10

0.97 ± 0.29
1.15 ± 0.45
0.91 ± 0.30
0.90 ± 0.40
1.12 ± 0.27

0.90 ± 0.25
1.59 ± 0.38
0.76 ± 0.27
1.59 ± 0.35
1.66 ± 0.63

0.94 ± 0.23
1.66 ± 0.43
1.15 ± 0.67
1.59 ± 0.32
1.78 ± 0.35

-0.04 ± 0.29
0.51 ± 0.54
0.24 ± 0.78
0.70 ± 0.36
0.66 ± 0.44

0.07

ANCOVA P3
Group
Time
Group X
time
< 0.01
<0.05
<0.05

0.9

0.22

0.68

0.96

0.12

<0.01

<0.05

0.11

0.08

<0.01

<0.01

<0.01

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.

3

Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-means.
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Table 13. Effects of a 16-week supplementation intervention on dietary amino acid profile in dietary intervention and control groups1
(Cont.)
Amino Acid Profile
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Glutamic Acid, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Glycine, g/d
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
Try/LNAAs
CON
PRO
n-3 PUFA
PRO + PLA
PRO + n-3 PUFA
1

Treatment effect2
Δ 16 wk 2
P

ANCOVA P3
Group
Time
Group X
time
0.59 <0.05
0.08
0.65

0

Weeks of Intervention
8

16

13.53 ± 3.31
15.98 ± 7.10
12.94 ± 4.85
13.21 ± 5.18
16.49 ± 5.00

14.53 ± 4.67
16.57 ± 5.26
11.83 ± 3.66
17.20 ± 4.59
18.88 ± 8.18

14.60 ± 3.48
16.83 ± 5.09
13.20 ± 4.27
17.23 ± 4.43
18.48 ± 4.63

1.07 ± 3.02
0.85 ± 7.39
0.27 ± 3.46
4.02 ± 3.59
1.99 ± 5.39

3.76 ± 2.39
3.90 ± 1.38
2.95 ± 1.27
3.03 ± 1.52
3.38 ± 0.90

2.77 ± 0.75
3.32 ± 1.55
2.45 ± 1.10
3.03 ± 1.29
3.62 ± 1.34

2.85 ± 0.87
3.39 ± 1.49
2.77 ± 1.50
3.37 ± 1.25
3.52 ± 1.36

-0.91 ± 2.33
-0.51 ± 1.65
-0.17 ± 1.18
0.35 ± 1.12
0.14 ± 1.81

0.05 ± 0.01
0.05 ± 0.00
0.05 ± 0.00
0.05 ± 0.00
0.06 ± 0.00

0.05 ± 0.01
0.07 ± 0.01
0.05 ± 0.01
0.07 ± 0.01
0.06 ± 0.01

0.06 ± 0.00
0.07 ± 0.00
0.06 ± 0.00
0.07 ± 0.00
0.07 ± 0.01

0.03 ± 0.10
0.04 ± 0.61
0.05 ± 0.04
0.13 ± 0.07*
0.10 ± 0.07*

0.64

0.12

0.27

0.80

0.04

<0.01

<0.01

<0.01

Values are mean ± SD. Control, no intervention and free living, CON, n=6; whey protein isolate, PRO, n=6; omega-3
polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid, n-3 PUFA, n=10; whey protein isolate + placebo soybean
oil, PRO + PLA, n=7; whey protein isolate + omega-3 polyunsaturated fatty acids, eicosapentaenoic acid + docosahexaenoic acid,
PRO + n-3 PUFA, n=9.
2
Treatment effect between groups were tested by one-way ANOVA with baseline measurements subtracted from 16-week values. LSmeans significant differences: * P < 0.05.
3
Differences in raw data were analyzed at 0, 8, and 16 using ANCOVA with age and BMI as covariates. P-values are indicated for
main effects of group and time and an interaction effect of group X time. * P < 0.05 for main effect of intervention; # significantly
different from control within time point following LS-means; $ significantly different compared to baseline follow LS-mean.

Figures
Assessed for eligibility
(n=170)
Excluded: 125
• Not meeting inclusion criteria: 116
• Declined to participate: 8
• Requested control group only: 1

Randomized (n=45)

Allocated to PRO: 8
Received PRO INT: 8

Allocated to O3FAs: 12
Received O3FA INT: 12

Allocated to PRO+PLA: 7
Received PRO + PLA INT: 7

Allocated to PRO+O3FA: 12
Did not receive PRO+O3FA
INT: 1a
Received PRO+O3FA INT:11

Lost to follow-up: 0

Lost to follow-up: 0

Lost to follow-up: 0

Lost to follow-up: 0

Lost to follow-up: 0
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Discontinued INT: 2e,f

Analyzed: 6

Analyzed: 7

Analyzed: 10

Analyzed: 7

Analyzed: 9
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Allocated to CON: 6
Received CON INT:6

Figure 1: Flow chart showing number of subjects recruited and their attrition patters during the 16-wk intervention study. Int,
intervention; CON, control; n-3 PUFA, omega-3 polyunsaturated fatty acids, Eicosapentaenoic acid + docosahexaenoic acid, PRO +
PLA, whey protein isolate + placebo soybean oil; PRO + n-3 PUFA, whey protein isolate + omega-3 polyunsaturated fatty acids,
Eicosapentaenoic acid + docosahexaenoic acid. Reason for subject withdrawal were as follows: a discomfort wearing the ActiGraph

sleep monitor (1), b unexpected menstrual cycle (1), c fall resulting in injury and pain medication (1), d discomfort while swallowing
the supplement capsules (1), e dislike of the WPI (1), and F time constraints (1).
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Figure 2: Ratings of subjective sleep quality and duration during and following the 16-week supplementation intervention in the
control (CON, n=7), whey protein isolate (PRO, n=7), EPA + DHA (n-3 PUFA, n=10), protein + placebo (PRO + PLA, n=7), and
whey protein isolate + EPA +DHA (PRO + n-3 PUFA, n=9) using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Global
sleeping score (GSS) = Sum of seven sub-component scores; range from 0-21. Line graphs represent the GSS over time and bar
graphs represent the treatment effect (16-week – baseline values) per treatment group. (A) GSS. Data are expressed as mean ± SD. * P
< 0.05 is considered significant.
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Figure 3. Fasting plasma orexin-A (OXA), cortisol, and brain-derived neurotrophic factor
(BDNF) response during and following the 16-week supplementation intervention in the control
(CON, n=7), whey protein isolate (PRO, n=7), EPA + DHA (n-3 PUFA, n=10), protein +
placebo (PRO + PLA, n=7), and whey protein isolate + EPA +DHA (PRO + n-3 PUFA, n=9).
Line graphs represent fasting plasma concentrations over time and bar graphs represent the
treatment effect (16-week – baseline values) per treatment group. (A) OXA concentrations; (B)
cortisol concentrations; (C) BDNF concentrations. Data is expressed as mean ± SD. * P < 0.05 is
considered significant.
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CHAPTER 6. Conclusion
The current growth rate of the older population is recognized as one of the most
substantial demographic trends in United States (U.S.) history [1, 2]. This robust shift in
demographics emphasizes the importance of independence, quality of life, and health across the
lifespan to promote successful aging (SA) [3]. The concept of SA is associated with longevity,
the absence of disease and disability, and a positive state of well-being which are strongly
associated with body composition [4-10]. We defined SA as low cardiometabolic risk,
preservation of physical function, and a positive state of well-being with nutrition as an integral
component. Research suggests nutritional strategies focused on the incorporation of high-quality
protein and omega-3 polyunsaturated fatty acids (n-3 PUFAs) are potential methods to mitigate
age-related decline in skeletal muscle mass, fat mass gain, cardiometabolic risk, physical
function, and well-being in adults to promote SA [11-16]. The overall objective of this
dissertation was to determine the effect of nutrition, specifically dietary protein and n-3 PUFAs,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on SA outcomes of
cardiometabolic risk, physical function, and well-being. The central hypothesis tested in this
dissertation was that increased intake of high-quality dietary protein or n-3 PUFAs would
improve SA outcomes of cardiometabolic risk, preservation physical function, and well-being in
middle-aged and older adults. This dissertation includes three independent research studies
investigating the effect of nutrition on components of SA. Collectively, the results suggest highquality protein and n-3 PUFAs act as potential regulators of SA.
Study 1, a meta-analysis and systematic review, was designed to evaluate the available
evidence of randomized controlled trials (RCTs) incorporating beef and nutrients found in beef, a
high-quality dietary protein, on components of SA with a focus on well-being. Nine RCTs were
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included in the meta-analysis and an overall positive effect of beef (n=1) and beef’s nutrients
(n=8) was found on well-being with substantial heterogeneity among sample populations. In this
meta-analysis well-being outcomes included LBM, cognitive function, and physical function.
Physical function significantly improved following intervention supplementation of beef and
beef’s nutrients. Although quality of life and subjective well-being outcomes were included in
the search processes, RCTs incorporating quality of life and subjective outcomes of well-being
did not meet our inclusion criteria. According to the Center for Disease Control and Prevention
(CDC) [8], physical well-being and psychological well-being are specific components which are
included under the well-being concept. Therefore, although subjective outcomes of well-being
were not included, LBM, physical function, and cognitive function components were analyzed
within the well-being model. Furthermore, and evident need was identified for additional welldesigned RCTs evaluating the efficacy of beef and nutrients found in beef in healthy adults ≥ 50
years of age to promote well-being and SA. Future research should adopt a population
representative sample of healthy older adults, absent of chronic diseases, and examine the effect
of lean beef on outcomes of well-being. Furthermore, RCTs implementing dietary interventions
should incorporate a multidimensional approach with homologous defined functional outcomes
of LBM, cognitive function, physical function, and quality of life to advance research in the field
of aging, nutrition, and SA in healthy adults.
Study two, a clinical trial with a randomized cross-over design, was designed to
investigate the effect of a high protein breakfast containing whey protein isolate (WPI) or pea
protein isolate (PPI) on appetite, energy expenditure, and 24-hour energy intake in young
compared to older healthy men to decrease cardiometabolic risk and promote SA. To our
knowledge, this is the first study to examine the short-term effect of a high-protein breakfast
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from plant- or animal-derived protein sources on energy expenditure and appetite response in
healthy, young and older men. Collectively, the results of this study suggest an isocaloric,
isovolumetric, macronutrient- and fiber-matched protein-based breakfast beverages from an
animal-based whey protein isolate and a plant-based pea protein isolate exerts comparable effects
on appetite, energy expenditure, and 24-hour energy intake in both young and older healthy adult
men. The lack of differences observed between protein source may have been due to the 40
grams of protein used in the test breakfast beverages which was a larger dose compared to the
doses used in other studies demonstrating differences in energy metabolism [17, 18] and appetite
[19] between protein sources. In addition, we did not provide the pea protein and whey protein in
mixed-meal context. Data from the 2017-2018 National Health and Nutrition Examination
Survey (NHANES) demonstrate that adults in the U.S. skew protein (and energy) consumption
toward the evening meal [20]. Moreover, mean protein consumption for adults aged 20 and over
is ~13 grams at the breakfast meal [21]. Therefore, further research is needed to determine the
effect of a plant-based compared to an animal-based protein breakfast meal in a comparable
quantity to a standard American breakfast of ~13 grams in young compared to older adults.
Study three, a 16-week randomized controlled trial, was designed to investigate the effect
of protein and n-3 PUFA supplementation individually and in combination on LBM, physical
function, cardiometabolic risk, and well-being in postmenopausal women to promote SA. To our
knowledge, this is the first RCT to examine the effect of 16-weeks of dietary protein and/or n-3
PUFA supplementation on LBM, physical function, cardiometabolic risk, and well-being in
postmenopausal women. The present study tested the hypothesis that combined dietary protein
and n-3 PUFA supplementation would have a greater effect on body composition,
cardiometabolic risk, and indexes of sleep and mood states in postmenopausal women when
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supplemented in combination as WPI and n-3 PUFA compared to individual supplementation.
Collectively, the results of this study suggest protein and n-3 PUFA combined supplementation
when compared to individual supplementation for 16-weeks does not provide additional benefits
on body composition, cardiometabolic risk, and well-being. However, we observed a potential
additive effect of protein and n-3 PUFAs on orexin-A (OXA) concentration. To our knowledge,
comparable dietary interventions have yet to be conducted and a mechanism of action of OXA in
cardiometabolic risk, physical function, and well-being is yet to be elucidated in humans.
Moreover, data from our lab indicate obese Zucker rats assigned a high-protein (40% energy)
diet had reduced liver and skeletal muscle lipid deposition, and higher OXA concentrations
compared to obese Zucker rats consuming a moderate-protein (20% energy) diet for 12-weeks
[22]. There is a need to further assess the effect of dietary protein and n-3 PUFA intake on OXA
concentrations in post-menopausal women. Furthermore, a relationship between SA and OXA
[23] warrants further investigation.
Collectively, the results of this dissertation suggest high-quality protein and n-3 PUFAs
act as potential regulators of SA outcomes. However, additional research is necessary to
determine the effectiveness of protein and n-3 PUFA-based nutrition strategies to promote SA.
Altogether, further research is recommended to implement RCTs with longer duration and larger
study populations to identify the effects of high-quality protein (e.g., whey protein isolate and
lean beef) and n-3 PUFAs, EPA + DHA, on middle-aged and older adults to promote outcomes
of SA. Moreover, additional research is necessary to determine the effect of dietary protein and
n-3 PUFAs on OXA as a potential mechanism of SA. For example, future RCTs should
implement WPI and lean beef supplementation alone and in combination with n-3 PUFAs within
a multidimensional approach with homologous defined functional outcomes of LBM, physical
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function, and well-being to advance research in the field of aging and nutrition. In addition,
future studies should investigate the molecular mechanisms underlying the potential effect of
dietary protein and n-3 PUFAs, apart from exercise and weight-loss, on OXA and SA in healthy
older adults.
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